

ACTEMRA IV (S)

MEDICATION(S)

ACTEMRA 200 MG/10 ML VIAL, ACTEMRA 400 MG/20 ML VIAL, ACTEMRA 80 MG/4 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Actemra therapy. Systemic Juvenile Idiopathic arthritis (SJIA) (Initial): Diagnosis of active SJIA. Failure, contraindication, or intolerance to one NSAID or systemic glucocorticoid. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of active PJIA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Actemra therapy. All indications (Initial, reauth): Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION

All uses (Initial, reauth): 12 months

OTHER CRITERIA

All uses (Reauth): Documentation of positive clinical response to Actemra therapy.

ACTEMRA SC (S)

MEDICATION(S)

ACTEMRA 162 MG/0.9 ML SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Actemra therapy. Giant Cell Arteritis (GCA) (Initial): Diagnosis of GCA. Trial and failure, contraindication, or intolerance to a glucocorticoid (i.e., prednisone). RA, GCA (Initial) Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA, GCA (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION

RA, GCA (initial, reauth): 12 months

OTHER CRITERIA

RA, GCA (Reauth): Documentation of positive clinical response to Actemra therapy. Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

ADAGEN (S)

MEDICATION(S)

ADAGEN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Excluded if patient has severe thrombocytopenia

REQUIRED MEDICAL INFORMATION

Adenosine deaminase (ADA) deficiency: Diagnosis of ADA deficiency in a patient with severe combined immunodeficiency disease (SCID) AND patient is not a suitable candidate for, or who has failed, bone marrow transplantation, hematopoietic stem cell transplant, or gene therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ADAPALENE (S)

MEDICATION(S)

ADAPALENE 0.1% CREAM, ADAPALENE 0.1% GEL, ADAPALENE 0.3% GEL, ADAPALENE 0.3% GEL PUMP, ADAPALENE-BENZOYL PEROXIDE, EPIDUO, EPIDUO FORTE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Diagnosis of acne.

AGE RESTRICTION

PA applies to members 26 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

ADCIRCA (S)

MEDICATION(S)

ADCIRCA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA

PAH (Reauth): Documentation of positive clinical response to therapy.

ADDERALL XR (S)

MEDICATION(S)

DEXTROAMPHETAMINE-AMPHET ER

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

ADEMPAS (S)

MEDICATION(S)

ADEMPAS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH AND PAH is symptomatic AND One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. Chronic thromboembolic pulmonary hypertension (CTEPH) (Initial): One of the following: A) Both of the following: 1) Diagnosis of inoperable or persistent/recurrent CTEPH and 2) CTEPH is symptomatic OR B) Patient is currently on any therapy for the diagnosis of CTEPH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH, CTEPH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH, CTEPH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA

PAH, CTEPH (Reauth): Documentation of positive clinical response to therapy.

AFINITOR (S)

MEDICATION(S)

AFINITOR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Subependymal Giant Cell Astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Diagnosis of SEGA associated with TSC that requires therapeutic intervention but patient is not a candidate for curative surgical resection. Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma AND History of failure, contraindication, or intolerance to SUTENT (sunitinib) or NEXAVAR (sorafenib). Neuroendocrine tumors of pancreatic origin (pNET): Diagnosis of progressive pNET that are unresectable, locally advanced, or metastatic. Renal angiomyolipoma: Diagnosis of renal angiomyolipoma and TSC AND Patient does not require immediate surgery. Breast Cancer: Patient is a postmenopausal woman AND Diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer AND History of failure, contraindication, or intolerance to FEMARA (letrozole) or ARIMIDEX (anastrozole) AND Afinitor will be used in combination with AROMASIN (exemestane). Neuroendocrine tumors of gastrointestinal (GI) or lung origin: Diagnosis of progressive, well-differentiated, non-functional NET of GI or lung origin AND patient has unresectable, locally advanced or metastatic disease.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION

All Indications: 12 months

OTHER CRITERIA

All Indications: Approve for continuation of prior therapy.

AFINITOR DISPERZ (S)

MEDICATION(S)

AFINITOR DISPERZ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Subependymal Giant Cell Astrocytoma (SEGA): Diagnosis of SEGA associated with tuberous sclerosis complex (TSC) that requires therapeutic intervention but patient is not a candidate for curative surgical resection

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ALDURAZYME (S)

MEDICATION(S)

ALDURAZYME

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Mucopolysaccharidosis I: confirmed diagnosis of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), OR confirmed diagnosis of Scheie form of Mucopolysaccharidosis I (MPS I) who have moderate to severe symptoms.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

ALECENSA (S)

MEDICATION(S)

ALECENSA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): A) Diagnosis of metastatic NSCLC AND B) Patient has anaplastic lymphoma kinase (ALK)-positive disease as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND C) History of failure, contraindication, intolerance, or progressed on XALKORI (crizotinib)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ALPHA-1 PROTEINASE INHIBITORS (S)

MEDICATION(S)

ARALAST NP, GLASSIA, PROLASTIN C, ZEMAIRA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency: All of the following: A) Patient has an alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency AND B) Diagnosis of emphysema AND C) One of the following: 1) Patient has a high risk phenotype: PiZZ, PiZ(), Pi()() OR 2) Patient has serum alpha-1 antitrypsin concentrations of less than 11 M/L (80 mg/dL) AND D) One of the following: FEV1 level is between 30% and 65% of predicted OR the patient has experienced a rapid decline in lung function (i.e., reduction of FEV1 more than 120 mL/year) that warrants treatment.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

ALUNBRIG (S)

MEDICATION(S)

ALUNBRIG

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC. Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. Trial and failure or intolerance to Xalkori (crizotinib).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

AMPYRA (S)

MEDICATION(S)

AMPYRA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS) (initial): Diagnosis of MS. Physician confirmation that patient has difficulty walking (eg, timed 25 foot walk test). One of the following: expanded disability status scale (EDSS) score less than or equal to 7, or not restricted to using a wheelchair (if EDSS is not measured).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

MS (Initial): Prescribed by or in consultation with a neurologist.

COVERAGE DURATION

MS (Initial): 6 months. (Reauth): 12 months.

OTHER CRITERIA

MS (Reauth): Physician confirmation that the patient's walking improved with Ampyra therapy. One of the following: EDSS score less than or equal to 7, or not restricted to using a wheelchair (if EDSS is not measured).

ANADROL-50 (S)

MEDICATION(S)

ANADROL-50

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Anemia (initial): Diagnosis of anemia caused by deficient red cell production AND History of failure or intolerance to standard therapies for anemia (ie, erythropoiesis-stimulating agents, immunosuppressants) AND Treatment will not replace other supportive measures (e.g., transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy, corticosteroids)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial and reauth: 12 months

OTHER CRITERIA

Anemia (reauth): patient has experienced an objective improvement in anemia (e.g., increased hemoglobin, increased reticulocyte count, reduction/elimination for need of blood transfusions)

APOKYN (S)

MEDICATION(S)

APOKYN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

PD (Initial, reauth): Patient is using Apokyn with any 5-HT3 antagonist (eg, ondansetron, granisetron, dolasetron, palonosetron, alosetron)

REQUIRED MEDICAL INFORMATION

Parkinson's disease (PD) (Initial): Diagnosis of advanced PD. Patient is experiencing acute intermittent hypomobility (defined as off episodes characterized by muscle stiffness, slow movements, or difficulty starting movements). Patient is receiving Apokyn in combination with other medications for the treatment of PD (e.g., carbidopa/levodopa, pramipexole, ropinirole, bztropine, etc.).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

PD (Initial, reauth): 12 months

OTHER CRITERIA

PD (Reauth): Patient is benefiting from therapy (eg, patient had an improvement in motor function).

ARANESP (S)

MEDICATION(S)

ARANESP 10 MCG/0.4 ML SYRINGE, ARANESP 100 MCG/0.5 ML SYRINGE, ARANESP 100 MCG/ML VIAL, ARANESP 150 MCG/0.3 ML SYRINGE, ARANESP 200 MCG/0.4 ML SYRINGE, ARANESP 200 MCG/ML VIAL, ARANESP 25 MCG/0.42 ML SYRING, ARANESP 25 MCG/ML VIAL, ARANESP 300 MCG/0.6 ML SYRINGE, ARANESP 300 MCG/ML VIAL, ARANESP 40 MCG/0.4 ML SYRINGE, ARANESP 40 MCG/ML VIAL, ARANESP 500 MCG/1 ML SYRINGE, ARANESP 60 MCG/0.3 ML SYRINGE, ARANESP 60 MCG/ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Anemia with Chronic Kidney Disease (CKD) (Initial): Diagnosis (Dx) of CKD. Anemia by lab values (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. One of the following: Patient is on dialysis, OR all of the following: patient is not on dialysis, the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion, and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Anemia with chemo (Initial): Other causes of anemia have been ruled out. Anemia by lab values (Hct less than 30%, Hgb less than 10 g/dL) collected within the prior 2 weeks of request. Cancer is a non-myeloid malignancy. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. Anemia in Myelodysplastic Syndrome (MDS) (Initial): Dx of MDS. Serum erythropoietin level is 500 mU/mL or less, or dx of transfusion-dependent MDS. CKD (init, reauth), Chemo (init), MDS (init): Verify iron evaluation for adequate iron stores.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

CKD (Init): 6 mo. CKD (reauth): 12 mo. Chemo(init, reauth): 3 mo. MDS: (init) 3 mo,(reauth) 12 mo.

OTHER CRITERIA

Subject to ESRD review. CKD (Reauth): Dx of CKD. Most recent or average (avg) Hct over 3 mo is 33% or less OR most recent or avg Hgb over 3 months is 11 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Chemo (Reauth): Anemia by lab values (Hgb less than 10 g/dl or Hct less than 30%) collected within the prior 2 weeks of request. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. MDS (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Off-label uses (except MDS): Will not be approved if patient has Hgb greater than 10 g/dL or Hct greater than 30%.

ARCALYST (S)

MEDICATION(S)

ARCALYST

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cryopyrin-Associated Periodic Syndromes (CAPS) (Initial): Diagnosis of CAPS, including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS). The medication will not be used in combination with another biologic.

AGE RESTRICTION

CAPS (Initial): 12 years of age or older

PRESCRIBER RESTRICTION

CAPS (Initial): Prescribed by or in consultation with an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist.

COVERAGE DURATION

CAPS (initial, reauth): 12 months

OTHER CRITERIA

CAPS (Reauth): Patient has experienced disease stability or improvement in clinical symptoms while on therapy as evidence by one of the following: A) improvement in rash, fever, joint pain, headache, conjunctivitis, B) decreased number of disease flare days, C) normalization of inflammatory markers (CRP, ESR, SAA), D) corticosteroid dose reduction, OR E) improvement in MD global score or active joint count.

AUBAGIO (S)

MEDICATION(S)

AUBAGIO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

AUSTEDO (S)

MEDICATION(S)

AUSTEDO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chorea associated with Huntington's disease (initial): Diagnosis of Chorea associated with Huntington's disease.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with a neurologist

COVERAGE DURATION

initial: 3 months, Reauth: 12 months

OTHER CRITERIA

Chorea associated with Huntington's disease (reauth): Documentation of positive clinical response to therapy and trial/failure or contraindication to tetrabenazine

BAVENCIO (S)

MEDICATION(S)

BAVENCIO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Merkel Cell Carcinoma (MCC): Diagnosis of metastatic Merkel cell carcinoma. Urothelial Carcinoma (UC): Diagnosis of locally advanced or metastatic urothelial carcinoma. One of the following: 1) Patient has disease progression during or following platinum-containing chemotherapy, OR 2) Patient has disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

AGE RESTRICTION

MCC: Patient is 12 years of age or older.

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

BELEODAQ (S)

MEDICATION(S)

BELEODAQ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Peripheral T-cell lymphoma (PTCL): Diagnosis of PTCL. History of failure, contraindication, or intolerance to at least one prior therapy (e.g., conventional chemotherapy).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

BENLYSTA (S)

MEDICATION(S)

BENLYSTA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Systemic lupus erythematosus (SLE) (init): Diagnosis of active SLE. Autoantibody positive (ie, anti-nuclear antibody [ANA] titer greater than or equal to 1:80 or anti-dsDNA level greater than or equal to 30 IU/mL). Currently receiving at least one standard of care treatment for active SLE (eg, antimalarials [eg, Plaquenil (hydroxychloroquine)], corticosteroids [eg, prednisone], or immunosuppressants [eg, methotrexate, Imuran (azathioprine), CellCept (mycophenolate mofetil)]).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

SLE (init): Prescribed by or in consultation with a rheumatologist

COVERAGE DURATION

SLE (init, reauth): 6 months

OTHER CRITERIA

SLE (reauth): Documentation of positive clinical response to Benlysta therapy

BERINERT (S)

MEDICATION(S)

BERINERT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Firazyr, Kalbitor, or Ruconest).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HAE: Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

BOSULIF (S)

MEDICATION(S)

BOSULIF

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic myelogenous leukemia (CML): Diagnosis of Philadelphia chromosome-positive (Ph+) CML AND one of the following: A) Ph+ CML with resistance, relapse, or inadequate response to prior therapy with one of the following tyrosine kinase inhibitors (TKI): Gleevec [imatinib], Tasigna [nilotinib], Sprycel [dasatinib] AND Patient has received mutation testing AND does not have the T315I or V299L mutation OR B) Ph+ CML with intolerance to prior therapy with one of the following tyrosine kinase inhibitors (TKI): Gleevec [imatinib], Tasigna [nilotinib], Sprycel [dasatinib]

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

BOTOX (S)

MEDICATION(S)

BOTOX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Neuromuscular Disorders (init): Strabismus, blepharospasm associated with dystonia (eg, benign essential blepharospasm), treatment of upper or lower limb spasticity, VII cranial nerve disorders (hemifacial spasms), cervical dystonia Hyperhidrosis(HH): (Init) Dx of primary axillary HH. Score of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS) or skin maceration with secondary infection. Failure, contraindication, or intolerance (F/C/I) to topical prescription strength drying agents [eg, Drysol, Hypercare, Xerac AC (aluminum chloride hexahydrate)]. Migraine:(Init) Dx of chronic migraines (greater than or equal to 15 migraine headache days per month with headache lasting 4 hours a day or longer). F/C/I to prophylactic therapy with at least two of the following agents, each given for a trial of at least two months: antidepressants [ie, Effexor (venlafaxine)], antiepileptics [ie, Depakote/Depakote ER (divalproex sodium), Topamax (topiramate)], beta-blockers [eg, atenolol, Inderal (propranolol), nadolol, timolol, Toprol XL (metoprolol)] Achalasia:(Init) High risk of complication from or failure to pneumatic dilation or myotomy, or prior dilation caused esophageal perforation, or patient has an epiphrenic diverticulum or hiatal hernia. Anal Fissure (AF)(Init): Dx of chronic AF. At least 2 months of either nocturnal pain and bleeding or postdefecation pain. Chronic Back Pain (CBP):(Init) Dx of low back pain lasting greater than or equal to six months. Urinary incontinence (UI):(init) Neurogenic detrusor overactivity associated with a neurologic condition (eg, spinal cord injury [SCI], multiple sclerosis) or detrusor sphincter dyssynergia with SCI. Overactive bladder (OAB): (init) Dx of OAB. One of the following symptoms: urge urinary incontinence, urgency, frequency.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Migraine (Initial): Prescribed by a neurologist or pain specialist. CBP (Initial): Prescribed by a neurologist, neurosurgeon, orthopedist, or pain specialist. UI, OAB (initial): Prescribed by a neurologist, neurosurgeon, or urologist.

COVERAGE DURATION

Achalasia: 6mo CBP: 1 tx (series of injxs) UI: 3mo (1 dose, 200 units) Other: 3mo

OTHER CRITERIA

UI, OAB, CBP, Neuromuscular Disorders: (Reauth) Confirmed improvement in symptoms with initial Botox treatment. At least 3 months have or will have elapsed since the last treatment with Botox
HH: (Reauth) At least a 2-point improvement in HDSS. Migraine: (Reauth) Reduction in headache frequency or intensity. Confirmation of decreased utilization of pain medications (eg, narcotic analgesics, NSAIDs) or triptans, or a reduction in the number of ER visits. Achalasia: (Reauth) Documentation of improvement or reduction in symptoms of achalasia (ie, dysphagia, regurgitation, chest pain). At least 6 months have or will have elapsed since last series of injections
AF: (Reauth) Incomplete healing of fissure or recurrence of fissure. Improved symptoms with prior treatment with Botox.

CABOMETYX (S)

MEDICATION(S)

CABOMETYX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Renal cell carcinoma (RCC): Diagnosis of RCC. RCC is advanced. History of failure, contraindication, or intolerance to at least one prior anti-angiogenic therapy [e.g., Nexavar (sorafenib), Sutent (sunitinib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

CAPRELSA (S)

MEDICATION(S)

CAPRELSA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Thyroid Cancer: Diagnosis of medullary thyroid cancer (MTC)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with oncologist or endocrinologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

CAYSTON (S)

MEDICATION(S)

CAYSTON

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cystic fibrosis (CF) (Initial, Reauth): Diagnosis of CF AND Patient has evidence of Pseudomonas aeruginosa in the lungs

AGE RESTRICTION

CF (Initial): 7 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

CF (Initial, reauth): 12 months

OTHER CRITERIA

CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations)

CERDELGA (S)

MEDICATION(S)

CERDELGA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Gaucher disease (Initial): Diagnosis of Gaucher disease type 1. Patient is an extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) of cytochrome P450 enzyme (CYP) 2D6 as detected by an FDA-cleared test.

AGE RESTRICTION

Gaucher disease (initial): 18 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Gaucher disease (initial, reauth): 12 months

OTHER CRITERIA

Gaucher disease (Reauth): Patients condition has not progressed, as defined by ALL of the following:
A) Hemoglobin level decreased greater than 1.5 g/dL from baseline, AND B) Platelet count decreased greater than 25% from baseline, AND C) Spleen volume increased greater than 25% from baseline, AND D) Liver volume increased greater than 20% from baseline.

CEREZYME (S)

MEDICATION(S)

CEREZYME 400 UNITS VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Gaucher disease: Diagnosis of type 1 Gaucher disease. Patient has evidence of symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Gaucher disease: 12 months

OTHER CRITERIA

N/A

CHOLBAM (S)

MEDICATION(S)

CHOLBAM

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Bile acid synthesis disorders due to single enzyme defects (BAS) (initial): diagnosis of a bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorders (PD) (initial): All of the following: 1) diagnosis of peroxisomal disorder, 2) patient exhibits at least one of the following: a) liver disease (eg, jaundice, elevated serum transaminases), OR b) steatorrhea, OR c) complications from decreased fat-soluble vitamin absorption (eg, poor growth), AND 3) Cholbam will be used as an adjunctive treatment.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses (initial): Prescribed by a hepatologist, medical geneticist, pediatric gastroenterologist, OR other specialist that treats inborn errors of metabolism.

COVERAGE DURATION

All uses (initial, reauth): 12 months

OTHER CRITERIA

All uses (reauth): documentation of positive clinical response to Cholbam therapy

CHORIONIC GONADOTROPIN (S)

MEDICATION(S)

CHORIONIC GONAD 10,000 UNIT VL, NOVAREL 10,000 UNITS VIAL, PREGNYL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prepubertal Cryptorchidism: Diagnosis of prepubertal cryptorchidism not due to anatomical obstruction.
Male Hypogonadotropic Hypogonadism (MHH) (initial): Diagnosis of male hypogonadism secondary to pituitary deficiency, and low testosterone (below normal reference value provided by the physician's laboratory) and one of the following: a) low LH (below normal reference value provided by the physician's laboratory) or b) low FSH (below normal reference value provided by the physician's laboratory).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Prepubertal Cryptorchidism: 6 wks. MHH (initial, reauth): 12 months.

OTHER CRITERIA

Excluded if used to promote fertility. MHH (Reauth): Documentation of positive clinical response to therapy.

CIALIS (S)

MEDICATION(S)

CIALIS 2.5 MG TABLET, CIALIS 5 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Concurrent use of nitrates.

REQUIRED MEDICAL INFORMATION

Diagnosis of benign prostatic hyperplasia (BPH). Patient has experienced intolerance to or treatment failure with an alpha-blocker (e.g., doxazosin, prazosin, tamsulosin) or a 5-alpha reductase inhibitor (e.g., dutasteride, finasteride).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

CICLOPIROX (S)

MEDICATION(S)

CICLOPIROX 8% SOLUTION

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

All of the following: 1) Patient does not have dermatophytomas or lunula (matrix) involvement, 2) one of the following: a) Diagnosis of onychomycosis of the toenails, OR b) Diagnosis of onychomycosis of the fingernails, 3) Diagnosis of onychomycosis has been confirmed by one of the following: a) positive potassium hydroxide (KOH) preparation, OR b) culture, OR c) histology, 4) Patient has mild to moderate disease defined by the presence of all of the following: a) Involvement of at least 1 great toenail, AND b) the target great toenail (TGT) includes at least a 3 mm section of clear nail (measured from the proximal nail fold) and less than or equal to a 3 mm distal toenail plate thickness, AND c) 20% to 65% clinical involvement of the target toenail, 5) Patients condition is causing debility or a disruption in their activities of daily living, AND 6) Trial and inadequate response, intolerance or hypersensitivity to oral terbinafine.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

48 weeks.

OTHER CRITERIA

N/A

CIMZIA (S)

MEDICATION(S)

CIMZIA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA, initial): Diagnosis (dx) of moderately to severely active RA. Crohn's Disease (CD, initial): Dx of moderately to severely active CD. History (Hx) of failure, contraindication, or intolerance (F/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), Azathioprine (Imuran), Corticosteroid (eg, prednisone, methylprednisolone), Methotrexate (Rheumatrex, Trexall). Hx of F/C/I to Humira OR for continuation of prior Cimzia therapy. Psoriatic Arthritis (PsA, initial): Dx of active PsA. Ankylosing Spondylitis (AS, initial): Dx of active AS. RA, PsA, AS (initial): Hx of F/C/I to Enbrel and Humira OR for continuation of prior Cimzia therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

CD (init): Prescribed by or in consultation with a gastroenterologist. RA, AS (init): Prescribed by or in consultation with a rheumatologist. PsA (init): Prescribed by or in consultation with a dermatologist or rheumatologist.

COVERAGE DURATION

RA, PsA, AS (init,reauth): 12 mos. CD (init): 16 wks. (reauth): 12 mos.

OTHER CRITERIA

Reauthorization (all indications): Documentation of positive clinical response to Cimzia therapy. All indications (initial and reauth): Patient is not receiving Cimzia in combination with either of the following: Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept)] or Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]. For a diagnosis of PsA, Patient is not receiving Cimzia in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

CINRYZE (S)

MEDICATION(S)

CINRYZE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prophylaxis of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For prophylaxis against HAE attacks. For continuation of prior therapy or History of failure, contraindication, or intolerance of one of the following: 17-alpha alkylated androgen (eg, danazol, oxandrolone) or antifibrinolytics (eg, aminocaproic acid, tranexamic acid).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HAE (prophylaxis, treatment): Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

COMETRIQ (S)

MEDICATION(S)

COMETRIQ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Medullary thyroid cancer (MTC): Diagnosis of Metastatic MTC. Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC and positive for RET gene rearrangements. Renal cell carcinoma (RCC): Diagnosis of RCC. History of failure, contraindication, or intolerance to at least one prior anti-angiogenic therapy [eg, Inlyta (axitinib), Votrient (pazopanib), Nexavar (sorafenib), Sutent (sunitinib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

MTC: Prescribed by or in consultation with an oncologist/hematologist or endocrinologist. NSCLC: Prescribed by or in consultation with an oncologist/hematologist. RCC: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

All uses: 12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

COSENTYX (S)

MEDICATION(S)

COSENTYX (2 SYRINGES), COSENTYX PEN, COSENTYX PEN (2 PENS), COSENTYX SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: Failure, contraindication, or intolerance to Enbrel (etanercept) OR Humira (adalimumab), OR for continuation of prior Cosentyx therapy. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. One of the following: Failure, contraindication, or intolerance to either Enbrel (etanercept) or Humira (adalimumab), OR for continuation of prior Cosentyx therapy. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. One of the following: Failure, contraindication, or intolerance to either Enbrel (etanercept) or Humira (adalimumab), OR for continuation of prior Cosentyx therapy. All indications (Initial, reauth): Patient is not receiving Cosentyx in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Plaque psoriasis (Initial): Prescribed by or in consultation with a dermatologist. PsA (Initial): Prescribed by or in consultation with a rheumatologist or dermatologist. AS (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION

All indications (Initial, reauth): 12 months

OTHER CRITERIA

All indications (Reauth): Documentation of positive clinical response to Cosentyx therapy.

COTELLIC (S)

MEDICATION(S)

COTELLIC

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis of unresectable or metastatic melanoma. Patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test (e.g., cobas 4800 BRAF V600 Mutation Test) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Used in combination with vemurafenib.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

CRINONE (S)

MEDICATION(S)

CRINONE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

All indications: Excluded if for fertility uses.

REQUIRED MEDICAL INFORMATION

Secondary amenorrhea: Diagnosis of secondary amenorrhea (the absence of menses in women who have already started menstruation who are not pregnant, breastfeeding, or in menopause).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

CYRAMZA (S)

MEDICATION(S)

CYRAMZA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Gastric cancer: All of the following: 1) diagnosis of one of the following: a) gastric adenocarcinoma, OR b) gastro-esophageal junction (GEJ) adenocarcinoma, AND 2) disease is one of the following: a) locally advanced, OR b) metastatic, AND 3) disease has progressed on or after one of the following first-line therapies: a) fluoropyrimidine-containing chemotherapy (eg, fluorouracil, capecitabine), OR b) platinum-containing chemotherapy (eg, cisplatin, carboplatin, oxaliplatin). Non-small cell lung cancer: All of the following: 1) diagnosis of metastatic non-small cell lung cancer, AND 2) used in combination with docetaxel, AND 3) disease has progressed on or after platinum-based chemotherapy (eg, cisplatin, carboplatin, oxaliplatin). Metastatic colorectal cancer (mCRC): 1) Diagnosis of metastatic CRC AND 2) Patient had disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

CYSTARAN (S)

MEDICATION(S)

CYSTARAN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cystinosis: Diagnosis of cystinosis, confirmed by elevated leukocyte cystine levels (LCL), genetic analysis of the CTNS gene or corneal cystine crystal accumulation AND Patient is concomitantly receiving treatment with oral cysteamine

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

DACOGEN (S)

MEDICATION(S)

DECITABINE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Myelodysplastic syndrome (MDS): Diagnosis of myelodysplastic syndrome.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

DAKLINZA (S)

MEDICATION(S)

DAKLINZA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Criteria will be applied consistent with current AASLD/IDSA guideline. For genotype 1, ONE of the following: 1) Patient has a contraindication or intolerance to Harvoni and Zepatier OR 2) For continuation of prior Daklinza therapy. All: One of the following: 1) Patient has not failed a prior HCV NS5A-containing regimen (eg, Daklinza) OR 2) patient has failed prior therapy with an NS5A-containing regimen AND submission of medical records (eg, chart notes) documenting that the patient does not have NS5A inhibitor resistance-associated variants detected using commercially available assays. All: One of the following: 1) requested daily dosage is less than 90 mg OR 2) both of the following: requested daily dosage is equal to 90 mg and patient is concomitantly receiving a moderate CYP3A inducer (eg, bosentan, dexamethasone, efavirenz, etravirine, modafinil).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

DALIRESP (S)

MEDICATION(S)

DALIRESP

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic Obstructive Pulmonary Disease (COPD): (Initial) Diagnosis of severe COPD. Patient has chronic bronchitis. Failure/contraindication/intolerance to two prior therapies for COPD.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

COPD (init, reauth): 12 months

OTHER CRITERIA

COPD (reauth): Documentation of positive clinical response to Daliresp therapy.

DARAPRIM (S)

MEDICATION(S)

DARAPRIM

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Toxoplasmosis: 1) Patient is using Daraprim for the treatment of toxoplasmic encephalitis, secondary prophylaxis of toxoplasmic encephalitis, or treatment of congenital toxoplasmosis OR 2) Patient is using Daraprim for the primary prophylaxis of toxoplasmic encephalitis, patient has experienced intolerance to prior prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX), and one of the following: patient has been re-challenged with TMP-SMX using a desensitization protocol and is still unable to tolerate, or evidence of life-threatening reaction to TMP-SMX in the past (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome). Malaria: Patient is using Daraprim for the treatment of acute malaria or chemoprophylaxis of malaria. Patient does not have megaloblastic anemia due to folate deficiency. The provider acknowledges that Daraprim is not recommended by the Centers for Disease Control and Prevention (CDC) for the treatment and/or prophylaxis of malaria.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an infectious disease specialist

COVERAGE DURATION

12 months

OTHER CRITERIA

Toxoplasmosis only: Approve for continuation of prior therapy.

DARZALEX (S)

MEDICATION(S)

DARZALEX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Myeloma (MM): Diagnosis of MM. One of the following: A) Patient has received at least three prior treatment regimens which included both a proteasome inhibitor (eg, bortezomib [Velcade], carfilzomib [Kyprolis]) and an immunomodulatory agent (eg, lenalidomide [Revlimid], thalidomide [Thalomid]) or patient is double-refractory to a proteasome inhibitor and an immunomodulatory agent. OR B) Patient has received at least one prior therapy. Darzalex will be used in combination with either 1) lenalidomide and dexamethasone or 2) bortezomib and dexamethasone. OR C) Patient has received at least two prior therapies including lenalidomide and a proteasome inhibitor (e.g., bortezomib [Velcade], carfilzomib [Kyprolis]) AND Darzalex will be used in combination with both pomalidomide and dexamethasone.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

DEFERASIROX (S)

MEDICATION(S)

EXJADE, JADENU

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic Iron Overload Due to Blood Transfusions (Initial): Diagnosis of chronic iron overload due to blood transfusions (transfusional hemosiderosis). Patient has a baseline ferritin level more than 1,000 mcg/L. Patient has required the transfusion of at least 100 mL/kg packed red blood cells.

Myelodysplastic Syndrome (MDS) (Initial): Diagnosis of MDS. Patient has Low or Intermediate-1 disease or is a potential transplant patient. Patient has received more than 20 red blood cell transfusions.

Chronic iron overload due to non-transfusion-dependent thalassemia (NTDT) (Initial): Diagnosis of chronic iron overload due to NTDT. Liver iron concentration (LIC) 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) or higher. Serum ferritin level greater than 300 mcg/L.

AGE RESTRICTION

Iron Overload Due to Blood Transfusions (initial): 2 years of age or older. NTDT (initial): 10 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Iron Overload Due to Blood Transfusions, MDS (initial, reauth):12 mo. NTDT (initial, reauth): 6mo.

OTHER CRITERIA

Iron Overload Due to Blood Transfusions, MDS (Reauth): Patient experienced a reduction from baseline in serum ferritin level or LIC. NTDT (Reauth): Patient has LIC 3 mg Fe/g dw or higher. Patient experienced a reduction from baseline in serum ferritin level or LIC.

DEXMETHYLPHENIDATE (S)

MEDICATION(S)

DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, FOCALIN XR 25 MG CAPSULE, FOCALIN XR 35 MG CAPSULE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

DEXTROAMPHETAMINE (S)

MEDICATION(S)

DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE SULFATE ER, ZENZEDI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

DUPIXENT (S)

MEDICATION(S)

DUPIXENT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Atopic dermatitis (initial): Diagnosis of moderate to severe atopic dermatitis. Trial and failure, contraindication, or intolerance to one medium to high potency topical corticosteroid. One of the following: A) Trial and failure or intolerance to Elidel (pimecrolimus) topical cream, unless the patient is not a candidate for Elidel therapy (e.g., immunocompromised, severe atopic dermatitis), B) Trial and failure or intolerance to tacrolimus topical ointment, unless the patient is not a candidate for tacrolimus ointment therapy (e.g., immunocompromised).

AGE RESTRICTION

Initial: Age 18 years of age or older

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with one of the following: dermatologist, allergist/immunologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Atopic dermatitis (reauth): Documentation of a positive clinical response to Dupixent therapy (e.g., reduction in body surface area involvement, reduction in pruritus severity)

EGRIFTA (S)

MEDICATION(S)

EGRIFTA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

HIV-associated lipodystrophy (initial): All of the following: 1) diagnosis of HIV-associated lipodystrophy, 2) one of the following: a) waist-circumference of greater than or equal to 95 cm (37.4 inches) in men, OR b) waist-circumference of greater than or equal to 94 cm (37 inches) for women, 3) one of the following: a) Waist-to-hip ratio of greater than or equal to 0.94 for men, OR b) waist-to-hip ratio of greater than or equal to 0.88 for women, 4) body mass index (BMI) greater than 20 kg/m², AND 5) fasting blood glucose (FBG) levels less than or equal to 150 mg/dL (8.33 mmol/L), AND 6) patient has been on a stable regimen of antiretrovirals (eg, NRTIs, NNRTI, Protease Inhibitors, Integrase Inhibitors) for at least 8 weeks.

AGE RESTRICTION

(Initial): 18 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

(initial, reauth): 6 months

OTHER CRITERIA

(reauth): documentation of clinical improvement (eg, improvement in visceral adipose tissue [VAT], decrease in waist circumference, belly appearance, etc) while on Egrifta therapy.

ELAPRASE (S)

MEDICATION(S)

ELAPRASE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Diagnosis of Hunter Syndrome (Mucopolysaccharidosis II (MPS II))

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

ELIGARD (S)

MEDICATION(S)

ELIGARD

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. History of failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

EMFLAZA (S)

MEDICATION(S)

EMFLAZA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Initial: Diagnosis of Duchenne muscular dystrophy (DMD). Patient has received genetic testing for a mutation of the dystrophin gene. One of the following: A) Documentation of a confirmed mutation of the dystrophin gene or B) Muscle biopsy confirmed an absence of dystrophin protein. Patient has had a trial and failure or intolerance to prednisone or prednisolone. Emflaza dose will not exceed 0.9 milligrams per kilogram of body weight once daily.

AGE RESTRICTION

Initial: Patient is 5 years of age or older

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with a neurologist who has experience treating children

COVERAGE DURATION

12 months

OTHER CRITERIA

(Reauth): Patient has experienced a benefit from therapy (e.g., improvement or preservation of muscle strength)

EMPLICITI (S)

MEDICATION(S)

EMPLICITI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple myeloma: Diagnosis of multiple myeloma. Patient has received at least one prior therapy for multiple myeloma [eg, Revlimid (lenalidomide), Thalomid (thalidomide), Velcade (bortezomib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ENBREL (S)

MEDICATION(S)

ENBREL 25 MG KIT, ENBREL 25 MG/0.5 ML SYRINGE, ENBREL 50 MG/ML SURECLICK SYR, ENBREL 50 MG/ML SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Failure, contraindication, or intolerance to one disease-modifying antirheumatic drug (DMARD) [eg, methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of moderately to severely active pJIA. Failure, contraindication, or intolerance to one of the following DMARDs: Arava (leflunomide) or methotrexate (Rheumatrex/Trexall). Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. Failure, contraindication, or intolerance to two NSAIDs. All indications (Initial, reauth): Patient is not receiving Enbrel in combination with a biologic DMARD [eg, Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]. Patient is not receiving Enbrel in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]. For a diagnosis of PsA or plaque psoriasis, Patient is not receiving Enbrel in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA (Initial), PJIA (Initial), AS (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation with a rheumatologist or dermatologist. Plaque Psoriasis (Initial): Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION

All indications (Initial, reauth): 12 months

OTHER CRITERIA

PAGE 60
HPMS Approved Formulary ID: 00017485 Version 23

LAST UPDATED 12/2017

All indications (Reauth): Documentation of positive clinical response to Enbrel therapy.

ENTRESTO (S)

MEDICATION(S)

ENTRESTO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Initial, reauth: Excluded if patient has a history of angioedema associated with use of the following: Angiotensin converting enzyme (ACE) Inhibitor therapy, Angiotensin receptor blocker (ARB) therapy.

REQUIRED MEDICAL INFORMATION

Heart failure (HF) (initial): Diagnosis of heart failure (with or without hypertension). Ejection fraction is less than or equal to 40 percent. Heart failure is classified as NYHA Class II, III or IV. Patient is receiving concomitant therapy with one of the following beta-blockers at a maximally tolerated dose or has a contraindication or intolerance to beta-blocker therapy: bisoprolol, carvedilol or metoprolol succinate. Patient is not concomitantly on aliskiren therapy. Patient is not pregnant. Patient will discontinue use of any concomitant ACE Inhibitor or ARB. ACE inhibitors must be discontinued at least 36 hours prior to initiation of Entresto.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HF (initial): Prescribed by or in consultation with a cardiologist

COVERAGE DURATION

HF (initial reauth): 12 months

OTHER CRITERIA

HF (reauth): documentation of positive clinical response to therapy.

EPCLUSA (S)

MEDICATION(S)

EPCLUSA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Criteria will be applied consistent with current AASLD/IDSA guideline. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral agent [e.g., Sovaldi (sofosbuvir), Olysio (simeprevir)]. One of the following: a) genotypes 2, 3, 5, or 6, or b) genotypes 1 or 4: history of failure, contraindication, or intolerance to Harvoni and Zepatier or, for patients with decompensated cirrhosis, history of failure, contraindication, or intolerance to Harvoni, or c) patient is currently on Epclusa therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hepatologist, gastroenterologist, infectious disease specialist, or HIV specialist certified through the American Academy of HIV Medicine.

COVERAGE DURATION

12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.

OTHER CRITERIA

N/A

EPOETIN ALFA (S)

MEDICATION(S)

PROCRIT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Anemia with Chronic Kidney Disease (CKD) (Initial): Diagnosis (Dx) of CKD. Anemia by lab values (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. One of the following: Patient is on dialysis, OR all of the following: patient is not on dialysis, the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion, and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Anemia with HIV (Initial): Anemia by lab values (Hgb less than 12 g/dL or Hct less than 36%) collected within 30 days of request. Serum erythropoietin level less than or equal to 500 mU/mL. Receiving zidovudine therapy or dx of HIV. Anemia with chemo (Initial): Other causes of anemia have been ruled out. Anemia by lab values (Hct less than 30%, Hgb less than 10 g/dL) collected within the prior 2 weeks of request. Cancer is a non-myeloid malignancy. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 mos, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. Preoperative for reduction of allogeneic blood transfusion: Patient is scheduled to undergo elective, non-cardiac, non-vascular surgery. Hgb is greater than 10 to less than or equal to 13 g/dL. Patient is at high risk for perioperative transfusions. Patient is unwilling or unable to donate autologous blood pre-operatively. Anemia in hepatitis C virus (HCV)-infected pts due to ribavirin in combination with interferon or peg-interferon (Initial): Dx of HCV infection. Anemia by labs (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. Patient is receiving ribavirin and one of the following: interferon alfa or peginterferon alfa. Anemia in Myelodysplastic Syndrome (MDS) (Initial): Dx of MDS. Serum erythropoietin level is 500 mU/mL or less, or dx of transfusion-dependent MDS.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

CKD,HIV(Init):6mo. CKD,HIV(reauth):12mo. Chemo,HCV(all):3mo. MDS:(init) 3mo,(reauth)12mo. Preop:1mo.

OTHER CRITERIA

Subject to ESRD review. CKD (Reauth): Dx of CKD. Most recent or average (avg) Hct over 3 months is 33% or less OR most recent or avg Hgb over 3 months is 11 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. HIV (Reauth): Most recent or avg Hct over 3 months is below 36% or most recent or avg Hgb over 3 months is below 12 g/dl. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Chemo (Reauth): Anemia by lab values (Hgb less than 10 g/dl or Hct less than 30%) collected within the prior 2 weeks of request. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. HCV (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. If patient has demonstrated response to therapy, authorization will be issued for the full course of ribavirin therapy. MDS (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Off-label uses (except MDS): Will not be approved if patient has Hgb greater than 10 g/dL or Hct greater than 30%. CKD (init, reauth), HIV (init), Chemo (init), Preop, MDS (init), HCV (init): Verify iron evaluation for adequate iron stores.

ERBITUX (S)

MEDICATION(S)

ERBITUX 100 MG/50 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Head and Neck Cancer: Diagnosis of locally or regionally advanced squamous cell head and neck cancer and used in combination with radiation therapy, or diagnosis of recurrent or metastatic squamous cell head and neck cancer and 1 of the following: failure of platinum-based chemotherapy, or used in combination with 1 of the following: cisplatin (Platinol AQ), carboplatin (Paraplatin), cisplatin (Platinol AQ) plus 5-FU (Acrucil), or carboplatin (Paraplatin) plus 5-FU (Acrucil). Colorectal Cancer: Diagnosis of metastatic carcinoma of the colon or rectum. One of the following: Used in combination with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin, and irinotecan), OR failure or intolerance to irinotecan-based chemotherapy, oxaliplatin-based chemotherapy, or intensive therapy (eg, FOLFOX or FOLFIRI), OR used as monotherapy in patients not appropriate for intensive therapy. Tumor expresses wild-type KRAS gene and wild type NRAS gene. Non-Small Cell Lung Cancer (NSCLC): Diagnosis of recurrent or metastatic NSCLC stage IIIB or IV. One of the following: Used in combination with vinorelbine (Navelbine) and cisplatin (Platinol AQ), OR used as a single-agent for continuation maintenance therapy and Erbitux was given first-line with chemotherapy. ECOG performance status 0-2. Epidermal growth factor receptor (EGFR) expression by immunohistochemistry.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months.

OTHER CRITERIA

Approve for continuation of prior therapy.

ERIVEDGE (S)

MEDICATION(S)

ERIVEDGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Basal cell carcinoma: One of the following: A) Diagnosis of metastatic basal cell carcinoma OR B) Both of the following: 1) Diagnosis of locally advanced basal cell carcinoma AND 2) One of the following: a) Disease recurred following surgery or b) Patient is not a candidate for surgery and radiation.

AGE RESTRICTION

18 years of age or older

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ESBRIET (S)

MEDICATION(S)

ESBRIET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Idiopathic pulmonary fibrosis (IPF) (initial): Both of the following: 1) diagnosis of IPF as documented by all of the following: a) exclusion of other known causes of interstitial lung disease (ILD) (eg, domestic and occupational environmental exposures, connective tissue disease, drug toxicity), AND b) one of the following: i) in patients not subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF, OR ii) in patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern revealing IPF or probable IPF, AND 2) not used in combination with Ofev (nintedanib).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

IPF (initial): Prescribed by a pulmonologist

COVERAGE DURATION

initial, reauth: 12 months

OTHER CRITERIA

IPF (reauth): Documentation of positive clinical response to Esbriet therapy

EXONDYS 51 (S)

MEDICATION(S)

EXONDYS 51

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Initial: Diagnosis of Duchenne muscular dystrophy (DMD). Documentation of a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. Patient is ambulatory. Initial/Reauth: Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

(initial, reauth): Prescribed by or in consultation with a neurologist who has experience treating children

COVERAGE DURATION

Initial: 6 months, Reauth: 12 months

OTHER CRITERIA

Reauth: One of the following: 1) All of the following: Patient has been on therapy for less than 12 months, patient is maintaining ambulatory status, and patient is tolerating therapy, OR 2) All of the following: Patient has been on therapy for 12 months or more, Patient is maintaining ambulatory status, patient has experienced a benefit from therapy (e.g., disease amelioration compared to untreated patients), and patient is tolerating therapy.

FABRAZYME (S)

MEDICATION(S)

FABRAZYME

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Fabry Disease: Diagnosis of Fabry disease.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Fabry Disease: 12 months

OTHER CRITERIA

N/A

FARYDAK (S)

MEDICATION(S)

FARYDAK

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Myeloma (MM): Diagnosis of MM. Used in combination with both of the following: Velcade (bortezomib) and dexamethasone. Patient has received at least two prior treatment regimens which included both of the following: Velcade (bortezomib) and an immunomodulatory agent [eg, Revlimid (lenalidomide), Thalomid (thalidomide)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

FENTANYL (S)

MEDICATION(S)

ABSTRAL, FENTANYL CIT OTFC 1,200 MCG, FENTANYL CIT OTFC 1,600 MCG, FENTANYL CITRATE OTFC 200 MCG, FENTANYL CITRATE OTFC 400 MCG, FENTANYL CITRATE OTFC 600 MCG, FENTANYL CITRATE OTFC 800 MCG

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

For the management of breakthrough cancer pain. Patient is currently taking a long-acting opioid around the clock for cancer pain. Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids: Morphine sulfate at doses of greater than or equal to 60 mg/day, Fentanyl transdermal patch at doses greater than or equal to 25 g/hr, Oxycodone at a dose of greater than or equal to 30 mg/day, Oral hydromorphone at a dose of greater than or equal to 8 mg/day, Oral oxymorphone at a dose of greater than or equal to 25 mg/day, or an alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 mg/day).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

FERRIPROX (S)

MEDICATION(S)

FERRIPROX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Transfusional iron overload due to thalassemia syndromes (Initial): Patient has a diagnosis of transfusional iron overload due to thalassemia syndromes. Absolute neutrophil count (ANC) greater than $1.5 \times 10^9/L$. One of the following: A) Patient has failed prior chelation therapy (e.g., Exjade) [failure defined as serum ferritin greater than 2,500 mcg/L] OR B) Patient has a contraindication or intolerance to Desferal (deferroxamine) or Exjade (deferasirox).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All uses (initial, reauth): 12 months

OTHER CRITERIA

All uses (reauth): Patient has experienced greater than or equal to 20% decline in serum ferritin levels from baseline. ANC greater than $0.5 \times 10^9/L$.

FIRAZYR (S)

MEDICATION(S)

FIRAZYR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Berinert, Kalbitor, or Ruconest).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HAE: Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

FIRMAGON (S)

MEDICATION(S)

FIRMAGON

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Diagnosis of advanced or metastatic prostate cancer.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

FOLOTYN (S)

MEDICATION(S)

FOLOTYN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Peripheral T-cell lymphoma: Diagnosis of relapsed or refractory PTCL

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

FORTEO (S)

MEDICATION(S)

FORTEO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Postmenopausal Osteoporosis or osteopenia or men with primary or hypogonadal osteoporosis or osteopenia: One of the following: A) Bone mineral density (BMD) T score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) or B) Both of the following: 1) BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and 2) either a history of one of the following fractures (fx) resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) OR failure, contraindication, or intolerance (F/C/I) to one bisphosphonate (BP) [e.g., Fosamax (alendronate)] or C) Both of the following: 1) One of the following: a) History of one of the following fx resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) or b) both diagnosis of osteopenia defined as BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) and one of the following FRAX 10-year probabilities: major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or hip fracture is 3% or more in the U.S., or the country-specific threshold in other countries or regions and 2) F/C/I to one BP [e.g., Fosamax (alendronate)]. Glucocorticoid-Induced Osteoporosis: Dx of glucocorticoid-induced osteoporosis. History of prednisone or equivalent at a dose of 5mg/day or greater for 3 months or greater.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All indications: 12 months, max 2 years of therapy.

OTHER CRITERIA

All indications: Treatment duration of parathyroid hormones (e.g., Forteo, Tymlos (abaloparatide)) has not exceeded a total of 24 months during the patient's lifetime. Glucocorticoid-Induced Osteoporosis: One of the following: A) BMD T score of -2.0 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) or B) Both of the following: 1) BMD T score between -1.0 and -2.0 (BMD T-score greater than -2.0 and less than or equal to -1.0) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and 2) either history of one of the following fx resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) or F/C/I to one BP [e.g., Fosamax (alendronate)] or C) Both of the following: 1) history of one of the following fx resulting from minimal trauma (vertebral compression fx, fx of the hip, or fx of the distal radius) and 2) F/C/I to one BP [e.g., Fosamax (alendronate)].

GAMASTAN S/D (S)

MEDICATION(S)

GAMASTAN S-D

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication).

REQUIRED MEDICAL INFORMATION

Immune globulin is being used intramuscularly. The immune globulin will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. Patient requires immunization for hepatitis A, measles, rubella, or varicella.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

3 months (Approve one dose only)

OTHER CRITERIA

Subject to Part B vs D review.

GATTEX (S)

MEDICATION(S)

GATTEX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Short Bowel Syndrome (SBS) (Initial) Diagnosis of SBS. Patient is dependent on parenteral nutrition/intravenous (PN/IV) support for at least 12 consecutive months.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

SBS (Init): 6 months. SBS (Reauth): 12 months.

OTHER CRITERIA

SBS (Reauth): Documentation of positive clinical response to Gattex therapy.

GILENYA (S)

MEDICATION(S)

GILENYA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

GILOTRIF (S)

MEDICATION(S)

GILOTRIF

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): A) Diagnosis of advanced or metastatic (stage IIIB or IV) NSCLC AND B) One of the following: 1) Both of the following: a) Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions, exon 21 (L858R) substitution, exon 18 (G719X, G719) or exon 20 (S7681) mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND b) GILOTRIF will be used as first-line treatment, OR 2) All of the following: a) disease progressed after platinum-based chemotherapy and b) squamous NSCLC

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

GLATIRAMER ACETATE (S)

MEDICATION(S)

COPAXONE, GLATOPA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

GLEEVEC (S)

MEDICATION(S)

IMATINIB MESYLATE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

For adults 18 years of age or older, One of the following: A) Diagnosis of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) AND Patient is found to be Ph+ or BCR-ABL positive as detected by bone marrow cytogenetics, FISH or PCR OR B) Ph+ acute lymphoblastic leukemia (ALL) OR C) Gastrointestinal stromal tumor (GIST) AND one of the following: 1) Patient has documented c-KIT (CD117) positive unresectable or metastatic malignant GIST, OR 2) Patient had resection of c-KIT (CD117) positive GIST and imatinib will be used as adjuvant therapy OR D) Dermatofibrosarcoma protuberans that is unresectable, recurrent, or metastatic OR E) Hypereosinophilic syndrome or chronic eosinophilic leukemia OR F) Myelodysplastic syndrome (MDS) or myeloproliferative disease associated with platelet-derived growth factor receptor gene rearrangements OR G) Aggressive systemic mastocytosis without the D816V c-KIT mutation or with c-KIT mutational status unknown. For Pediatric patients younger than 18 years of age, One of the following: A) Diagnosis of Ph+ CML that is newly diagnosed in the chronic phase OR B) Diagnosis of newly diagnosed Ph+ALL.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION

All uses: 12 months

OTHER CRITERIA

All uses: Approve for continuation of prior therapy.

GRANIX (S)

MEDICATION(S)

GRANIX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with a history of FN during a previous course of chemotherapy. All indications: History of failure or intolerance to Zarxio (filgrastim-sndz).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses: Prescribed by or in consultation with a hematologist/oncologist or infectious disease specialist

COVERAGE DURATION

CFN, secondary prophylaxis of FN:3mo or duration of tx

OTHER CRITERIA

N/A

GROWTH HORMONE (S)

MEDICATION(S)

GENOTROPIN, HUMATROPE, NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NUTROPIN AQ NUSPIN, OMNITROPE 10 MG/1.5 ML CRTG, OMNITROPE 5 MG/1.5 ML CRTG, SAIZEN, SAIZEN-SAIZENPREP

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

PGHD(initial):less than 4mo w/GD,or hx neonatal hypoglycemia assoc w/pituitary dz,or panhypopituitarism dx,or all of the following: PGHD dx [confrmd by ht (utilizing age and gender grwth charts related to ht) documented(doc) by ht more than 2.0SD below midparental ht or more than 2.25SD below population(pop) mean (below 1.2 percentile for age and gender),or grwth velocity more than 2SD below mean for age and gender, or delayed skeletal maturation more than 2SD below mean for age and gender (eg,delayed more than 2yrs compared w/chronological age)], and ped GH dosing used as defined by PI. PWS(reauth):evidence of positive response to tx(eg,incr in total LBM, decr in fat mass),or ht incr at least 2cm/yr over previous yr of tx (doc by previous ht and date and current ht and date) and expctd adult ht not attained and doc of expctd adult ht goal. GFSGA(initial):SGA dx based on catchup grwth failure in 1st 24mo of life using 0-36mo grwth chart confrmd by birth wt or length below 3rd percentile for gestational age(more than 2SD below pop mean) and ht remains at or below 3rd percentile (more than 2SD below pop mean). TS,NS(initial):ped grwth failure dx assoc w/TS w/doc female w/bone age less than 14yrs, or NS and ht below 5th percentile on grwth charts for age and gender. SHOX(initial):ped grwth failure dx w/SHOX gene deficiency confirmed by genetic testing. GFCRI(initial): ped grwth failure dx assoc w/CRI. ISS(initial):ISS dx, diagnostic eval excluded other causes assoc w/short stature(eg GHD, chronic renal insufficiency), doc ht at or below -2.25SD score below corresponding mean ht for age and gender, doc grwth velocity less than 25th percentile for bone age. PGHD,NS,SHOX,GFCRI,ISS (initial): doc male w/bone age less than 16yrs or female w/bone age less than 14yrs. PGHD,GFSGA,TS/NS,SHOX,GFCRI,ISS(reauth):ht incr of at least 2 cm/yr over previous yr of tx (doc by previous ht and date and current ht and date) and expctd adult ht not attained and doc of expctd adult ht goal.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PGHD, PWS, GFSGA, TS/NS, SHOX, AGHD, TPAP, IGHDA, ISS: prescribed by endocrinologist.

GFCRI: prescribed by endocrinologist or nephrologist

COVERAGE DURATION

All indications (initial, reauth): 12 months

OTHER CRITERIA

All(init): No prerequisites needed for Genotropin and Nutropin. All others: h/o failure or intolerance to Genotropin and Nutropin. AGHD(initial):dx of AGHD with clin records supporting dx of childhood-onset GHD, or adult-onset GHD w/clin records doc hormone deficiency d/t hypothalamic-pituitary dz from organic or known causes (eg,damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and pt has 1GH stim test (insulin tolerance test [ITT], arginine/GHRH,glucagon,arginine) to confirm adult GHD w/peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or doc deficiency of 3 anterior pituitary hormones (prolactin,ACTH,TSH,FSH/LH) and IGF-1/somatomedinC below age and gender adjstd nrml range as provided by physicians lab.

AGHD(init,reauth):panhypopituitarism OR other dx and not used in combo w/aromatase inhibitors(eg,anastrozole,letrozole) or androgens(eg,testosterone cypionate), and adult dosing used as def by PI. AGHD,IGHDA(reauth):monitoring as demonstrated by doc w/in past 12mo of IGF-1/somatomedinC level. TransitionPhaseAdolescent Pts(TPAP)(initial):adult GH dosing used as def by PI/AACE 2009 tx GL, attained expctd adult ht or closed epiphyses on bone radiograph, and doc high risk of GHD d/t GHD in childhood (from embryopathic/congenital defects, genetic mutations, irreversible structural hypothalamic-pituitary dz, panhypopituitarism, or deficiency of 3 anterior pituitary hormones:ACTH,TSH,prolactin,FSH/LH), w/IGF-1/somatomedinC below age and gender adj nrml range as provided by physicians lab, or pt does not have low IGF-1/somatomedinC and d/c GH tx for at least 1mo, and pt has 1 GH stim test (ITT,GHRH+ARG,ARG,glucagon) after d/c of tx for at least 1mo w/peak GH value [ITT at or below 5mcg/L], [GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2], [glucagon at or below 3mcg/L], [Arg at or below 0.4mcg/L], or at low risk of severe GHD(eg d/t isolated and/or idiopathic GHD) and d/c GH tx for at least 1mo, and pt has 1 GH stim test (ITT, GHRH+ARG, ARG, glucagon) after d/c of tx for at least 1mo w/corresponding peak GH value [ITT at or below 5mcg/L], [GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2], [glucagon at or below 3mcg/L], [Arg at or below 0.4mcg/L]. TPAP(reauth): evidence of positive response to therapy (eg,incr in total lean body mass, exercise capacity or IGF-1 and IGFBP-3), and cont adult GH dosing used as def by PI/AACE 2009 tx GL. IGHDA(initial):doc GHD by failure to produce peak serum GH greater than 5 mcg/L after 2 provocative pharmacol stim tests(insulin,L-ARG,glucagon).

H.P. ACTHAR GEL (S)

MEDICATION(S)

H.P. ACTHAR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Infantile Spasm (West Syndrome): Diagnosis of infantile spasms (West Syndrome). Multiple Sclerosis (MS): Acute exacerbations of MS. Rheumatic disorders: As adjunctive therapy for short-term administration in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis). Dermatologic diseases: Severe erythema multiforme, Stevens-Johnson syndrome. Allergic states: Serum sickness. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation. Respiratory diseases: Symptomatic sarcoidosis. Edematous state: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. All indications except for infantile spasms: History of failure, contraindication, or intolerance to treatment with two corticosteroids.

AGE RESTRICTION

Infantile spasms: less than 2 years old

PRESCRIBER RESTRICTION

Infantile Spasm, MS: neurologist. Rheumatic disorder, collagen disease: rheumatologist. Dermatologic: dermatologist. Allergic state: allergist, immunologist. Ophthalmic disease: optometrist, ophthalmologist. Respiratory diseases: pulmonologist. Edematous state: nephrologist, rheumatologist.

COVERAGE DURATION

Infantile Spasms: 4 weeks. MS: 3 weeks. All other FDA-approved uses: 3 months.

OTHER CRITERIA

N/A

HALAVEN (S)

MEDICATION(S)

HALAVEN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast Cancer: Diagnosis of recurrent or metastatic breast cancer. Previous treatment with both of the following: one anthracycline [eg, doxorubicin, Ellence (epirubicin)] and one taxane [eg, paclitaxel, Taxotere (docetaxel)]. Liposarcoma: Diagnosis of unresectable or metastatic liposarcoma. Previous treatment with one anthracycline-containing regimen.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Uses: prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

HARVONI (S)

MEDICATION(S)

HARVONI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND B) Patient is not receiving Harvoni in combination with another HCV direct acting antiviral agent [eg, Sovaldi (sofosbuvir), Olysio (simeprevir)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 to 24 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

HERCEPTIN (S)

MEDICATION(S)

HERCEPTIN 440 MG VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. One of the following treatment regimens: a) As adjuvant treatment, b) metastatic disease and one of the following: 1) used in combination with a taxane (eg, docetaxel, paclitaxel), or 2) used as a single agent in a patient who has received one or more chemotherapy regimens for metastatic disease, or c) used in combination with Perjeta (pertuzumab). Gastric Cancer: Diagnosis of HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma (locally advanced, recurrent, or metastatic). Used in combination with one of the following treatment regimens: a) Adrucil (5-fluorouracil), or b) Platinol (cisplatin) and Xeloda (capecitabine).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

HETLIOZ (S)

MEDICATION(S)

HETLIOZ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-24-Hour Sleep-Wake Disorder (Non-24) (initial): Both of the following: 1) Diagnosis of non-24-hour sleep-wake disorder (also known as free-running disorder, free-running or non-entrained type circadian rhythm sleep disorder, or hypernycthemeral syndrome), AND 2) patient is totally blind (has no light perception).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Non-24 (initial): Prescribed by or in consultation with a specialist in sleep disorders or neurologist

COVERAGE DURATION

Non-24 (initial): 6 mo. (reauth): 12 mo

OTHER CRITERIA

Non-24 (reauth): Documentation of positive clinical response to HetlioZ therapy.

HRM - ANTIHISTAMINES

MEDICATION(S)

CYPROHEPTADINE 2 MG/5 ML SYRUP, CYPROHEPTADINE 4 MG TABLET, CYPROHEPTADINE 4 MG/10 ML SYRUP, HYDROXYZINE 10 MG/5 ML SOLN, HYDROXYZINE 10 MG/5 ML SYRUP, HYDROXYZINE 100 MG/2 ML VIAL, HYDROXYZINE 25 MG/ML VIAL, HYDROXYZINE 50 MG/25 ML SYRUP, HYDROXYZINE 50 MG/ML VIAL, HYDROXYZINE 500 MG/10 ML VIAL, HYDROXYZINE HCL 10 MG TABLET, HYDROXYZINE HCL 25 MG TABLET, HYDROXYZINE HCL 50 MG TABLET, HYDROXYZINE PAM 100 MG CAP, HYDROXYZINE PAM 25 MG CAP, HYDROXYZINE PAM 50 MG CAP, PHENADOZ 12.5 MG SUPPOSITORY, PHENERGAN 12.5 MG SUPPOSITORY, PHENERGAN 25 MG SUPPOSITORY, PHENERGAN 50 MG SUPPOSITORY, PROMETHAZINE 12.5 MG SUPPOS, PROMETHAZINE 12.5 MG TABLET, PROMETHAZINE 25 MG SUPPOSITORY, PROMETHAZINE 25 MG TABLET, PROMETHAZINE 25 MG/ML AMPUL, PROMETHAZINE 25 MG/ML VIAL, PROMETHAZINE 50 MG SUPPOSITORY, PROMETHAZINE 50 MG TABLET, PROMETHAZINE 50 MG/ML AMPUL, PROMETHAZINE 50 MG/ML VIAL, PROMETHAZINE 6.25 MG/5 ML SYRUP, PROMETHAZINE VC, PROMETHAZINE-PHENYLEPHRINE, PROMETHEGAN 25 MG SUPPOSITORY, PROMETHEGAN 50 MG SUPPOSITORY

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

PAGE 93
HPMS Approved Formulary ID: 00017485 Version 23

LAST UPDATED 12/2017

N/A

HRM - ANTIHYPERTENSIVE AGENTS

MEDICATION(S)

GUANFACINE HCL, METHYLDOPA, METHYLDOPA-HYDROCHLOROTHIAZIDE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Trial, intolerance or contraindication to at least one Non-HRM alternative: Low dose thiazide or a second generation calcium channel blocker OR ACE inhibitor, ARB, beta-blocker or combination product based on specific chronic conditions

HRM - ANTIPARKINSON AGENTS

MEDICATION(S)

BENZTROPINE MES 0.5 MG TAB, BENZTROPINE MES 1 MG TABLET, BENZTROPINE MES 2 MG TABLET, TRIHEXYPHENIDYL HCL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

HRM - ANTIPSYCHOTICS

MEDICATION(S)

THIORIDAZINE HCL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Applies to New Starts only. Requires trial of at least one Non-HRM alternative: haloperidol, atypical antipsychotic

HRM - BARBITURATES

MEDICATION(S)

BUTALBITAL-ACETAMINOPHN 50-325, BUTALBITAL-ASA-CAFFEINE CAP, PHENOBARBITAL 100 MG TABLET, PHENOBARBITAL 15 MG TABLET, PHENOBARBITAL 16.2 MG TABLET, PHENOBARBITAL 20 MG/5 ML ELIX, PHENOBARBITAL 20 MG/5 ML SOLN, PHENOBARBITAL 30 MG TABLET, PHENOBARBITAL 32.4 MG TABLET, PHENOBARBITAL 60 MG TABLET, PHENOBARBITAL 64.8 MG TABLET, PHENOBARBITAL 97.2 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Verify the medication is being used for an FDA-approved diagnosis AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Phenobarbital, pentobarbital: Approve for continuation of therapy.

HRM - CARDIOVASCULAR, ANTI-ARRHYTHMICS

MEDICATION(S)

DIGITEK 250 MCG TABLET, DIGOX 250 MCG TABLET, DIGOXIN 0.05 MG/ML SOLUTION, DIGOXIN 0.25 MG TABLET, DIGOXIN 0.25 MG/ML SYRINGE, DIGOXIN 250 MCG TABLET, DIGOXIN 500 MCG/2 ML AMPULE, DISOPYRAMIDE PHOSPHATE, LANOXIN 187.5 MCG TABLET, LANOXIN 250 MCG TABLET, NORPACE CR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

HRM - CARDIOVASCULAR, CALCIUM CHANNEL BLOCKER

MEDICATION(S)

NIFEDIPINE 10 MG CAPSULE, NIFEDIPINE 20 MG CAPSULE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Trial, intolerance or contraindication to at least one Non-HRM alternative: extended-release nifedipine, nicardipine, amlodipine

HRM - DEMENTIA AGENTS

MEDICATION(S)

ERGOLOID MESYLATES 1 MG TAB

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Trial, intolerance or contraindication to at least one Non-HRM alternative: donepezil, galantamine, rivastigmine, memantine

MEDICATION(S)

MEGESTROL 20 MG TABLET, MEGESTROL 40 MG TABLET, MEGESTROL 625 MG/5 ML SUSP,
MEGESTROL ACET 40 MG/ML SUSP, MEGESTROL ACET 400 MG/10 ML

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Applies to New Starts only.

HRM - ENDOCRINE, ORAL AND TRANSDERMAL ESTROGENS AND PROGESTINS

MEDICATION(S)

AMABELZ, CLIMARA PRO, COMBIPATCH, ESTRADIOL 0.025 MG PATCH, ESTRADIOL 0.0375 MG PATCH, ESTRADIOL 0.0375 MG/DAY PATCH, ESTRADIOL 0.05 MG PATCH, ESTRADIOL 0.06 MG/DAY PATCH, ESTRADIOL 0.075 MG PATCH, ESTRADIOL 0.075 MG/DAY PATCH, ESTRADIOL 0.1 MG PATCH, ESTRADIOL 0.5 MG TABLET, ESTRADIOL 1 MG TABLET, ESTRADIOL 2 MG TABLET, ESTRADIOL TDS 0.025 MG/DAY, ESTRADIOL TDS 0.0375 MG/DAY, ESTRADIOL TDS 0.05 MG/DAY, ESTRADIOL TDS 0.06 MG/DAY, ESTRADIOL TDS 0.075 MG/DAY, ESTRADIOL TDS 0.1 MG/DAY, ESTRADIOL-NORETHINDRONE ACETAT, ESTROPIPATE, FYAVOLV, JINTELI, MENEST 0.3 MG TABLET, MENEST 0.625 MG TABLET, MENEST 1.25 MG TABLET, MIMVEY, MIMVEY LO, NORETHIN-ETH ESTRAD 1 MG-5 MCG, NORETHIND-ETH ESTRAD 0.5-2.5, PREMARIN 0.3 MG TABLET, PREMARIN 0.45 MG TABLET, PREMARIN 0.625 MG TABLET, PREMARIN 0.9 MG TABLET, PREMARIN 1.25 MG TABLET, PREMPHASE, PREMPRO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Menest only: Approve for continuation of therapy. Estrace/estradiol and Premarin only (dx of breast cancer and prostatic carcinoma only): Approve for continuation of therapy.

MEDICATION(S)

TRIMETHOBENZAMIDE 300 MG CAP

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Trimethobenzamide: Subject to Part B vs. Part D review.

HRM - PAIN MEDICATIONS

MEDICATION(S)

ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALB-CAFF-ACETAMINOPH-CODEIN, BUTALBITAL COMPOUND-CODEINE, BUTALB-ACETAMIN-CAFF 50-325-40, BUTALBIT-ACETAMINOPHEN-CAFF CP, INDOMETHACIN 25 MG CAPSULE, INDOMETHACIN 50 MG CAPSULE, INDOMETHACIN ER, KETOROLAC 10 MG TABLET, KETOROLAC 15 MG/ML VIAL, KETOROLAC 30 MG/ML CARPUJECT, KETOROLAC 30 MG/ML VIAL, KETOROLAC 60 MG/2 ML CARPUJECT, PENTAZOCINE-NALOXONE HCL, TENCON, VANATOL LQ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Trial, intolerance or contraindication to at least one Non-HRM alternative: Mild pain: acetaminophen, codeine. Moderate to severe pain: short-term NSAIDs, tramadol, tramadol/APAP, morphine sulfate, hydrocodone/APAP, oxycodone, oxycodone/APAP, fentanyl.

HRM - PLATELET INHIBITORS

MEDICATION(S)

DIPYRIDAMOLE 25 MG TABLET, DIPYRIDAMOLE 50 MG TABLET, DIPYRIDAMOLE 75 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Requires trial of at least one Non-HRM alternative: clopidogrel, Aggrenox

HRM - SEDATIVE HYPNOTIC AGENTS

MEDICATION(S)

ESZOPICLONE, ZALEPLON, ZOLPIDEM TARTRATE, ZOLPIDEM TART ER 6.25 MG TAB

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) when used longer than 90 days and wishes to proceed with the originally prescribed medication AND intended duration of therapy will be verified.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

HRM - SKELETAL MUSCLE RELAXANTS

MEDICATION(S)

CHLORZOXAZONE 500 MG TABLET, CYCLOBENZAPRINE 10 MG TABLET, CYCLOBENZAPRINE 5 MG TABLET, CYCLOBENZAPRINE 7.5 MG TABLET, METHOCARBAMOL 500 MG TABLET, METHOCARBAMOL 750 MG TABLET, ORPHENADRINE ER 100 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

HRM - SULFONYLUREAS

MEDICATION(S)

GLYBURIDE 1.25 MG TABLET, GLYBURIDE 2.5 MG TABLET, GLYBURIDE 5 MG TABLET, GLYBURIDE MICRONIZED, GLYBURIDE-METFORMIN HCL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (listed in OTHER CRITERIA) unless alternative(s) is/are contraindicated or inappropriate for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Trial, intolerance or contraindication to at least one Non-HRM alternative: glimepiride, glipizide

MEDICATION(S)

AMITRIPTYLINE HCL 10 MG TAB, AMITRIPTYLINE HCL 100 MG TAB, AMITRIPTYLINE HCL 150 MG TAB, AMITRIPTYLINE HCL 25 MG TAB, AMITRIPTYLINE HCL 50 MG TAB, AMITRIPTYLINE HCL 75 MG TAB, CHLORDIAZEPOXIDE-AMITRIPTYLINE, CLOMIPRAMINE 25 MG CAPSULE, CLOMIPRAMINE 50 MG CAPSULE, CLOMIPRAMINE 75 MG CAPSULE, DOXEPIN 10 MG CAPSULE, DOXEPIN 10 MG/ML ORAL CONC, DOXEPIN 100 MG CAPSULE, DOXEPIN 150 MG CAPSULE, DOXEPIN 25 MG CAPSULE, DOXEPIN 50 MG CAPSULE, DOXEPIN 75 MG CAPSULE, IMIPRAMINE HCL 10 MG TABLET, IMIPRAMINE HCL 25 MG TABLET, IMIPRAMINE HCL 50 MG TABLET, IMIPRAMINE PAMOATE, PERPHENAZINE-AMITRIPTYLINE, TRIMIPRAMINE MALEATE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication .

AGE RESTRICTION

PA applies to patients 65 years or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Applies to New Starts only.

HUMIRA (S)

MEDICATION(S)

HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN-UC-HS STARTER, HUMIRA PEN PSORIASIS-UVEITIS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Failure, contraindication, or intolerance (F/C/I) to one disease modifying antirheumatic drug (DMARD) [eg, methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]. Juvenile Idiopathic Arthritis (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. F/C/I to one of the following DMARDs: Arava (leflunomide) or methotrexate (Rheumatrex/Trexall). Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. F/C/I to two NSAIDs. Crohn's Disease (CD) (Initial): Diagnosis of moderately to severely active CD. F/C/I to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex/Trexall), or failure (ie, lost response) or intolerance to Remicade (infliximab). Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. F/C/I to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), aminosalicylate [eg, mesalamine (Asacol, Pentasa, Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)]. Hidradenitis suppurativa (Initial): Diagnosis of moderate to severe hidradenitis suppurativa (ie, Hurley Stage II or III). All indications (initial, reauth): Patient is not receiving Humira in combination with a biologic DMARD [eg, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]. Patient is not receiving Humira in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]. For a diagnosis of PsA or plaque psoriasis, Patient is not receiving Humira in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA, AS, JIA (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by

or in consultation with a dermatologist or rheumatologist. Plaque Psoriasis, HS (Initial): Prescribed by or in consultation with a dermatologist. CD, UC (Initial): Prescribed by or in consultation with a gastroenterologist. Uveitis (initial): Prescribed by or in consultation with an ophthalmologist or rheumatologist.

COVERAGE DURATION

UC (Initial): 12 wks. UC (reauth): 12 mo. All other indications (initial, reauth): 12 mo.

OTHER CRITERIA

RA, JIA, PsA, Plaque psoriasis, AS, CD, Hidradenitis suppurativa (HS) (Reauth): Documentation of positive clinical response to Humira therapy. UC (Reauth): For patients who initiated Humira therapy within the past 12 weeks: Documentation of clinical remission or significant clinical benefit by eight weeks (Day 57) of therapy OR For patients who have been maintained on Humira therapy for longer than 12 weeks: Documentation of positive clinical response to Humira therapy. Uveitis (initial): Diagnosis of non-infectious uveitis, classified as intermediate, posterior, or panuveitis. Uveitis (initial and reauth): Patient is not receiving Humira in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

HYDROXYPROGESTERONE (S)

MEDICATION(S)

HYDROXYPROGESTERONE 1.25 G/5ML

COVERED USES

All medically accepted indications not otherwise excluded from Part D

EXCLUSION CRITERIA

All uses (initial): Pregnant patients.

REQUIRED MEDICAL INFORMATION

Amenorrhea: Diagnosis of primary or secondary amenorrhea. Amenorrhea is due to hormonal imbalance in the absence of organic pathology (e.g., submucous fibroids or uterine cancer) Secretory endometrium and desquamation: Used for production of secretory endometrium and desquamation in patients with endometrial disorder. Adenocarcinoma: Diagnosis of Stage III or IV adenocarcinoma of the uterine corpus. Estrogen production test: Used for the testing of endogenous estrogen production.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Adenocarcinoma (initial): Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Renewal (All uses): For continuation of therapy

IBRANCE (S)

MEDICATION(S)

IBRANCE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast Cancer: Diagnosis of breast cancer. Disease is a) locally advanced or metastatic, b) estrogen-receptor (ER)-positive, and c) human epidermal growth factor receptor 2 (HER2)-negative. One of the following: a) used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) and patient is a postmenopausal woman, OR b) all of the following: used in combination with Faslodex (fulvestrant), disease has progressed following endocrine therapy, and one of the following: 1) patient is a postmenopausal woman OR 2) both of the following: patient is a premenopausal or perimenopausal woman and patient is receiving a luteinizing hormone-releasing hormone (LHRH) agonist [eg, Zoladex (goserelin)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ICLUSIG (S)

MEDICATION(S)

ICLUSIG

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic myelogenous leukemia: Diagnosis of chronic myelogenous leukemia AND One of the following: A) History of failure, resistance, relapse, contraindication, or intolerance to at least TWO other tyrosine kinase inhibitors (i.e., GLEEVEC [imatinib], SPRYCEL, TASIGNA, and BOSULIF), or B) Patient has the T315I mutation. Acute Lymphoblastic Leukemia: Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) AND One of the following: A) History of failure, resistance relapse, contraindication, or intolerance to at least TWO other FDA-approved tyrosine kinase inhibitors (i.e., GLEEVEC [imatinib], SPRYCEL), or B) Patient has the T315I mutation.

AGE RESTRICTION

All Uses: 18 years of age or older

PRESCRIBER RESTRICTION

All Uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION

All uses: 12 months

OTHER CRITERIA

All uses: Approve for continuation of prior therapy.

IDHIFA (S)

MEDICATION(S)

IDHIFA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acute Myeloid Leukemia (AML): Diagnosis of AML. Disease is relapsed or refractory. Patient has an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH2 assay) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ILARIS (S)

MEDICATION(S)

ILARIS 180 MG VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Periodic Fever Syndromes (Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF)). (Initial) Diagnosis of one of the autoinflammatory Periodic Fever Syndromes: CAPS (including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS)), TRAPS, HIDS/MKD, or FMF, AND The medication will not be used in combination with another biologic agent. Systemic juvenile idiopathic arthritis (sJIA) (Initial): Diagnosis of active sJIA AND The medication will not be used in combination with another biologic

AGE RESTRICTION

SJIA (initial): 2 years of age or older

PRESCRIBER RESTRICTION

Periodic Fever Syndromes (CAPS, TRAPS, HIDS/MKD, FMF) (initial): Prescribed by or in consultation with an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist

COVERAGE DURATION

All indications (initial, reauth): 12 months

OTHER CRITERIA

Periodic Fever Syndrome (CAPS, TRAPS, HIDS/MKD, FMF) ((Reauth) and SJIA (Reauth): Documentation of positive clinical response to therapy.

IMBRUVICA (S)

MEDICATION(S)

IMBRUVICA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Mantle cell lymphoma (MCL): Diagnosis of MCL AND patient has relapsed or is refractory to at least one prior therapy for the treatment of MCL. Chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Waldenstrom's macroglobulinemia: Diagnosis of Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma. Small lymphocytic lymphoma (SLL): Diagnosis of SLL. Marginal zone lymphoma (MZL): Diagnosis of MZL AND patient has received at least one prior anti-CD20-based therapy for MZL [e.g., Rituxan (rituximab), Zevalin (ibritumomab), Gazyva (obinutuzumab, etc.)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION

All Uses: 12 months

OTHER CRITERIA

All Uses: Approve for continuation of prior therapy.

IMFINZI (S)

MEDICATION(S)

IMFINZI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Urothelial carcinoma: 1) Diagnosis of locally advanced or metastatic urothelial carcinoma AND 2) One of the following: a) Patient has experienced disease progression during or following platinum-containing chemotherapy OR b) Patient has experienced disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

INFLECTRA (S)

MEDICATION(S)

INFLECTRA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (initial): Dx of moderately to severely active CD or FCD. Ulcerative colitis (UC) (initial): Dx of moderately to severely active UC. Rheumatoid arthritis (RA) (initial): Diagnosis (Dx) of moderately to severely active RA. Ankylosing spondylitis (AS) (initial): Dx of active AS. Psoriatic arthritis (PsA) (initial): Dx of active PsA. Plaque psoriasis (initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis. Reauthorization for all indications: Documentation of positive clinical response to infliximab therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA, AS: Prescribed or recommended by a rheumatologist. PsA: Prescribed or recommended by rheumatologist or dermatologist. Crohn's Disease, Fistulizing Crohn's Disease, UC: Prescribed or recommended by a gastroenterologist. Plaque Psoriasis: Prescribed or recommended by a dermatologist.

COVERAGE DURATION

All indications (initial, reauth): 12 months

OTHER CRITERIA

CD, FCD (initial): Failure, contraindication or intolerance to one of the following conventional therapies: 6-mercaptopurine (Purinethol), azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex, Trexall). History of failure, contraindication or intolerance to Remicade, unless already receiving Inflectra. UC (initial): Failure, contraindication or intolerance to one of the following conventional therapies: corticosteroids, aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine/Sulfazine)], azathioprine (Imuran), 6-mercaptopurine (Purinethol). History of failure, contraindication or intolerance

to Remicade, unless already receiving Inflectra. RA (initial): Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), or failure, contraindication or intolerance to methotrexate. AS (initial): Failure, contraindication or intolerance to two or more NSAIDs. History of failure, contraindication or intolerance to Remicade, unless already receiving Inflectra. All indications (Initial and re-auth): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)] or Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

INGREZZA (S)

MEDICATION(S)

INGREZZA 40 MG CAPSULE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Tardive Dyskinesia (initial): Diagnosis of moderate to severe tardive dyskinesia. One of the following:
a) patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication OR b) patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with a neurologist or psychiatrist.

COVERAGE DURATION

Initial: 3 months, Reauth: 12 months

OTHER CRITERIA

Tardive Dyskinesia (reauth): Documentation of positive clinical response to Ingrezza therapy.

INLYTA (S)

MEDICATION(S)

INLYTA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Renal cell cancer (RCC): Diagnosis of RCC. One of the following: (1) disease has relapsed or (2) both of the following: medically or surgically unresectable tumor and diagnosis of stage IV disease.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

INTRON A (S)

MEDICATION(S)

INTRON A

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic hepatitis B: Diagnosis of chronic hepatitis B infection, and patient is without decompensated liver disease. Chronic Hepatitis C: Diagnosis of chronic hepatitis C, patient without decompensated liver disease, patient has not previously been treated with interferon, and one of the following - 1) used in combination with ribavirin or 2) contraindication or intolerance to ribavirin. Metastatic renal cell carcinoma (RCC): diagnosis of metastatic RCC, used in combination with Avastin (bevacizumab). Other: diagnosis of condylomata acuminata (genital or perianal), diagnosis of hairy cell leukemia, diagnosis of AIDS-related Kaposi sarcoma, diagnosis of malignant melanoma, diagnosis of Stage III or IV follicular Non-Hodgkins Lymphoma, as maintenance therapy for the treatment of multiple myeloma.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RCC: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

HepB, HepC: 48 wks. Condylomata acuminata (genital or perianal): 6 wks. Other: 12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

MEDICATION(S)

IRESSA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC AND Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ISOTRETINOIN (S)

MEDICATION(S)

CLARAVIS, MYORISAN, ZENATANE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acne (initial): Diagnosis of acne. History of failure, contraindication or intolerance to an adequate trial (at least 6 weeks) on both of the following conventional therapy regimens: a) topical retinoid or retinoid-like agent [eg, Retin-A/Retin-A Micro (tretinoin)] AND b) combination therapy with benzoyl peroxide and one of the following: 1) oral antibiotic [eg, Ery-Tab (erythromycin), Minocin (minocycline)] OR 2) topical antibiotic with or without benzoyl peroxide [eg, Cleocin-T (clindamycin), erythromycin, BenzaClin (benzoyl peroxide/clindamycin), Benzamycin (benzoyl peroxide/erythromycin)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Acne (Initial): Prescribed by a dermatologist

COVERAGE DURATION

Acne (initial, reauth): 5 months

OTHER CRITERIA

Acne (reauth): One of the following: A) After more than 2 months off therapy, persistent or recurring severe recalcitrant nodular acne is still present, OR B) the total cumulative dose is less than 150 mg/kg (will be approved up to a total of 150 mg/kg).

ISTODAX (S)

MEDICATION(S)

ISTODAX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cutaneous T-cell lymphoma (CTCL): Diagnosis of CTCL. Patient has tried and had an inadequate response, intolerance or contraindication to at least one prior therapy (eg, retinoids, corticosteroids).
Peripheral T-cell lymphoma (PTCL): Diagnosis of PTCL. Patient has tried and had an inadequate response, intolerance or contraindication to at least one prior therapy (eg, conventional chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone), Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate and cytarabine).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

CTCL, PTCL: Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

IVIG (S)

MEDICATION(S)

BIVIGAM, CARIMUNE NF NANOFILTERED, FLEBOGAMMA DIF 10% VIAL, GAMMAGARD LIQUID, GAMMAGARD S-D, GAMMAKED, GAMMAPLEX, GAMUNEX, GAMUNEX-C, OCTAGAM, PRIVIGEN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

All uses (initial, reauth): Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication). Privigen only: Hyperprolinemia. Octagam only: Allergy to corn. Gammaplex only: Hereditary intolerance to fructose. Infants for whom sucrose or fructose tolerance has not been established.

REQUIRED MEDICAL INFORMATION

Initial: Immune globulin (Ig) will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. For IVIG Ig is being used intravenously (IV) AND One of the following diagnoses: [A] Primary Immunodeficiency 1) Common variable immunodeficiency. 2) Congenital agammaglobulinemia (X-linked or autosomal recessive). 3) Severe combined immunodeficiencies. 4) Wiskott-Aldrich syndrome. OR 5) Other PI with an immunologic evaluation including IgG levels below the normal laboratory value for the patients age at the time of diagnosis and the patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine). [B] Secondary Acquired Antibody Deficiency 1) B-cell chronic lymphocytic leukemia with an Ig level less than 500 mg/dL OR history of recurrent bacterial infections. 2) HIV infection with an Ig level less than 400 mg/dL OR Patient has active bleeding or a platelet count less than $10 \times 10^9/L$. 3) Multiple myeloma in plateau phase and patient has hypogammaglobulinemia. [C] Hematological Autoimmune Disorders 1) Acquired (pure) red cell aplasia (PRCA) that is immunologic and patient had failure, contraindication, or intolerance (F/C/I) to a corticosteroid and an immunosuppressant (i.e., cyclophosphamide, cyclosporine) OR patient has viral PRCA caused by parvovirus B19. 2) Fetal alloimmune thrombocytopenia. 3) Hemolytic disease of the newborn and the patient has established hyperbilirubinemia. 4) Idiopathic thrombocytopenic purpura and patient had F/C/I to a corticosteroid OR a platelet count less than 30,000 cells/mm³. 5) Post-transfusion purpura. Continued in Other Criteria Section.

AGE RESTRICTION

HIV (initial): patient is less than or equal to 12 years of age.

PRESCRIBER RESTRICTION

All uses (initial, reauth): Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g., immunologist, hematologist, neurologist, etc.).

COVERAGE DURATION

4 months: Solid organ transplant. 12 months: all other diagnoses.

OTHER CRITERIA

[D] Neuromuscular Autoimmune Disorders 1) Chronic inflammatory demyelinating polyneuropathy. 2) Guillain-Barr syndrome. 3) Inflammatory myopathies (dermatomyositis and polymyositis) AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (i.e., azathioprine, methotrexate, cyclosporine A, cyclophosphamide, or tacrolimus). 4) Lambert-Eaton myasthenic syndrome AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (e.g., azathioprine). 5) Multifocal motor neuropathy. 6) Myasthenia gravis with severe exacerbations or myasthenic crises AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (i.e., azathioprine, cyclosporine, cyclophosphamide, or mycophenolate mofetil). 7) Stiff person syndrome AND Patient had F/C/I to at least 2 standard therapies (i.e., benzodiazepines, muscle relaxants, or anti-convulsants). [E] Other Disorders 1) Autoimmune blistering disease AND Patient had F/C/I to a corticosteroid AND an immunosuppressant (i.e., cyclophosphamide, dapson, methotrexate, azathioprine, or mycophenolate mofetil). 2) Kawasaki syndrome. 3) Solid organ transplant and IVIG is being used for CMV prophylaxis, or patient is a kidney transplant recipient and has donor specific antibodies, or patient has steroid-resistant rejection and had F/C/I to standard therapies. For SCIG (Gamunex-C, Gammagard Liquid, Gammaked only)- Immune globulin is being used subcutaneously AND One of the following PI diagnoses: 1) Common variable immunodeficiency. 2) Congenital agammaglobulinemia (X-linked or autosomal recessive). 3) Severe combined immunodeficiencies. 4) Wiskott-Aldrich syndrome. OR 5) Other PI with an immunologic evaluation including IgG levels below the normal laboratory value for the patients age at the time of diagnosis and patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine). All products: Subject to Part B vs. Part D review. For non-oncology renewal, the patient has experienced an objective improvement on immune globulin therapy and the immune globulin will be administered at the minimum effective dose (by decreasing the dose, increasing the frequency, or implementing both strategies) for maintenance therapy.

JAKAFI (S)

MEDICATION(S)

JAKAFI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Myelofibrosis: Diagnosis of primary myelofibrosis, OR post-polycythemia vera myelofibrosis, OR post-essential thrombocythemia myelofibrosis. Polycythemia vera: Diagnosis of polycythemia vera, AND history of failure, contraindication, or intolerance to hydroxyurea.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION

Myelofibrosis, Polycythemia vera: 12 months.

OTHER CRITERIA

Approve for continuation of prior therapy.

JEVTANA (S)

MEDICATION(S)

JEVTANA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prostate Cancer: Diagnosis of castration-resistant metastatic prostate cancer AND patient has been previously treated with a docetaxel-containing regimen AND patient is receiving concurrent prednisone

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

JUXTAPID (S)

MEDICATION(S)

JUXTAPID

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Homozygous familial hypercholesterolemia (HoFH) (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents. Patient has been receiving at least 12 consecutive weeks of ONE LDL-C lowering prescription therapy and will continue to receive an LDL-C lowering prescription therapy. History of failure after 12 consecutive weeks or intolerance to Repatha therapy. One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: LDL-C greater than or equal to 100 mg/dL with ASCVD OR LDL-C greater than or equal to 130 mg/dL without ASCVD. Not used in combination with Kynamro (mipomersen). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient is not pregnant. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests. Patient is not concomitantly on moderate or strong CYP 3A4 inhibitors (eg, clarithromycin).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HoFH (initial, reauth): Prescribed by a cardiologist, endocrinologist, or lipid specialist.

COVERAGE DURATION

HoFH (initial): 6 months. (reauth): 12 months

OTHER CRITERIA

HoFH (reauthorization): Patient continues to receive statin at the maximally tolerated dose (or other

LDL-C lowering prescription therapy if patient is unable to take a statin). Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior Juxtapid therapy) while on Juxtapid therapy. Not used in combination with Kynamro (mipomersen). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient is not pregnant. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests. Patient is not concomitantly on moderate or strong CYP 3A4 inhibitors (eg, clarithromycin).

KADCYLA (S)

MEDICATION(S)

KADCYLA 100 MG VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast cancer: A) Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer AND B) Patient has been previously treated with Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of therapy.

KALYDECO (S)

MEDICATION(S)

KALYDECO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cystic Fibrosis (CF) (Initial): Diagnosis of cystic fibrosis. Patient has one of the following mutations on at least one allele in the cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N, S549R, A455E, A1067T, D110E, D110H, D579G, D1152H, D1270N, E56K, E193K, F1052V, F1074L, G1069R, K1060T, L206W, P67L, R74W, R117C, R347H, R352Q, R1070Q, R1070W, S945L, or S977F. The presence of a mutation was documented by an FDA-cleared cystic fibrosis mutation test and followed by verification with bi-directional sequencing when recommended by the mutation test instructions.

AGE RESTRICTION

CF (Initial): 2 years of age or older

PRESCRIBER RESTRICTION

CF (Initial): Prescribed by or in consultation with a specialist affiliated with a CF care center

COVERAGE DURATION

CF (initial, reauth): 12 months

OTHER CRITERIA

CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).

KANUMA (S)

MEDICATION(S)

KANUMA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Lysosomal acid lipase deficiency: Diagnosis of lysosomal acid lipase deficiency (LAL-D). Diagnosis was confirmed by an enzymatic blood (e.g., dried blood spot test) or genetic test.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism, gastroenterologist, or lipidologist

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

KEVEYIS (S)

MEDICATION(S)

KEVEYIS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

All Uses (Initial and Reauth): Hepatic insufficiency (e.g., Child-Pugh class A). Severe pulmonary disease [e.g., severe chronic obstructive pulmonary disease]. Concomitant use with high dose aspirin (i.e., greater than 100 mg per day).

REQUIRED MEDICAL INFORMATION

Periodic paralysis (Initial): Diagnosis of one of the following: Primary hyperkalemic periodic paralysis, Primary hypokalemic periodic paralysis, or Paramyotonia Congenita with periodic paralysis

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses (Initial): Prescribed by or in consultation with a neurologist

COVERAGE DURATION

All uses (Initial): 3 months. (Reauth): 12 months

OTHER CRITERIA

All uses (Reauth): Documentation of positive clinical response to Keveyis therapy.

KEVZARA (S)

MEDICATION(S)

KEVZARA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (initial): Diagnosis of moderately to severely active RA. One of the following:
a) Trial and failure, contraindication, or intolerance (TF/C/I) to both Enbrel (etanercept) and Humira (adalimumab) OR b) For continuation of prior Kevzara therapy. (Initial, Reauth): Patient is not receiving Kevzara in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with a rheumatologist

COVERAGE DURATION

Initial, Reauth: 12 months

OTHER CRITERIA

RA (reauth): Documentation of positive clinical response to Kevzara therapy.

KEYTRUDA (S)

MEDICATION(S)

KEYTRUDA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis (dx) of melanoma and disease is unresectable or metastatic. Non-Small Cell Lung Cancer (NSCLC): Dx of metastatic NSCLC. One of the following: 1) Both of the following: tumors express PD-L1 as determined by an FDA-approved test AND patient has history of failure, contraindication, or intolerance to platinum-containing therapy (eg, cisplatin, carboplatin), 2) All of the following: tumors express high PD-L1 [Tumor proportion score (TPS) greater than or equal to 50%]] as determined by an FDA-approved test, absence of EGFR or ALK genomic tumor aberrations, AND used as first-line treatment, or 3) Both of the following: prescribed medication is being used for first line treatment in patients with nonsquamous NSCLC AND prescribed medication is being used in combination with pemetrexed and carboplatin. Head and neck squamous cell carcinoma (HNSCC): Dx of recurrent or metastatic HNSCC. Patient had disease progression on or after platinum-containing chemotherapy. Classical Hodgkin lymphoma (cHL): Dx of cHL AND One of the following: A) disease is refractory or B) disease has relapsed after 3 or more prior lines of therapy. Urothelial Carcinoma: Dx of locally advanced or metastatic urothelial carcinoma AND one of the following: 1) Patient is not eligible for cisplatin-containing chemotherapy, 2) Disease progression during or following platinum-containing chemotherapy, or 3) Disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Microsatellite Instability-High Cancer (MSI-H): One of the following: 1) Dx of unresectable or metastatic, MSI-H or mismatch repair deficient solid tumors AND disease progression following prior treatment AND patient has no satisfactory alternative treatment options, OR 2) Dx of unresectable or metastatic, MSI-H or mismatch repair deficient colorectal cancer AND patient has experienced progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months.

OTHER CRITERIA

Approve for continuation of prior therapy.

KINERET (S)

MEDICATION(S)

KINERET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Kineret therapy. Neonatal-Onset Multisystem Inflammatory Disease (NOMID) (initial): Diagnosis of NOMID AND dx of NOMID has been confirmed by one of the following: NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation OR evidence of active inflammation including both of the following: clinical symptoms (eg, rash, fever, arthralgia) and elevated acute phase reactants (eg, ESR, CRP). All Uses (initial, reauth): Patient is not receiving Kineret in combination with a biologic disease modifying antirheumatic drug (DMARD) [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Kineret in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA (initial): Prescribed by or in consultation with a rheumatologist. NOMID (initial): Prescribed by or in consultation with allergist/immunologist or rheumatologist or pediatrician.

COVERAGE DURATION

All Uses (initial, reauth): 12 months

OTHER CRITERIA

All Uses (Reauth): Documentation of positive clinical response to Kineret therapy.

KISQALI (S)

MEDICATION(S)

KISQALI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast cancer: Diagnosis of advanced or metastatic breast cancer. Patient is a postmenopausal woman. Cancer is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Kisqali is used in combination with an aromatase inhibitor [(e.g., Femara (letrozole)).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

KISQALI-FEMARA PACK (S)

MEDICATION(S)

KISQALI FEMARA CO-PACK

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast cancer: Diagnosis of advanced or metastatic breast cancer. Patient is a postmenopausal woman. Cancer is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

KORLYM (S)

MEDICATION(S)

KORLYM

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cushing's syndrome (Initial): Diagnosis of endogenous Cushing's syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids). Diagnosis of either type 2 diabetes mellitus or diagnosis of glucose intolerance. Patient has either failed surgery or patient is not a candidate for surgery. Patient is not pregnant.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with an endocrinologist.

COVERAGE DURATION

Initial, reauth: 6 months

OTHER CRITERIA

Reauthorization: Documentation of one of the following: patient has improved glucose tolerance while on Korlym therapy or patient has stable glucose tolerance while on Korlym therapy.

KUVAN (S)

MEDICATION(S)

KUVAN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Phenylketonuria (PKU) (init): Diagnosis of PKU. Patient is a new start to Kuvan (sapropterin dihydrochloride). Patient will have blood Phe levels measured after 1 week of therapy and periodically for up to 2 months of therapy to determine response.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

PKU (Init): 2 months (Reauth): 12 months

OTHER CRITERIA

PKU (reauth): Patient is currently on therapy with Kuvan (sapropterin dihydrochloride). Patient has had an objective response to therapy, defined as a 30% or greater reduction in phenylalanine (Phe) blood levels from baseline. Patient will continue to have blood Phe levels measured periodically during therapy.

KYNAMRO (S)

MEDICATION(S)

KYNAMRO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Homozygous familial hypercholesterolemia (HoFH) (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH) , or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents. Patient has been receiving at least 12 consecutive weeks of ONE LDL-C lowering prescription therapy and will continue to receive an LDL-C lowering prescription therapy. History of failure after 12 consecutive weeks or intolerance to Repatha therapy. One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: LDL-C greater than or equal to 100 mg/dL with ASCVD OR LDL-C greater than or equal to 130 mg/dL without ASCVD. Not used in combination with Juxtapid (lomitapide). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HoFH (initial, reauth): Prescribed by a cardiologist, endocrinologist, or lipid specialist.

COVERAGE DURATION

HoFH (initial): 6 months. (reauth): 12 months

OTHER CRITERIA

HoFH (reauthorization): Patient continues to receive statin at the maximally tolerated dose (or other LDL-C lowering prescription therapy if patient is unable to take a statin). Submission of medical records

(eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior Juxtapid therapy) while on Kynamro therapy. Not used in combination with Juxtapid (Iomitapide). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Patient does not have moderate or severe hepatic impairment (ie, Child-Pugh category B or C) or active liver disease including unexplained persistent abnormal liver function tests.

KYPROLIS (S)

MEDICATION(S)

KYPROLIS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Myeloma (MM): Diagnosis of MM. Disease is relapsed or refractory. Patient has received at least one prior therapy for MM.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

LARTRUVO (S)

MEDICATION(S)

LARTRUVO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Soft Tissue Sarcoma (STS): Diagnosis of STS. All of the following: A) One of the following: 1) Disease is not amenable to curative treatment with radiotherapy or 2) Disease is not amenable to curative treatment with surgery AND B) Used in combination with doxorubicin for the first 8 cycles of treatment

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

LENVIMA (S)

MEDICATION(S)

LENVIMA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Differentiated thyroid cancer (DTC): Diagnosis of DTC. Disease is locally recurrent or metastatic. Patient has symptomatic or progressive disease. Disease is refractory to radioactive iodine treatment.
Renal Cell Carinoma (RCC): Diagnosis of advanced RCC following one prior anti-angiogenic therapy. Used in combination with everolimus.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

LETAIRIS (S)

MEDICATION(S)

LETAIRIS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH (Initial): 6 months. PAH (Reauth): 12 months

OTHER CRITERIA

PAH (Reauth): Documentation of positive clinical response to therapy.

LEUKINE (S)

MEDICATION(S)

LEUKINE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Bone marrow/stem cell transplant (BMSCT): One of the following: 1) patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy, AND age greater than or equal to 55 years. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Patient is receiving National Cancer Institutes Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with FN at high risk for infection-associated complications.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

(Initial): Prescribed by hematologist/oncologist except HIVN: Prescribed by hematologist/oncologist or infectious disease specialist

COVERAGE DURATION

BMSCT, AML, CFN, FN (prophylaxis), NDDC:3mo or duration of tx. HIVN:6mo. FN (treatment):1 mo.

OTHER CRITERIA

HIV-related neutropenia (HIVN)(off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm³).

LIDODERM (S)

MEDICATION(S)

LIDOCAINE 5% PATCH

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Diagnosis of post-herpetic neuralgia

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

LONSURF (S)

MEDICATION(S)

LONSURF

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Colorectal Cancer: Diagnosis of metastatic colorectal cancer AND history of failure, contraindication, or intolerance to at least one component in the following: fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (e.g., FOLFOX, FOLFIRI, FOLFOXIRI) AND history of failure, contraindication, or intolerance to at least one anti-VEGF therapy (e.g., Avastin) AND One of the following: A) patient has KRAS wild-type tumors and history of failure, contraindication, or intolerance to at least one anti-EGFR therapy (e.g., Vectibix, Erbitux) OR Patient has KRAS mutant tumors.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

LOTRONEX (S)

MEDICATION(S)

ALOSETRON HCL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) in Women (initial): All of the following: 1) diagnosis of severe diarrhea-predominant IBS, 2) symptoms for at least 6 months, 3) female patient, AND 4) history of failure, contraindication, or intolerance to an antidiarrheal agent [eg, loperamide].

AGE RESTRICTION

Initial: 18 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

IBS (initial): 12 weeks. IBS (reauth): 6 mo.

OTHER CRITERIA

IBS (reauthorization): Symptoms of IBS continue to persist, AND documentation of positive clinical response to Lotronex therapy.

LUMIZYME-MYOZYME (S)

MEDICATION(S)

LUMIZYME

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pompe disease: Diagnosis of Pompe disease [acid alpha-glucosidase (GAA) deficiency].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

LUPANETA PACK (S)

MEDICATION(S)

LUPANETA PACK

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Endometriosis (initial): Diagnosis of endometriosis. One of the following: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to one NSAID or one oral contraceptive. History of failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Endomet (init, reauth): 6 months

OTHER CRITERIA

Endometriosis (reauthorization): Patient is experiencing recurrence of symptoms after an initial course of therapy.

LUPRON (S)

MEDICATION(S)

LEUPROLIDE 1 MG/0.2 ML VIAL, LEUPROLIDE 2WK 1 MG/0.2 ML KIT, LEUPROLIDE 2WK 14 MG/2.8 ML KT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.

COVERAGE DURATION

CPP (initial, reauth), Prostate CA: 12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

LUPRON DEPOT (S)

MEDICATION(S)

LUPRON DEPOT, LUPRON DEPOT (LUPANETA), LUPRON DEPOT-PED 11.25 MG 3MO, LUPRON DEPOT-PED 30 MG 3MO KIT, LUPRON DEPOT-PED 7.5 MG KIT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prostate Cancer (7.5 mg, 22.5 mg, 30 mg, 45 mg): Diagnosis of advanced or metastatic prostate cancer. Endometriosis (3.75 mg, 11.25 mg) (initial): Diagnosis of endometriosis. One of the following: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to one NSAID and one oral contraceptive. Uterine Leiomyomata (UL) (3.75 mg, 11.25 mg): a) For use prior to surgery to reduce size of fibroids to facilitate a surgical procedure (eg, myomectomy, hysterectomy) OR b) all of the following: treatment of anemia, anemia is caused by uterine leiomyomata (fibroids), and for use prior to surgery.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Prostate CA: 12 mo. Endomet (init, reauth):6mo. UL (anemia):3 mo (fibroids):4 mo

OTHER CRITERIA

Approve for continuation of prior therapy.

LUPRON DEPOT PED (S)

MEDICATION(S)

LUPRON DEPOT-PED 11.25 MG KIT, LUPRON DEPOT-PED 15 MG KIT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.

COVERAGE DURATION

CPP (init,reauth): 12 months

OTHER CRITERIA

CPP (reauthorization): LH levels have been suppressed to pre-pubertal levels.

LYNPARZA (S)

MEDICATION(S)

LYNPARZA 50 MG CAPSULE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Ovarian Cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. History of failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

LYNPARZA TABLET (S)

MEDICATION(S)

LYNPARZA 100 MG TABLET, LYNPARZA 150 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Ovarian cancer, advanced disease with known or suspected BRCA mutation with 3 or more prior lines of chemotherapy: Diagnosis of advanced, persistent, or recurrent ovarian cancer. Presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test. History of failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin). Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of one of the following: recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer. Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

MAKENA (S)

MEDICATION(S)

MAKENA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Preterm birth prophylaxis: Patient had a previous singleton (single offspring) spontaneous preterm birth. Patient is having a singleton pregnancy. Therapy will be started between 16 weeks, 0 days and 20 weeks, 6 days of gestation. Therapy will be continued until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Preterm birth prophylaxis: Prescribed by a specialist in obstetrics and gynecology

COVERAGE DURATION

Preterm birth prophylaxis: 21 weeks

OTHER CRITERIA

N/A

MARINOL (S)

MEDICATION(S)

DRONABINOL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Nausea and Vomiting Associated with Cancer Chemotherapy (CINV): Patient is receiving cancer chemotherapy. Failure, contraindication, or intolerance to one 5HT-3 receptor antagonist (eg, Anzemet [dolasetron], Kytril [granisetron], or Zofran [ondansetron]). Failure, contraindication, or intolerance to one of the following: Compazine (prochlorperazine), Decadron (dexamethasone), Haldol (haloperidol), Zyprexa (olanzapine). AIDS anorexia: Diagnosis of anorexia with weight loss in patients with AIDS. Patient is on antiretroviral therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

CINV: 6 months. AIDS anorexia: 3 months.

OTHER CRITERIA

Subject to Part B vs. Part D review. CINV: Approve for continuation of therapy for treatment covered under Part B when patient is receiving cancer chemotherapy.

MAVYRET (S)

MEDICATION(S)

MAVYRET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Criteria will be applied consistent with current AASLD/IDSA guideline. Submission of medical records (e.g., chart notes, laboratory values) documenting diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6. All patients: Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C), and patient is not receiving Mavyret in combination with another HCV direct acting antiviral agent [e.g., Harvoni, Zepatier]. All genotype 1 (except patients with prior failure to an NS5A inhibitor) and 4: history of intolerance or contraindication to Harvoni and Zepatier therapy OR for continuation of prior Mavyret therapy. All genotype 2 and 3: history of intolerance or contraindication to Epclusa OR for continuation of prior Mavyret therapy. All genotype 5 and 6: history of intolerance or contraindication to Epclusa and Harvoni therapy OR for continuation of prior Mavyret therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

8 to 16 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

MEKINIST (S)

MEDICATION(S)

MEKINIST

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Non-small Cell Lung Cancer (NSCLC): All of the following: diagnosis of metastatic non-small cell lung cancer AND cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA) AND medication is used in combination with Tafinlar (dabrafenib).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

METADATE ER-RITALIN SR (S)

MEDICATION(S)

METADATE ER, METHYLPHENIDATE ER 10 MG TAB, METHYLPHENIDATE ER 20 MG TAB, METHYLPHENIDATE SR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

METHYLIN CHEW (S)

MEDICATION(S)

METHYLPHENIDATE 10 MG CHEW TAB, METHYLPHENIDATE 2.5 MG CHEW TB,
METHYLPHENIDATE 5 MG CHEW TAB

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

METHYLPHENIDATE (S)

MEDICATION(S)

METHYLPHENIDATE 10 MG TABLET, METHYLPHENIDATE 10 MG/5 ML SOL,
METHYLPHENIDATE 20 MG TABLET, METHYLPHENIDATE 5 MG TABLET, METHYLPHENIDATE 5
MG/5 ML SOLN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

METHYLPHENIDATE ER (S)

MEDICATION(S)

METHYLPHENIDATE ER 18 MG TAB, METHYLPHENIDATE ER 27 MG TAB, METHYLPHENIDATE ER 30 MG CAP, METHYLPHENIDATE ER 36 MG TAB, METHYLPHENIDATE ER 40 MG CAP, METHYLPHENIDATE ER 54 MG TAB, METHYLPHENIDATE HCL CD, METHYLPHENIDATE HCL ER, METHYLPHENIDATE LA 30 MG CAP, METHYLPHENIDATE LA 40 MG CAP, METHYLPHENIDATE LA 60 MG CAP, RITALIN LA 10 MG CAPSULE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD)

AGE RESTRICTION

PA applies to members 19 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

METHYLTESTOSTERONE (S)

MEDICATION(S)

METHITEST, METHYLTESTOSTERONE 10 MG CAP

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Hypogonadism (HG) (Initial): Diagnosis (dx) of HG in a male patient. 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Delayed puberty (DP): Dx of DP in males. Breast cancer (BC): Dx for the palliative treatment of inoperable BC in women. Gender Identity Disorder (GID) (off-label): Dx of GID. Patient is a female-to-male transsexual.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

HG(init): (New to T tx:6 mo. Cont T tx:12 mo), (reauth): 12 mo. BC, GID: 12 mo. DP: 6 mo.

OTHER CRITERIA

HG (Reauth): 1) Total serum T level within or below the normal limits of the reporting lab, or 2) Total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Calculated free or bioavailable T level within or below the normal limits of the reporting lab, or calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.

MIRVASO (S)

MEDICATION(S)

MIRVASO 0.33% GEL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rosacea (init): Diagnosis of rosacea. Patient has moderate to severe persistent (nontransient) facial erythema.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Rosacea (init, reauth): 12 months

OTHER CRITERIA

Rosacea (reauth) Documentation of positive clinical response to Mirvaso therapy.

MOZOBIL (S)

MEDICATION(S)

MOZOBIL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Hematopoietic Stem Cell (HSC) Mobilization: Patient with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who will be undergoing autologous HSC transplantation. Used in combination with granulocyte-colony stimulating factor (G-CSF).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION

One course of therapy up to 4 days

OTHER CRITERIA

N/A

MS INTEFERONS (S)

MEDICATION(S)

AVONEX, AVONEX PEN, BETASERON 0.3 MG KIT, EXTAVIA, PLEGRIDY 125 MCG/0.5 ML SYRING, PLEGRIDY PEN, REBIF, REBIF REBIDOSE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

MYALEPT (S)

MEDICATION(S)

MYALEPT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Lipodystrophy (initial): Diagnosis of congenital or acquired generalized lipodystrophy AND Patient is refractory to current standards of care for lipid and diabetic management AND One or more of the following metabolic abnormalities are present: A) Insulin resistance (defined as requiring more than 200 units per day), B) Hypertriglyceridemia, or C) Diabetes

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial: Prescribed by or in consultation with an endocrinologist

COVERAGE DURATION

Initial and reauth: 12 months

OTHER CRITERIA

Lipodystrophy (reauth): Patient has experienced an objective response to therapy, such as A) Sustained reduction in hemoglobin A1c (HbA1c) level from baseline OR B) Sustained reduction in triglyceride (TG) levels from baseline

NAGLAZYME (S)

MEDICATION(S)

NAGLAZYME

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Mucopolysaccharidosis (MPS VI): Diagnosis of MPS VI (Maroteaux-Lamy Syndrome)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

MPS VI: 12 months

OTHER CRITERIA

N/A

NATPARA (S)

MEDICATION(S)

NATPARA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Hypocalcemia (Initial): Diagnosis of hypocalcemia due to chronic hypoparathyroidism. NATPARA is not being used in the setting of acute post-surgical hypoparathyroidism. Patient does not have a known calcium-sensing receptor mutation. Patient has a documented parathyroid hormone concentration that is inappropriately low for the level of calcium, recorded on at least two occasions within the previous 12 months. Patient has been optimized on adequate doses of oral calcium (more than 2,000 mg daily) and vitamin D (calcitriol at least 1 microgram/day) supplementation. Patient has normal thyroid-stimulating hormone concentrations if not on thyroid hormone replacement therapy (or if on therapy, the dose had to have been stable for greater than or equal to 3 months). Patient has normal magnesium and serum 25-hydroxyvitamin D concentrations. Creatinine clearance is at least 30 mL/min on two separate measurements, or greater than 60 mL/min (one measurement) with an accompanying serum creatinine concentration of less than 1.5 mg/dL. NATPARA will be used as an adjunct to calcium and vitamin D.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Hypocalcemia (Initial): Prescribed by or in consultation with an endocrinologist.

COVERAGE DURATION

Initial: 4 months. Reauth: 12 months

OTHER CRITERIA

Hypocalcemia (Reauth): One of the following: A) Patient has achieved and maintained serum calcium levels in the ideal range (8 - 9 mg/dL), OR B) Patient has experienced a 50% or greater reduction in oral calcium intake, OR C) Patient has experienced a 50% or greater reduction in oral vitamin D intake.

NERLYNX (S)

MEDICATION(S)

NERLYNX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast cancer: Diagnosis of early stage breast cancer. Disease is human epidermal growth factor receptor 2 (HER2)-positive. Patient has received adjuvant Herceptin (trastuzumab)-based therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy if treatment duration of Nerlynx has not exceeded a total of 12 months

NEULASTA (S)

MEDICATION(S)

NEULASTA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with a history of FN during a previous course of chemotherapy.

Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) patient is receiving National Cancer Institutes Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS): Patient was acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of ARS).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses (initial): Prescribed by a hematologist/oncologist

COVERAGE DURATION

FN (treatment), ARS: 1 mo. CFN, NDDC, FN (prophylaxis): 3 mo or duration of tx.

OTHER CRITERIA

N/A

NEUPOGEN (S)

MEDICATION(S)

NEUPOGEN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Bone marrow/stem cell transplant (BMSCT): One of the following: 1) pts with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) pts who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) Pt is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) Pt receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) Pts receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) Pts with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Pt is receiving National Cancer Institute's Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) Pt is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Severe chronic neutropenia (SCN): Pts with SCN (ie, congenital, cyclic, and idiopathic neutropenias with chronic ANC less than or equal to 500 cells/mm³). Treatment of FN (off-label): Both of the following: 1) Pts receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) Pts with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS): Pt is/was acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrom

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by hematologist/oncologist except HIVN: Prescribed by hematologist/oncologist or
PAGE 184 LAST UPDATED 12/2017

infectious disease specialist

COVERAGE DURATION

BMSCT,AML,CFN,secondary ppx of FN,NDDC:3mo or tx duration. SCN,HCN:12mo. HIVN:6mo .ARS,FN Tx:1 mo.

OTHER CRITERIA

HIV-related neutropenia (HIVN)(off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm³). Hepatitis C treatment-related neutropenia (HCN)(off-label): One of the following: 1) patients infected with Hepatitis C virus undergoing treatment with Peg-Intron (peginterferon alfa-2b) or Pegasys (peginterferon alfa-2a) who experience neutropenia (ANC less than or equal to 500 cells/mm³) after dose reduction of Peg-Intron or Pegasys, OR 2) patients who experience interferon-induced neutropenia (ANC less than or equal to 500 cells/mm³) due to treatment with Peg-Intron (peginterferon alfa-2b) or Pegasys (peginterferon alfa-2a), AND one of the following: a) patient with HIV co-infection, OR b) status post liver transplant, OR c) patient with established cirrhosis. All indications: History of failure or intolerance to Zarxio (filgrastim-sndz).

NEXAVAR (S)

MEDICATION(S)

NEXAVAR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Renal cell carcinoma (RCC): Diagnosis of RCC. One of the following: Relapsed disease OR both medically/surgically unresectable tumor and dx of Stage IV disease. Hepatocellular carcinoma (HCC): Diagnosis of HCC. One of the following: patient has metastatic disease, or patient has extensive liver tumor burden, or patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only), or both of the following: patient is not a transplant candidate and disease is unresectable. Differentiated thyroid carcinoma (DTC): Diagnosis of DTC (ie, follicular carcinoma, Hurthle cell carcinoma, or papillary carcinoma). One of the following: locally recurrent disease or metastatic disease. One of the following: patient has symptomatic disease or patient has progressive disease. Disease is refractory to radioactive iodine (RAI) treatment. Medullary thyroid carcinoma (MTC): Diagnosis of MTC. Patient has symptomatic disease. History of failure, contraindication, or intolerance to Caprelsa (vandetanib) or Cometriq (cabozantinib).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RCC, DTC, MTC: Prescribed by or in consultation with an oncologist. HCC: Prescribed by or in consultation with an oncologist, hepatologist, or gastroenterologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

NINLARO (S)

MEDICATION(S)

NINLARO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple myeloma: Diagnosis of multiple myeloma. Used in combination with Revlimid (lenalidomide) and dexamethasone. Patient has received at least one prior therapy for multiple myeloma [eg, Revlimid (lenalidomide), Thalomid (thalidomide), Velcade (bortezomib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

NON-PREFERRED TIRF (S)

MEDICATION(S)

FENTORA, LAZANDA, SUBSYS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

For the management of breakthrough cancer pain. Patient is currently taking a long-acting opioid around the clock for cancer pain. Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids: Morphine sulfate at doses of greater than or equal to 60 mg/day, Fentanyl transdermal patch at doses greater than or equal to 25 g/hr, Oxycodone at a dose of greater than or equal to 30 mg/day, Oral hydromorphone at a dose of greater than or equal to 8 mg/day, Oral oxymorphone at a dose of greater than or equal to 25 mg/day, or an alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 mg/day). History of failure or intolerance to generic fentanyl lozenge AND Abstral sublingual tablets.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

NORTHERA (S)

MEDICATION(S)

NORTHERA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Neurogenic orthostatic hypotension (NOH) (init): Diagnosis of symptomatic NOH. NOH is caused by one of the following conditions: primary autonomic failure (eg, Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy. History of failure, contraindication, or intolerance to one of the following agents: fludrocortisone acetate, midodrine.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

NOH (init): Prescribed by or in consultation with a cardiologist, neurologist, or nephrologist

COVERAGE DURATION

NOH (init): 1 month (reauth): 12 months

OTHER CRITERIA

NOH (reauth): Documentation of positive clinical response to therapy

NOVANTRONE (S)

MEDICATION(S)

MITOXANTRONE HCL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS) (init): Diagnosis (dx) of one of the following: secondary progressive MS: gradually worsening disability with or without superimposed relapses, progressive relapsing MS: progression of disability from the onset with superimposed relapses, or worsening relapsing-remitting MS: neurological status remains significantly abnormal in between MS relapses. Disease progression despite one of the following therapies: Avonex, Aubagio, Betaseron, Copaxone, Glatopa, Extavia, Gilenya, Lemtrada, Rebif, Tecfidera, Tysabri. Left ventricular ejection fraction (LVEF) greater than or equal to 50%. Neutrophil count greater than or equal to 1500 cell/mm³. Lifetime cumulative dose less than 140 mg/m². Prostate Cancer (PC) (init): Dx of advanced hormone-refractory (castration-resistant) PC. Used in combination with corticosteroids (eg, prednisone, methylprednisolone). LVEF greater than or equal to 50%. Neutrophil count greater than or equal to 1500 cell/mm³. Acute Non-Lymphocytic Leukemia (ANLL) (init): Dx of ANLL (eg, myelogenous, promyelocytic, monocytic, and erythroid). Used in combination with other medications used for the treatment of ANLL. LVEF greater than or equal to 50%.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All Uses (init, reauth): 12 weeks

OTHER CRITERIA

ALL(reauth): Approve for continuation of therapy.

NULOJIX (S)

MEDICATION(S)

NULOJIX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Kidney transplant: The medication is being used for prevention of kidney transplant organ rejection AND The patient is immune to the Epstein-Barr virus (i.e. EBV seropositive) AND The patient is prescribed concurrent therapy with mycophenolate and corticosteroids

AGE RESTRICTION

Kidney transplant: 18 years of age or older

PRESCRIBER RESTRICTION

Kidney transplant: Prescriber is experienced in immunosuppressive therapy and management of transplant patients

COVERAGE DURATION

12 months

OTHER CRITERIA

Subject to Part B vs. Part D review. Approve for continuation of prior therapy.

NUPLAZID (S)

MEDICATION(S)

NUPLAZID

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Parkinson's disease psychosis: Diagnosis of Parkinson's disease. Patient has at least one of the following: hallucinations or delusions.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

OBETICHOLIC ACID (S)

MEDICATION(S)

OICALIVA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Primary Biliary Cholangitis (PBC) (initial): Diagnosis of PBC (aka primary biliary cirrhosis). One of the following: a) patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after at least 12 consecutive months of treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol) AND used in combination with UDCA, OR b) history of contraindication or intolerance to UDCA.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PBC (initial): Prescribed by or in consultation with a hepatologist or gastroenterologist.

COVERAGE DURATION

PBC (initial): 6 months, (reauth): 12 months

OTHER CRITERIA

PBC (reauthorization): Submission of medical records (eg, laboratory values) documenting a reduction in ALP level from pre-treatment baseline (ie, prior Ocaliva therapy) while on Ocaliva therapy.

ODOMZO (S)

MEDICATION(S)

ODOMZO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Basal cell carcinoma: Diagnosis of locally advanced basal cell carcinoma AND One of the following: 1) Cancer has recurred following surgery or radiation therapy or 2) Patient is not a candidate for surgery or radiation therapy

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

OFEV (S)

MEDICATION(S)

OFEV

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Idiopathic pulmonary fibrosis (IPF) (initial): Both of the following: 1) diagnosis of IPF as documented by all of the following: a) exclusion of other known causes of interstitial lung disease (ILD) (eg, domestic and occupational environmental exposures, connective tissue disease, drug toxicity) AND b) one of the following: i) in patients not subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF, OR ii) in patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern revealing IPF or probable IPF, AND 2) not used in combination with Esbriet (pirfenidone).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

IPF (initial): Prescribed by a pulmonologist

COVERAGE DURATION

Initial, reauth: 12 months

OTHER CRITERIA

IPF (reauth): Documentation of positive clinical response to Ofev therapy.

OLYSIO (S)

MEDICATION(S)

OLYSIO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Both of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND B) Patient is without decompensated liver disease (defined as Child-Pugh Class B or C). All genotype 1 (except Sovaldi plus Olysio therapy) and 4: history of intolerance or contraindication to Harvoni and Zepatier therapy OR patient is currently on Olysio therapy. All Sovaldi plus Olysio therapy: one of the following: a) history of failure, intolerance or contraindication to Harvoni and Zepatier therapy OR b) both of the following: 1. history of failure to Harvoni OR Zepatier AND 2. the patient has NS5A inhibitor resistant-associated variants detected using commercially available assays, OR c) patient is currently on Olysio therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 to 24 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

ONMEL (S)

MEDICATION(S)

ONMEL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

All of the following: 1) Diagnosis of onychomycosis of the toenail as confirmed by one of the following: a) positive potassium hydroxide (KOH) preparation, OR b) culture, OR c) histology, AND 2) patient's condition is causing debility or a disruption in their activities of daily living, AND 3) patient has had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

3 months

OTHER CRITERIA

N/A

OPDIVO (S)

MEDICATION(S)

OPDIVO 40 MG/4 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis of melanoma and disease is unresectable or metastatic. Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC, disease is metastatic, and history of failure, contraindication, or intolerance to platinum-based chemotherapy (eg, cisplatin, carboplatin). Renal cell carcinoma (RCC): Diagnosis of renal cell carcinoma, and disease is advanced, and history of failure, contraindication, or intolerance to anti-angiogenic therapy (eg, Sutent, Nexavar). Classical Hodgkin Lymphoma: Diagnosis of classical Hodgkin lymphoma and one of the following: A) Patient has had relapse or progression after autologous hematopoietic stem cell transplantation (HSCT) and Adcetris (brentuximab vedotin), or B) Patient has had relapse or progression after three or more lines of systemic therapy that includes autologous HSCT. Head and neck squamous cell carcinoma (HNSCC): Diagnosis of recurrent or metastatic HNSCC AND patient had disease progression on or after platinum-containing chemotherapy. Urothelial Carcinoma: Diagnosis of urothelial carcinoma. Disease is locally advanced or metastatic. One of the following: Patient has disease progression during or following platinum-containing chemotherapy OR Patient has disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months.

OTHER CRITERIA

Approve for continuation of prior therapy.

OPSUMIT (S)

MEDICATION(S)

OPSUMIT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA

PAH (Reauth): Documentation of positive clinical response to therapy.

ORENCIA IV (S)

MEDICATION(S)

ORENCIA 250 MG VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. All indications (Initial): One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Orencia therapy. Patient is not receiving Orencia in combination with a biologic disease modifying antirheumatic drug (DMARD) [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA, JIA (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation with a dermatologist or rheumatologist.

COVERAGE DURATION

All indications (Initial, reauth): 12 months

OTHER CRITERIA

All indications (Reauth): Documentation of positive clinical response to Orencia therapy. Patient is not receiving Orencia in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

ORENCIA SC (S)

MEDICATION(S)

ORENCIA 125 MG/ML SYRINGE, ORENCIA 50 MG/0.4 ML SYRINGE, ORENCIA 87.5 MG/0.7 ML SYRINGE, ORENCIA CLICKJECT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Orencia SC therapy, OR prior maintenance therapy of at least 4 weeks with Orencia IV. Patient is not receiving Orencia in combination with a biologic disease modifying antirheumatic drug (DMARD) [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Orencia in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION

RA (Initial, reauth): 12 months

OTHER CRITERIA

RA (Reauth): Documentation of positive clinical response to Orencia therapy. Patient is not receiving Orencia in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving Orencia in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

ORENITRAM (S)

MEDICATION(S)

ORENITRAM ER

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA

PAH (Reauth): Documentation of positive clinical response to therapy.

ORKAMBI (S)

MEDICATION(S)

ORKAMBI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cystic Fibrosis (CF) (Initial): Diagnosis of CF. Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene. The presence of the mutation was documented by an FDA-cleared cystic fibrosis mutation test or Clinical Laboratory Improvement Amendments-approved facility.

AGE RESTRICTION

CF (Initial): Patient is 6 years of age or older

PRESCRIBER RESTRICTION

CF (Initial): Prescribed by or in consultation with a specialist affiliated with a CF care center

COVERAGE DURATION

CF (initial, reauth): 12 months

OTHER CRITERIA

CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV₁)], decreased number of pulmonary exacerbations)

OXANDRIN (S)

MEDICATION(S)

OXANDROLONE 10 MG TABLET, OXANDROLONE 2.5 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Promote weight gain (initial): Medication will be used as an adjunct therapy to promote weight gain AND One of the following: Extensive surgery, Chronic infections, Severe trauma, Failure to gain or maintain at least 90% of ideal body weight without definite pathophysiologic reasons AND History of failure, contraindication, or intolerance to nutritional supplements AND a nutritional consult was performed. Counterbalance protein catabolism (initial): Oxandrin will be used to counterbalance protein catabolism associated with chronic corticosteroid administration. Bone pain (initial): Diagnosis of bone pain associated with osteoporosis.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

bone pain (initial, reauth): 1 month. Others (initial, reauth): 3 months

OTHER CRITERIA

All diagnoses (reauth): patient has experienced an objective improvement (i.e. weight gain, increase in lean body mass, or reduction in muscle pain/weakness)

PART D VS PART B

MEDICATION(S)

ABELCET, ACETYLCYSTEINE 10% VIAL, ACETYLCYSTEINE 20% VIAL, ACYCLOVIR 1,000 MG/20 ML VIAL, ACYCLOVIR 500 MG/10 ML VIAL, ADRIAMYCIN 20 MG/10 ML VIAL, ADRUCIL, ALBUTEROL 15 MG/3 ML SOLUTION, ALBUTEROL 2.5 MG/0.5 ML SOL, ALBUTEROL 20 MG/4 ML SOLUTION, ALBUTEROL 5 MG/ML SOLUTION, ALBUTEROL SUL 0.63 MG/3 ML SOL, ALBUTEROL SUL 1.25 MG/3 ML SOL, ALBUTEROL SUL 2.5 MG/3 ML SOLN, AMBISOME, AMINO ACIDS 15% SOLUTION, AMINOSYN II 10% IV SOLUTION, AMINOSYN II 7% IV SOLUTION, AMINOSYN II WITH ELECTROLYTES, AMINOSYN WITH ELECTROLYTES, AMINOSYN-HBC, AMINOSYN-PF, AMINOSYN-RF, AMPHOTERICIN B 50 MG VIAL, ANZEMET 100 MG TABLET, ANZEMET 50 MG TABLET, APREPITANT, ASTAGRAF XL, ATGAM, AVASTIN, AZASAN, AZATHIOPRINE 50 MG TABLET, AZATHIOPRINE SODIUM, BETHKIS, BLEOMYCIN SULFATE 30 UNIT VIAL, BROVANA, BUDESONIDE 0.25 MG/2 ML SUSP, BUDESONIDE 0.5 MG/2 ML SUSP, BUDESONIDE 1 MG/2 ML INH SUSP, CELLCEPT 500 MG VIAL, CLADRIBINE, CLINIMIX, CLINIMIX E, CROMOLYN 20 MG/2 ML NEB SOLN, CYCLOPHOSPHAMIDE 25 MG CAPSULE, CYCLOPHOSPHAMIDE 50 MG CAPSULE, CYCLOSPORINE 100 MG CAPSULE, CYCLOSPORINE 100 MG/ML SOLN, CYCLOSPORINE 25 MG CAPSULE, CYCLOSPORINE 50 MG/ML AMPUL, CYCLOSPORINE MODIFIED, CYTARABINE 100 MG/5 ML VIAL, CYTARABINE 2 G/20 ML VIAL, CYTARABINE 20 MG/ML VIAL, DOXORUBICIN 10 MG VIAL, DOXORUBICIN 10 MG/5 ML VIAL, DOXORUBICIN 150 MG/75 ML VIAL, DOXORUBICIN 20 MG/10 ML VIAL, DOXORUBICIN 200 MG/100 ML VIAL, DOXORUBICIN 50 MG/25 ML VIAL, DOXORUBICIN HCL LIPOSOME, EMEND 125 MG CAPSULE, EMEND 125 MG POWDER PACKET, EMEND 40 MG CAPSULE, EMEND 80 MG CAPSULE, EMEND TRIPACK, ENGERIX-B 20 MCG/ML SYRN, ENGERIX-B PEDIATRIC-ADOLESCENT, ENVARUSUS XR, FLUOROURACIL 1,000 MG/20 ML VL, FLUOROURACIL 2,500 MG/50 ML VL, FLUOROURACIL 2.5 GM/50 ML BTL, FLUOROURACIL 2.5 GM/50 ML VIAL, FLUOROURACIL 5 GM/100 ML VIAL, FLUOROURACIL 5,000 MG/100 ML, FLUOROURACIL 500 MG/10 ML VIAL, FREAMINE HBC, GABLOFEN 10,000 MCG/20 ML SYRG, GABLOFEN 10,000 MCG/20 ML VIAL, GABLOFEN 40,000 MCG/20 ML VIAL, GABLOFEN 50 MCG/ML SYRINGE, GANCICLOVIR SODIUM, GENGRAF, GRANISETRON HCL 1 MG TABLET, HEPATAMINE, HYPERRAB S-D, IMO GAM RABIES-HT, IMOVAX RABIES VACCINE, INTRALIPID 20% IV FAT EMUL, IPRATROPIUM BR 0.02% SOLN, IPRATROPIUM-ALBUTEROL, IRINOTECAN HCL 100 MG/5 ML VL, LEVALBUTEROL CONCENTRATE, LEVALBUTEROL 0.31 MG/3 ML SOL, LEVALBUTEROL 0.63 MG/3 ML SOL, LEVALBUTEROL 1.25 MG/3 ML SOL, LIORESAL IT 0.05 MG/1 ML AMP, LIORESAL IT 10 MG/20 ML KIT, LIORESAL IT 10 MG/5 ML KIT, LIORESAL IT 40 MG/20 ML KIT, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, NEBUPENT, NEPHRAMINE, NUTRILIPID, ONDANSETRON 4 MG/5 ML SOLUTION, ONDANSETRON HCL 24 MG TABLET, ONDANSETRON HCL 4 MG TABLET, ONDANSETRON HCL 8 MG TABLET, ONDANSETRON ODT, OXALIPLATIN 100 MG/20 ML VIAL, PERFORMIST, PREMASOL, PROCALAMINE, PROGRAF 5 MG/ML AMPULE, PROSOL, RABAVIR, RAPAMUNE 1 MG/ML ORAL SOLN, RECOMBIVAX HB 10 MCG/ML SYR, 12/2017

RECOMBIVAX HB 10 MCG/ML VIAL, RECOMBIVAX HB 40 MCG/ML VIAL, RECOMBIVAX HB 5 MCG/0.5 ML SYR, SANDIMMUNE 100 MG/ML SOLN, SIMULECT 20 MG VIAL, SIROLIMUS 0.5 MG TABLET, SIROLIMUS 1 MG TABLET, SIROLIMUS 2 MG TABLET, TACROLIMUS 0.5 MG CAPSULE, TACROLIMUS 1 MG CAPSULE, TACROLIMUS 5 MG CAPSULE, THYMOGLOBULIN, TOBRAMYCIN 300 MG/5 ML AMPULE, TRAVASOL, TROPHAMINE 10% IV SOLUTION, TWINRIX VACCINE VIAL, VECTIBIX 100 MG/5 ML VIAL, VINBLASTINE SULFATE, VINCASAR PFS, VINCRISTINE SULFATE

DETAILS

This drug may be covered under Medicare Part B or D depending on the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

PEG-INTRON (S)

MEDICATION(S)

PEGINTRON, PEGINTRON REDIPEN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic Hepatitis C: Criteria will be applied consistent with current AASLD-IDSA guidance

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

HepC: Initial: 28 wks. Reauth: 20 wks.

OTHER CRITERIA

HepC (reauth): patient has an undetectable HCV RNA at week 24, additional treatment weeks of peginterferon are required to complete treatment regimen, and patient has not exceeded 48 wks of therapy with peginterferon.

PEGASYS (S)

MEDICATION(S)

PEGASYS, PEGASYS PROCLICK

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic hepatitis B: Diagnosis of chronic hepatitis B infection, and patient is without decompensated liver disease. Chronic Hepatitis C: Criteria will be applied consistent with current AASLD-IDSA guidance

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

HepB: 48 wks. HepC: Initial: 28 wks. Reauth: 20 wks.

OTHER CRITERIA

N/A

PENNSAID (S)

MEDICATION(S)

DICLOFENAC 1.5% TOPICAL SOLN, PENNSAID 2% PUMP

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Initial, reauth: History of severe allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory (NSAIDs), including urticaria and asthma (aspirin-sensitive asthma).

REQUIRED MEDICAL INFORMATION

Osteoarthritis of the knees (initial): Diagnosis of osteoarthritis of the knees and diclofenac will not be used in the treatment of peri-operative pain in the setting of coronary artery bypass graft surgery. Patient meets one of the following: 1) Treatment failure with at least two prescription strength oral non-steroidal anti-inflammatory drugs (NSAIDs) OR 2) Documented swallowing disorder OR 3) History of peptic ulcer disease/gastrointestinal bleed OR 4) Patient is older than 65 years of age with one additional risk factor for gastrointestinal adverse events (e.g. use of anticoagulants, chronic corticosteroids).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial, reauth: 12 months

OTHER CRITERIA

Osteoarthritis of the knees (reauth): Patient has experienced a response to therapy (e.g., improvement in pain symptoms of osteoarthritis).

PERJETA (S)

MEDICATION(S)

PERJETA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Metastatic breast cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. One of the following: a) patient has not received prior anti-HER2 therapy or chemotherapy for metastatic disease AND used in combination with Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel), OR b) patient was previously treated with chemotherapy and Herceptin (trastuzumab) without Perjeta AND used in combination with Herceptin (trastuzumab). Non-metastatic breast cancer: One of the following diagnoses: HER2-positive early stage breast cancer, HER2-positive locally advanced breast cancer, or HER2-positive inflammatory breast cancer. Used in combination with both Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Uses: Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

POMALYST (S)

MEDICATION(S)

POMALYST

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Myeloma (MM): Diagnosis of MM. Used in combination with dexamethasone. Patient has received two prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor [eg, Velcade (bortezomib) or Kyprolis (carfilzomib)] or has a contraindication or intolerance to Revlimid and proteasome inhibitors. Patient has experienced disease progression on or within 60 days of completion of last therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

PRALUENT (S)

MEDICATION(S)

PRALUENT PEN, PRALUENT 75 MG/ML SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Initial: Submission of medical records (eg, chart notes, laboratory values) documenting one of the following diagnoses: Heterozygous familial hypercholesterolemia (HeFH) as confirmed by one of the following: (1) Documented assessment of patient using Dutch Lipid Clinic Network diagnostic criteria with a cumulative score greater than or equal to 9 points (ie, definite FH), (2) Presence of tendinous xanthomas in patient, first degree relative, or second degree relative, AND Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult, (3) Genetic confirmation of a mutation in the LDL receptor, ApoB, or PCSK9. OR Atherosclerotic cardiovascular disease (ASCVD) as confirmed by acute coronary syndromes, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: (1) LDL-C greater than or equal to 100 mg/dL with ASCVD. (2) LDL-C greater than or equal to 130 mg/dL without ASCVD.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial, reauth: Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist

COVERAGE DURATION

Initial: 6 months. Reauth: 12 months

OTHER CRITERIA

HeFH/ASCVD: Initial: One of the following: (1) Patient has been receiving at least 12 consecutive weeks of one high-intensity statin therapy and will continue to receive a HIGH-INTENSITY statin [ie, atorvastatin 40-80 mg, Crestor (rosuvastatin) 20-40 mg] at maximally tolerated dose, OR (2) Both of the following: A) Patient is unable to tolerate high-intensity statin as evidenced by intolerable and

persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), AND B) One of the following: a) Patient has been receiving at least 12 consecutive weeks of one moderate-intensity or low-intensity statin therapy and will continue to receive a MODERATE-INTENSITY or LOW-INTENSITY statin [ie, atorvastatin 10-20 mg, Crestor (rosuvastatin) 5-10 mg, simvastatin 10-40 mg, pravastatin 10-80 mg, lovastatin 20-40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1-4 mg] at maximally tolerated dose, OR b) Patient is unable to tolerate moderate-intensity or low-intensity statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), OR (3) Submission of medical records documenting patient has a labeled contraindication to all statins, OR (4) Patient has experienced rhabdomyolysis on one statin therapy. Reauth: Patient continues to receive statin at the maximally tolerated dose (unless patient has documented inability to take statins). Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior to Praluent therapy) while on Praluent therapy. Initial, reauth: Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

PROCYSBI (S)

MEDICATION(S)

PROCYSBI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Nephropathic cystinosis: Diagnosis of nephropathic cystinosis, confirmed by elevated leukocyte cystine levels (LCL) or genetic analysis of the CTNS gene AND History of failure or intolerance to therapy with Cystagon (immediate-release cysteamine bitartrate)

AGE RESTRICTION

2 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

PROLIA (S)

MEDICATION(S)

PROLIA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Postmenopausal osteoporosis (PMO) (initial): Diagnosis (dx) of PMO. History (hx) of vertebral compression fractures (fx), or fx of the hip, or distal radius resulting from minimal trauma, or bone mineral density score (BMD) indicative of osteoporosis (OP): T-score less than or equal to -2.5 (2.5 standard deviations [SD] or greater below the mean for young adults). PMO, prophylaxis (initial): For prevention of PMO. BMD scan indicative of osteopenia: T-score -1.0 to -2.5. Nonmetastatic prostate cancer (NMPC) bone loss (initial): Dx of NMPC. Pt is 70 years or older, or less than 70 years old with BMD T-score below -1.0 (1.0 SD or greater below the mean for young adults) or hx of vertebral compression fx or fx of the hip or distal radius resulting from minimal trauma. NMPC (reauth): No evidence of metastases. Breast cancer (BC) bone loss (initial): Dx of BC. BMD T-score below -1.0 (1.0 SD or greater below the mean for young adults) or hx of vertebral compression fx or fx of the hip or distal radius resulting from minimal trauma. OP in men (initial): Pt is a male with OP. Hx of vertebral compression fx or fx of the hip or distal radius resulting from minimal trauma, or BMD indicative of OP: T-score less than or equal to -2.0 (2.0 SD or greater below the mean for young adults).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All uses (initial, reauth): 12 months

OTHER CRITERIA

NMPC bone loss (initial and reauth): Receiving androgen deprivation therapy (ADT) from luteinizing hormone/gonadotropin releasing hormone (LHRH/GnRH) agonist [e.g., Eligard/Lupron (leuprolide), Trelstar (triptorelin), Vantas (histrelin), Zoladex (goserelin)] or bilateral orchiectomy (i.e. surgical

castration). BC bone loss (initial and reauth): Pt is receiving aromatase inhibitor (AI) therapy [e.g., Arimidex (anastrozole), Aromasin (exemestane), Femara (letrozole)]. All indications except NMPC (initial): One of the following A) Patient has a documented trial and therapeutic failure with a bisphosphonate, where therapeutic failure is defined as new fractures in compliant patients on therapy for at least 6 months, failure to produce a clinically significant change in a biochemical marker(s) of bone turnover, or significant loss of bone mineral density on follow-up scans after 12 to 24 months of therapy or B) Patient has a documented contraindication or intolerance to bisphosphonate therapy, or is unable to comply with appropriate administration recommendations for oral or injectable bisphosphonate therapy. All indications (renewal):The patient is benefiting from therapy (e.g., improved or stabilized BMD, no new fractures, or improved biochemical markers, etc.)

PROMACTA (S)

MEDICATION(S)

PROMACTA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic immune (idiopathic) thrombocytopenic purpura (ITP) (initial): Diagnosis of relapsed/refractory chronic ITP for greater than 6 months. Baseline platelet count is less than 50,000/mcL. Patient's degree of thrombocytopenia and clinical condition increase the risk of bleeding. One of the following: A) History of failure, intolerance, contraindication to corticosteroids or immune globulin OR B) History of failure or contraindication to splenectomy. Chronic hepatitis C (initial): Diagnosis of chronic hepatitis C. Patient has thrombocytopenia defined as platelets less than 90,000/mcL for initiation (pre-treatment) of interferon therapy. Severe aplastic anemia (initial): Diagnosis of severe aplastic anemia. Patient has a platelet count less than 30,000/mcL. History of failure, intolerance, or contraindication to immunosuppressive therapy with antithymocyte globulin and cyclosporine.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

ITP (init, reauth): 12mo. HepC: 9wks (init), 24wks (reauth). Aplas anemia (init, reauth): 16wks.

OTHER CRITERIA

ITP (reauth): After at least 4 weeks of therapy at the maximum weekly dose (10 mcg/kg), the platelet count increased to a sufficient level to avoid clinically important bleeding. Hepatitis C (reauth): Platelets less than 75,000/mcL for maintenance of optimal interferon-based therapy. Aplastic anemia (reauth): Patient has experienced an increase in platelet count.

PROVIGIL (S)

MEDICATION(S)

MODAFINIL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Obstructive sleep apnea/hypopnea syndrome (OSAHS) (Initial): Diagnosis (dx) of OSAHS defined by one of the following: 15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), or both of the following: 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), and 1 of the following symptoms: unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, waking up breath holding/gasping/choking, loud snoring, or breathing interruptions during sleep. Shift-work sleep disorder (SWSD) (Initial): Dx of SWSD confirmed by symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, or sleep study demonstrating loss of a normal sleep-wake pattern (ie, disturbed chronobiologic rhythmicity). No other medical condition or medication accounts for the symptoms. Narcolepsy (initial): Dx of narcolepsy as confirmed by sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). MS Fatigue (initial): Dx of multiple sclerosis (MS). Patient is experiencing fatigue. Depression (initial): Treatment-resistant depression defined as diagnosis of major depressive disorder (MDD) or bipolar depression, AND history of failure, contraindication, or intolerance to at least two antidepressants from different classes (eg, SSRIs, SNRIs, bupropion). Used as adjunctive therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

OSAHS/MS/dep(init), SWSD (init,reauth): 3 mo. OSAHS/dep(reauth): 12mo. MS (reauth): 6mo. Other:

12mo

PAGE 218

LAST UPDATED 12/2017

HPMS Approved Formulary ID: 00017485 Version 23

OTHER CRITERIA

OSAHS (Reauth): Documentation of positive clinical response to prior therapy. SWSD (Reauth): Documentation of positive clinical response to prior therapy. Patient still requires treatment for SWSD. Narcolepsy (reauth): Documentation of positive clinical response to prior therapy. MS Fatigue (reauth): Patient is experiencing relief of fatigue with modafinil therapy. Idiopathic Hypersomnia (reauth): Documentation of positive clinical response to modafinil therapy. Depression (reauth): Documentation of positive clinical response to modafinil therapy. Used as adjunctive therapy.

PULMOZYME (S)

MEDICATION(S)

PULMOZYME

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cystic Fibrosis (CF) (Initial, Reauth): Diagnosis of CF

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

CF (initial, reauth): 12 months

OTHER CRITERIA

Part B vs D determination applies. CF (reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).

QUALAQUIN (S)

MEDICATION(S)

QUININE SULFATE 324 MG CAPSULE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Malaria: Diagnosis of uncomplicated malaria. One of the following: 1) Treatment in areas of chloroquine-sensitive malaria, and failure, contraindication, or intolerance to chloroquine or hydroxychloroquine, OR 2) Treatment in areas of chloroquine-resistant malaria. Not used for the treatment or prevention of nocturnal leg cramps.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

7 days

OTHER CRITERIA

N/A

RADICAVA (S)

MEDICATION(S)

RADICAVA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Amyotrophic lateral sclerosis (ALS) (initial): Diagnosis of amyotrophic lateral sclerosis (ALS).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

ALS (initial): Prescribed by or in consultation with a neurologist.

COVERAGE DURATION

Initial: 6 months. Reauth: 12 months

OTHER CRITERIA

ALS (reauthorization): Documentation of a benefit from therapy (e.g., slowing in the decline of functional abilities).

RAVICTI (S)

MEDICATION(S)

RAVICTI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Urea cycle disorders (UCDs) (Initial): Diagnosis of UCDs.

AGE RESTRICTION

UCDs (Initial): Age greater than or equal to 2 months

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

UCDs (Initial, reauth): 12 months

OTHER CRITERIA

UCDs (reauth): Documentation of positive clinical response to Ravicti therapy.

REGRANEX (S)

MEDICATION(S)

REGRANEX

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Diabetic neuropathic ulcers: Patient has a lower extremity diabetic neuropathic ulcer. Treatment will be given in combination with ulcer wound care (eg, debridement, infection control, and/or pressure relief)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

5 months

OTHER CRITERIA

N/A

RELISTOR (S)

MEDICATION(S)

RELISTOR 12 MG/0.6 ML KIT, RELISTOR 12 MG/0.6 ML SYRINGE, RELISTOR 12 MG/0.6 ML VIAL, RELISTOR 8 MG/0.4 ML SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Opioid-induced constipation (OIC) (Initial): Diagnosis of OIC. Patient has used opioid medication for a minimum of 4 weeks. Patient is experiencing fewer than 3 bowel movements in a week or no bowel movement for longer than 2 days. One of the following: A) Patient is an adult with a diagnosis of chronic non-cancer pain AND patient has failure, contraindication, or intolerance to Amitiza (lubiprostone), OR B) Patient is receiving palliative care for an advanced illness.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

OIC (initial, reauth): 4 months

OTHER CRITERIA

OIC (Reauth): Diagnosis of OIC. One of the following: A) Patient is an adult with a diagnosis of chronic non-cancer pain, OR B) Both of the following: Patient is receiving palliative care for an advanced illness AND Patient has responded to therapy (e.g., increase in bowel movements).

RELISTOR TABLETS (S)

MEDICATION(S)

RELISTOR 150 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

OIC (non-cancer pain): Diagnosis of OIC. Patient has chronic non-cancer pain.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

6 months

OTHER CRITERIA

OIC (non-cancer): Documentation of opioid use for at least 4 weeks prior to the proposed start of therapy. Failure, contraindication, or intolerance to Amitiza.

REMICADE (S)

MEDICATION(S)

REMICADE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (Initial): Diagnosis (Dx) of moderately to severely active CD or FCD. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex/Trexall). Ulcerative colitis (UC) (Initial): Dx of moderately to severely active UC. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)]. Rheumatoid arthritis (RA) (Initial): Dx of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), OR failure, contraindication, or intolerance to methotrexate (Rheumatrex/Trexall). Ankylosing spondylitis (AS) (Initial): Dx of active AS. Failure, contraindication, or intolerance to two NSAIDs. Psoriatic arthritis (PsA) (Initial): Dx of active PsA. Plaque psoriasis (Initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis. Sarcoidosis (initial): Failure, contraindication, or intolerance to one immunosuppressant [eg, methotrexate (Rheumatrex/Trexall), cyclophosphamide, or azathioprine (Imuran)] AND failure, contraindication, or intolerance to one corticosteroid (eg, prednisone). All indications (Initial, reauth): Patient is not receiving Remicade in combination with a biologic DMARD [eg, Enbrel (etanercept), Rituxan (rituximab), Orencia (abatacept), Kineret (anakinra)]. Patient is not receiving Remicade in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]. For a diagnosis of PsA or plaque psoriasis, Patient is not receiving Remicade in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

CD, FCD, UC (Initial): Prescribed by or in consultation with a gastroenterologist. RA, AS (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation

with rheumatologist or dermatologist. Plaque Psoriasis (Initial): Prescribed by or in consultation with a dermatologist. Sarcoidosis (Initial): Prescribed by or in consultation with a pulmonologist, dermatologist, ophthalmologist.

COVERAGE DURATION

All indications (initial, reauth): 12 months

OTHER CRITERIA

All indications (Reauth): Documentation of positive clinical response to Remicade therapy.

REMODULIN (S)

MEDICATION(S)

REMODULIN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH: Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA

Subject to Part B vs. D Review. PAH (Reauth): Documentation of positive clinical response to therapy.

RENFLEXIS (S)

MEDICATION(S)

RENFLEXIS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (initial): Dx of moderately to severely active CD or FCD. Ulcerative colitis (UC) (initial): Dx of moderately to severely active UC. Rheumatoid arthritis (RA) (initial): Diagnosis (Dx) of moderately to severely active RA. Ankylosing spondylitis (AS) (initial): Dx of active AS. Psoriatic arthritis (PsA) (initial): Dx of active PsA. Plaque psoriasis (initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis. CD, FCD (initial): Trial and failure, contraindication or intolerance (TF/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex, Trexall). UC (initial): TF/C/I to one of the following conventional therapies: corticosteroids, aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine/Sulfazine)], azathioprine (Imuran), 6-mercaptopurine (Purinethol). RA (initial): Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), or TF/C/I to methotrexate. AS (initial): TF/C/I to two or more NSAIDs. All indications (initial): One of the following: 1) Trial and failure or intolerance to Remicade or 2) For continuation of prior Renflexis therapy. All indications (Initial): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)] or Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial: RA, AS: Prescribed by or in consultation with a rheumatologist. PsA: Prescribed or in consultation with a rheumatologist or dermatologist. Crohn's Disease, Fistulizing Crohn's Disease, UC: Prescribed by or in consultation with a gastroenterologist. Plaque Psoriasis: Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION

All indications (initial, reauth): 12 months

OTHER CRITERIA

Reauthorization for all indications: Documentation of positive clinical response to infliximab therapy. All indications (re-auth): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)] or Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

REPATHA (S)

MEDICATION(S)

REPATHA PUSHTRONEX, REPATHA SURECLICK, REPATHA SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

HeFH/ASCVD (initial): Submission of medical records (eg, chart notes, laboratory values) documenting one of the following diagnoses: Heterozygous familial hypercholesterolemia (HeFH) as confirmed by one of the following: (1) Documented assessment of patient using Dutch Lipid Clinic Network diagnostic criteria with a cumulative score greater than or equal to 9 points (ie, definite FH), or (2) Presence of tendinous xanthomas in patient, first degree relative, or second degree relative, AND Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult, or (3) Genetic confirmation of a mutation in the LDL receptor, ApoB, or PCSK9. OR Atherosclerotic cardiovascular disease (ASCVD) as confirmed by acute coronary syndromes, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. HoFH (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of homozygous familial hypercholesterolemia as confirmed by one of the following: (1) Genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or (2) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL, AND either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents.

HeFH/ASCVD/HoFH (initial): One of the following LDL-C values while on maximally tolerated lipid-lowering regimen within the last 30 days: (1) LDL-C greater than or equal to 100 mg/dL with ASCVD, or (2) LDL-C greater than or equal to 130 mg/dL without ASCVD.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HeFH/ASCVD/HoFH (init, reauth): Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist

COVERAGE DURATION

PAGE 232

LAST UPDATED 12/2017

HeFH/ASCVD (init): 6 mon. HoFH (init): 3 mon. HeFH/ASCVD/HoFH (reauth): 12 mon.

OTHER CRITERIA

HeFH/ASCVD (initial): One of the following: (1) Patient has been receiving at least 12 consecutive weeks of one maximally-tolerated statin therapy and will continue to receive a statin at maximally tolerated dose, or (2) Patient is unable to tolerate statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), or (3) Submission of medical records documenting patient has a labeled contraindication to all statins, or (4) Patient has experienced rhabdomyolysis on one statin therapy. HoFH (initial): One of the following: (1) Patient has been receiving at least 12 consecutive weeks of one maximally-tolerated statin therapy and will continue to receive a statin at maximally tolerated dose, or (2) both of the following: a) One of the following: 1. Patient is unable to tolerate statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), or 2. Submission of medical records documenting patient has a labeled contraindication to all statins, or 3. Patient has experienced rhabdomyolysis on one statin therapy, AND b) patient has been receiving at least 12 consecutive weeks of other LDL-C lowering prescription therapy and will continue to receive an LDL-C lowering prescription therapy. HeFH/ASCVD (reauth): Patient continues to receive statin at the maximally tolerated dose (unless patient has documented inability to take statins). HoFH (reauth): Patient continues to receive statin at the maximally tolerated dose (or other LDL-C lowering prescription therapy if patient is unable to take a statin). HeFH/ASCVD/HoFH (reauth): Submission of medical records (eg, laboratory values) documenting a sustained LDL-C reduction from pre-treatment baseline (ie, prior to Repatha therapy) while on Repatha therapy. HeFH/ASCVD/HoFH (Initial, reauth): Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. HoFH (Initial, reauth): Not used in combination with Juxtapid (lomitapide) or Kynamro (mipomersen).

REVATIO (S)

MEDICATION(S)

REVATIO 10 MG/ML ORAL SUSP, SILDENAFIL, SILDENAFIL 10 MG/12.5 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. For Revatio injection only (Initial): Patient is temporarily unable to take oral medications. For Revatio oral suspension only (initial, reauth): One of the following: A) History of intolerance to generic Revatio tablets, OR B) Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to one of the following: age, oral-motor difficulties, or dysphagia.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH: Initial - 6 months. Reauth - 12 months.

OTHER CRITERIA

PAH (Reauth): Documentation of positive clinical response to therapy

REVLIMID (S)

MEDICATION(S)

REVLIMID

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple myeloma (MM): Diagnosis of MM. Myelodysplastic syndromes (MDS): Patient has transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion. Mantle cell lymphoma (MCL): Diagnosis of MCL. Disease has relapsed, refractory, or progressed after at least one prior therapy (eg, bortezomib, bendamustine, cladribine, rituximab).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

RILUTEK (S)

MEDICATION(S)

RILUZOLE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Amyotrophic lateral sclerosis (ALS): Diagnosis of amyotrophic lateral sclerosis (ALS)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

ALS: 12 months

OTHER CRITERIA

N/A

RITUXAN (S)

MEDICATION(S)

RITUXAN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Rheumatoid Arthritis (RA) (init): Patient is not receiving Rituxan in combination with a biologic DMARD [eg, Enbrel (etanercept), Orencia (abatacept), Kineret (anakinra)]. Patient is not receiving Rituxan in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

REQUIRED MEDICAL INFORMATION

Non-Hodgkin's Lymphoma (NHL): As first-line treatment of diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or other anthracycline-based chemotherapy regimens, or as first-line treatment of follicular, CD20-positive, B-cell NHL in combination with chemotherapy, or as a single-agent maintenance therapy for the treatment of follicular, CD20-positive, B-cell NHL in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, or for the treatment of low-grade, CD20-positive, B-cell NHL in patients with stable disease following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/prednisone) chemotherapy or who achieve a partial or complete response following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/prednisone) chemotherapy, or diagnosis of relapsed or refractory, low grade or follicular CD20-positive, B-cell non-Hodgkin's lymphoma. Rheumatoid Arthritis (RA) (init): Concurrently on or contraindication, or intolerance to methotrexate. Failure, contraindication, or intolerance (F/C/I) to a TNF antagonist (eg, adalimumab, etanercept, infliximab). Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA): Patient is concurrently on glucocorticoids (eg, prednisone) OR contraindication or intolerance to glucocorticoids (eg, prednisone). Immune or idiopathic thrombocytopenic purpura (ITP): F/C/I to one of the following: corticosteroids, immunoglobulins, or splenectomy. Documented platelet count of less than $50 \times 10^9 /L$.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

ITP: Prescribed by or in consultation with a hematologist or oncologist. RA: Prescribed by or in consultation with a rheumatologist. WG, MPA: Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.

COVERAGE DURATION

All uses except RA, WG, MPA: 12 mos. RA: 3 months. WG, MPA: 3 months only.

OTHER CRITERIA

Approve for continuation of prior therapy.

RUBRACA (S)

MEDICATION(S)

RUBRACA 200 MG TABLET, RUBRACA 300 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Ovarian cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious BRCA mutation as detected by an FDA-approved diagnostic test (e.g., FoundationFocus CDxBRCA Assay) or Clinical Laboratory Improvement Amendments-approved facility. History of failure, contraindication, or intolerance to two or more chemotherapies (e.g., cisplatin, carboplatin).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

RUCONEST (S)

MEDICATION(S)

RUCONEST

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks (eg, Berinert, Firazyr, or Kalbitor).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

HAE: Prescribed by an immunologist, allergist, or rheumatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

RYDAPT (S)

MEDICATION(S)

RYDAPT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acute Myeloid Leukemia (AML): Newly diagnosed acute myeloid leukemia (AML), FMS-like tyrosine kinase 3 (FLT3) mutation-positive as detected by a U.S. Food and Drug Administration (FDA)-approved test, used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), Mast Cell Leukemia (MCL): Diagnosis of one of the following: aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All indications: Prescribed by or in consultation with a hematologist or oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

SABRIL (S)

MEDICATION(S)

SABRIL, VIGABATRIN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Complex Partial Seizures (CPS): For use as adjunctive therapy. Failure, contraindication, or intolerance to two formulary anticonvulsants [eg, Lamictal (lamotrigine), Depakene (valproic acid), Dilantin (phenytoin)]. Infantile Spasms (IS): Diagnosis of infantile spasms.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

SANDOSTATIN (S)

MEDICATION(S)

OCTREOTIDE 1,000 MCG/5 ML VIAL, OCTREOTIDE 1,000 MCG/ML VIAL, OCTREOTIDE 5,000 MCG/5 ML VIAL, OCTREOTIDE ACET 0.05 MG/ML VL, OCTREOTIDE ACET 100 MCG/ML AMP, OCTREOTIDE ACET 100 MCG/ML VL, OCTREOTIDE ACET 200 MCG/ML VL, OCTREOTIDE ACET 50 MCG/ML AMP, OCTREOTIDE ACET 50 MCG/ML VIAL, OCTREOTIDE ACET 500 MCG/ML AMP, OCTREOTIDE ACET 500 MCG/ML VL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acromegaly (initial): Diagnosis of acromegaly AND One of the following: A) History of failure to surgical resection and/or pituitary irradiation OR B) patient is not a candidate for surgical resection or pituitary irradiation AND History of failure or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses. Carcinoid tumor (initial): Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea and flushing episodes. Vasoactive intestinal peptide tumor (initial): Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All Uses (Initial and reauth): 12 months

OTHER CRITERIA

Acromegaly (reauth): Patient has had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). Carcinoid tumor (reauth): patient has improvement in number of diarrhea and flushing episodes. Vasoactive intestinal peptide tumor (reauth): patient has improvement in number of diarrhea episodes.

SANDOSTATIN LAR (S)

MEDICATION(S)

SANDOSTATIN LAR, SANDOSTATIN LAR DEPOT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acromegaly (initial): Diagnosis of acromegaly AND One of the following: A) History of failure to surgical resection and/or pituitary irradiation OR B) patient is not a candidate for surgical resection or pituitary irradiation AND History of failure or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses AND Patient had a trial of short-acting octreotide and responded to and tolerated therapy. Carcinoid tumor (initial): Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea and flushing episodes AND Patient had a trial of short-acting octreotide and responded to and tolerated therapy. Vasoactive peptide tumor (initial): Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea AND Patient had a trial of short-acting octreotide and responded to and tolerated therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All Uses (Initial and reauth): 12 months

OTHER CRITERIA

Acromegaly (reauth): Patient has had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). Carcinoid tumor (reauth): patient has improvement in number of diarrhea and flushing episodes. Vasoactive intestinal peptide tumor (reauth): patient has improvement in number of diarrhea episodes.

SEROSTIM (S)

MEDICATION(S)

SEROSTIM

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

HIV wasting (Initial): Diagnosis of HIV-associated wasting syndrome or cachexia, and one of the following: unintentional weight loss greater than 10% over the last 12 months, or unintentional weight loss greater than 7.5% over the last 6 months, or loss of 5% body cell mass (BCM) within 6 months, or body mass index (BMI) less than 20 kg/m², or patient is male and has BCM less than 35% of total body weight (TBW) and BMI less than 27 kg/m², or patient is female and has BCM less than 23% of TBW and BMI less than 27 kg/m². Nutritional evaluation since onset of wasting first occurred. Anti-retroviral tx has been optimized to decrease the viral load. Patient has not had weight loss as a result of other underlying treatable conditions (eg, depression, mycobacterium avium complex, chronic infectious diarrhea, or malignancy with the exception of Kaposi's sarcoma limited to skin or mucous membranes). Patient has tried and had an inadequate response or intolerance to dronabinol or megestrol acetate.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Initial, Reauth: Prescribed by or in consultation with an infectious disease specialist.

COVERAGE DURATION

Initial: 3 months, Reauth: 6 months

OTHER CRITERIA

HIV wasting (reauth): Evidence of positive response to therapy. One of the following targets or goals has not been achieved: weight, BCM, BMI. Patient is currently receiving treatment with antiretrovirals.

SIGNIFOR (S)

MEDICATION(S)

SIGNIFOR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cushing's disease (initial): Diagnosis of Cushings disease AND History of failure or patient is not a candidate for pituitary surgery.

AGE RESTRICTION

Initial: 18 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial: 3 months. Reauth: 12 months.

OTHER CRITERIA

Cushing's disease (reauth): a clinically meaningful reduction in 24-hour urinary free cortisol levels or improvement in signs or symptoms of the disease

SIGNIFOR LAR (S)

MEDICATION(S)

SIGNIFOR LAR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acromegaly (initial): Diagnosis of acromegaly AND History of failure to surgery or patient is not a candidate for surgery

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial: 6 months. Reauth: 12 months.

OTHER CRITERIA

Acromegaly (reauth): patients growth hormone (GH) level or insulin-like growth factor 1 (IGF-1) level for age and gender has normalized/improved

SIMPONI (S)

MEDICATION(S)

SIMPONI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall) OR failure, contraindication, or intolerance to methotrexate (Rheumatrex/Trexall). One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Simponi therapy. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Simponi therapy. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Simponi therapy. Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. Patient is corticosteroid dependent (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC), OR history of failure, contraindication, or intolerance to one of the following: oral aminosalicylate, oral corticosteroid, azathioprine, 6-mercaptopurine. One of the following: Failure, contraindication, or intolerance to Humira (adalimumab), OR for continuation of prior Simponi therapy. All indications (Initial, reauth): Patient is not receiving Simponi in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Orencia (abatacept)]. Patient is not receiving Simponi in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]. For a diagnosis of PsA, Patient is not receiving Simponi in combination with a phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA, AS (Initial): Prescribed by or in consultation with a rheumatologist. PsA (Initial): Prescribed by or in consultation with a rheumatologist or dermatologist. UC (Initial): Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION

UC (Initial): 12 weeks. UC (Reauth): 12 months. RA, AS, PsA (Initial, reauth): 12 months

OTHER CRITERIA

All indications (Reauth): Documentation of positive clinical response to Simponi therapy.

SIMPONI ARIA (S)

MEDICATION(S)

SIMPONI ARIA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), OR failure, contraindication, or intolerance to methotrexate (Rheumatrex/Trexall). One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR for continuation of prior Simponi Aria therapy. Patient is not receiving Simponi Aria in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Orencia (abatacept)]. Patient is not receiving Simponi Aria in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA (Initial): Prescribed by or in consultation with a rheumatologist.

COVERAGE DURATION

RA (Initial, reauth): 12 months

OTHER CRITERIA

RA (Reauth): Documentation of positive clinical response to Simponi Aria therapy. Patient is not receiving Simponi Aria in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Orencia (abatacept)]. Patient is not receiving Simponi Aria in combination with a Janus kinase inhibitor [eg, Xeljanz (tofacitinib)].

SIMVASTATIN (S)

MEDICATION(S)

SIMVASTATIN 80 MG TABLET

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Patient has been taking simvastatin 80 mg per day chronically (12 months or more) and no evidence of muscle toxicity/myopathy (eg, muscle pain, muscle tenderness, muscle weakness) on simvastatin 80 mg per day.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

SOMATULINE DEPOT (S)

MEDICATION(S)

SOMATULINE DEPOT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acromegaly (initial): Diagnosis of acromegaly AND One of the following: A) History of failure to one of the following: surgery or radiotherapy, OR B) not a candidate for one of the following: surgery or radiotherapy. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (initial): Diagnosis of unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All Indications (Initial and reauth): 12 months

OTHER CRITERIA

Acromegaly (reauth): patient had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). GEP-NETs (reauth): Approve for continuation of therapy.

SOMAVERT (S)

MEDICATION(S)

SOMAVERT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acromegaly (initial): Diagnosis of acromegaly AND History of failure to surgery and/or radiation therapy and/or other medical therapies (such as dopamine agonists [e.g., bromocriptine, cabergoline]) unless patient is not a candidate for these treatment options AND History of failure or intolerance to generic octreotide (a somatostatin analogue)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial and reauth: 12 months

OTHER CRITERIA

Acromegaly (reauth): Patient has experienced an objective response to therapy (biochemical control, decrease or normalization of IGF-1 levels).

SOVALDI (S)

MEDICATION(S)

SOVALDI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Criteria will be applied consistent with current AASLD/IDSA guideline. For genotype 1 patients and Sovaldi used in combination with Olysio: Patient is without decompensated liver disease (defined as Child-Pugh Class B or C). All genotype 1 (except Sovaldi plus Olysio therapy) and 4: history of intolerance or contraindication to Harvoni and Zepatier therapy OR patient is currently on Sovaldi therapy. For genotype 2 (except in 1) post-liver transplant patients, or 2) pediatric patients 12 to 17 years of age or 3) both of the following: a) patients weighing at least 35 kg and b) less than 18 years of age) or genotype 3 patients (except in 1) pediatric patients 12 to 17 years of age or 2) both of the following: a) patients weighing at least 35 kg and b) less than 18 years of age), using Sovaldi plus ribavirin: history of intolerance or contraindication to Epclusa OR patient is currently on Sovaldi therapy. All Sovaldi plus Olysio therapy: one of the following: a) history of failure, intolerance or contraindication to Harvoni and Zepatier therapy OR b) both of the following: 1. history of failure to Harvoni OR Zepatier AND 2. the patient has NS5A inhibitor resistant-associated variants detected using commercially available assays, OR c) patient is currently on Sovaldi therapy. All Sovaldi plus Daklinza therapy: One of the following: 1) Patient has not failed a prior HCV NS5A-containing regimen (eg, Daklinza) therapy, OR 2) patient has failed prior therapy with an NS5A-containing regimen AND submission of medical records (eg, chart notes) documenting that the patient does not have NS5A inhibitor resistance-associated variants detected using commercially available assays.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 to 48 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

SPORANOX (S)

MEDICATION(S)

ITRACONAZOLE 100 MG CAPSULE, SPORANOX 10 MG/ML SOLUTION

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: 1) patient has a systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis), OR 2) patient is resistant to topical antifungal treatment and has one of the following diagnoses: a) tinea corporis (ringworm), OR b) tinea cruris (jock itch), OR c) tinea pedis (athletes foot), OR d) tinea capitis (scalp ringworm), OR e) pityriasis versicolor, OR 3) all of the following: a) patient has a diagnosis of onychomycosis confirmed by one of the following (CAPSULE ONLY): i) positive potassium hydroxide (KOH) preparation, OR ii) culture, OR iii) histology, AND b) the patients condition is causing debility or a disruption in their activities of daily living, AND c) patient has had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine, OR 4) patient has a diagnosis of candidiasis (esophageal or oropharyngeal) that is refractory to treatment with fluconazole (ORAL SOLUTION ONLY).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

systemic fungal infxn:6mo.(candidiasis,fingernail onycho.):1 mo.(toenail onycho, other):3mo.

OTHER CRITERIA

N/A

SPRYCEL (S)

MEDICATION(S)

SPRYCEL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML): Diagnosis of Ph+ CML.
Ph+ acute lymphoblastic leukemia (ALL): Diagnosis of Ph+ ALL.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Uses: Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION

All Uses: 12 months

OTHER CRITERIA

All Uses: Approve for continuation of prior therapy.

STELARA (IV) (S)

MEDICATION(S)

STELARA 130 MG/26 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Diagnosis of moderately to severely active Crohn's disease. One of the following: a) History of failure, contraindication, or intolerance to Humira (adalimumab), or (b) History of failure, contraindication, or intolerance to treatment with at least one immunomodulator or corticosteroid [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)]. Patient is not receiving Stelara in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION

One time

OTHER CRITERIA

Stelara is to be administered as an intravenous induction dose. Stelara induction dosing is in accordance with the United States Food and Drug Administration approved labeled dosing for Crohn's Disease: 260 mg for patients weighing 55 kg or less, 390 mg for patients weighing more than 55 kg to 85 kg, or 520 mg for patients weighing more than 85 kg.

STELARA (S)

MEDICATION(S)

STELARA 45 MG/0.5 ML SYRINGE, STELARA 90 MG/ML SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Plaque psoriasis (Initial - 45mg/0.5mL): Diagnosis of moderate to severe plaque psoriasis. Plaque psoriasis (Initial - 90mg/1mL): Diagnosis of moderate to severe plaque psoriasis. Patient's weight is greater than 100 kg (220 lbs). Psoriatic arthritis (PsA) (Initial - 45mg/0.5mL): Diagnosis of active PsA. PsA (Initial - 90mg/1mL): Diagnosis of active PsA. Patient's weight is greater than 100 kg (220 lbs). Diagnosis of co-existent moderate to severe psoriasis. Plaque psoriasis (Initial): One of the following: a) History of failure, contraindication, or intolerance (F/C/I) to Enbrel (etanercept) OR Humira (adalimumab) OR b) for continuation of prior Stelara therapy. PsA (Initial): One of the following: a) History of failure, contraindication, or intolerance (F/C/I) to Enbrel (etanercept) and Humira (adalimumab) OR b) for continuation of prior Stelara therapy. Crohn's disease (CD) (Initial): Diagnosis of moderately to severely active Crohn's disease. One of the following: a) History of F/C/I to Humira (adalimumab) OR b) History of F/C/I to treatment with at least one immunomodulator or corticosteroid [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)], OR c) for continuation of prior Stelara therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist. CD (initial): Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION

All uses (Initial, reauth): 12 months

OTHER CRITERIA

Reauthorization (all indications): Documentation of positive clinical response to Stelara therapy. All

indications (initial, reauth): Patient is not receiving Stelara in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Otezla (apremilast)].

STIVARGA (S)

MEDICATION(S)

STIVARGA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Metastatic colorectal cancer (mCRC): All of the following: 1) diagnosis of mCRC, AND 2) history of failure, contraindication or intolerance to fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, AND 3) history of failure, contraindication or intolerance to an anti-VEGF therapy (e.g. Avastin [bevacizumab]), AND 4) one of the following: a) KRAS mutation, OR b) both of the following: KRAS wild-type and history of failure, contraindication or intolerance to an anti-EGFR therapy [e.g. Vectibix (panitumumab), Erbitux (cetuximab)]. Gastrointestinal stromal tumor (GIST): All of the following: 1) diagnosis of locally advanced, unresectable or metastatic GIST, AND 2) history of failure, contraindication or intolerance to both of the following: a) Gleevec (imatinib mesylate), AND b) Sutent (sunitinib malate). Hepatocellular Carcinoma (HCC): Diagnosis of hepatocellular carcinoma (HCC). Trial and failure or intolerance to Nexavar (sorafenib tosylate).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

STRENSIQ (S)

MEDICATION(S)

STRENSIQ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Hypophosphatasia: Diagnosis of perinatal/infantile or juvenile-onset hypophosphatasia AND for patients requesting the 80 mg/0.8 mL vial only: Patient's weight is greater than or equal to 40 kg

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Hypophosphatasia: Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism or endocrinologist

COVERAGE DURATION

Hypophosphatasia: 12 months

OTHER CRITERIA

N/A

SUTENT (S)

MEDICATION(S)

SUTENT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma. Gastrointestinal stromal tumor (GIST): Diagnosis of GIST after disease progression on or intolerance to Gleevec (imatinib). Pancreatic neuroendocrine tumors: Diagnosis of progressive, well-differentiated pancreatic neuroendocrine tumor that is unresectable locally advanced or metastatic disease.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION

All Indications: 12 months

OTHER CRITERIA

All Indications: Approve for continuation of prior therapy

SYLATRON (S)

MEDICATION(S)

SYLATRON, SYLATRON 4-PACK

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis of melanoma with microscopic or gross nodal involvement AND The prescribed medication will be used as adjuvant therapy within 84 days of definitive surgical resection, including complete lymphadenectomy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

SYLVANT (S)

MEDICATION(S)

SYLVANT 100 MG VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multicentric Castleman's disease (MCD) (Initial): Diagnosis of MCD. Patient is human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

MCD (Initial): Prescribed by or in consultation with hematologist/oncologist or rheumatologist.

COVERAGE DURATION

MCD (initial, reauth): 6 months

OTHER CRITERIA

MCD (reauth): Documentation of positive clinical response to Sylvant therapy. Patient is HIV negative and HHV-8 negative.

SYMLIN (S)

MEDICATION(S)

SYMLINPEN 120, SYMLINPEN 60

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

Gastroparesis.

REQUIRED MEDICAL INFORMATION

One of the following diagnoses: A) Type 1 diabetes OR B) Type 2 diabetes.

AGE RESTRICTION

18 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

SYNAGIS (S)

MEDICATION(S)

SYNAGIS 50 MG/0.5 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Patient will use palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) during the peak months of infection in the patient's geographic region AND Patient meets one of the following criteria: 1) Infants born at 28 weeks, six days gestation or earlier and who are younger than 12 months of age at the start of the RSV season OR 2) Diagnosis of chronic lung disease of prematurity, born before 32 weeks, 0 days gestation, received greater than 21% oxygen for at least the first 28 days after birth, and one of the following: a) 12 months of age or younger at the start of the RSV season OR b) greater than 12 months of age to 24 months of age at the start of the RSV season and received medical support (i.e., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) within 6 months before the start of the second RSV season. OR 3) Patient is 12 months of age or younger at the start of the RSV season and has one of the following: a) acyanotic heart failure that will require a cardiac surgical procedure and the patient is receiving medication to control congestive heart failure, OR b) moderate to severe pulmonary hypertension OR c) cyanotic heart defect. OR 4) patient is younger than 24 months of age and will or has undergone a cardiac transplantation during the RSV season. OR 5) Patient is 12 months of age or younger at the start of the RSV season with a congenital abnormality or neuromuscular disorder and has an impaired ability to clear secretions from the upper airway due to an ineffective cough. OR 6) Patient is younger than 24 months of age with a lymphocyte count below the normal range for patient's age and has received or will receive a solid organ transplant, hematopoietic stem cell transplant recipient, or chemotherapy during the RSV season.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a pediatric specialist (i.e., pulmonologist, neonatologist, neurologist, cardiologist, pediatric intensivist, or infectious disease specialist).

COVERAGE DURATION

PAGE 267

HPMS Approved Formulary ID: 00017485 Version 23

LAST UPDATED 12/2017

12 months

OTHER CRITERIA

N/A

SYNDROS (S)

MEDICATION(S)

SYNDROS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Nausea and Vomiting Associated with Cancer Chemotherapy (CINV): Patient is receiving cancer chemotherapy. Failure, contraindication, or intolerance to one 5HT-3 receptor antagonist (eg, Anzemet [dolasetron], Kytril [granisetron], or Zofran [ondansetron]). Failure, contraindication, or intolerance to one of the following: Compazine (prochlorperazine), Decadron (dexamethasone), Haldol (haloperidol), Zyprexa (olanzapine). AIDS anorexia: Diagnosis of anorexia with weight loss in patients with AIDS. Patient is on antiretroviral therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

CINV: 6 months. AIDS anorexia: 3 months.

OTHER CRITERIA

Subject to Part B vs. Part D review. CINV: Approve for continuation of therapy for treatment covered under Part B when patient is receiving cancer chemotherapy.

SYNRIBO (S)

MEDICATION(S)

SYNRIBO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic myelogenous leukemia (CML): Diagnosis of CML in the chronic or accelerated phase AND Patient has tried and has had resistance, relapse, inadequate response, intolerance or is contraindicated to TWO tyrosine kinase inhibitors (i.e., GLEEVEC [imatinib], SPRYCEL, TASIGNA, BOSULIF, ICLUSIG)

AGE RESTRICTION

CML: 18 years of age or older

PRESCRIBER RESTRICTION

CML: Prescribed by or in consultation with a hematologist/oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

TAFINLAR (S)

MEDICATION(S)

TAFINLAR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Non-small Cell Lung Cancer (NSCLC): All of the following: diagnosis of metastatic non-small cell lung cancer AND cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA) AND medication is used in combination with Mekinist (trametinib).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TAGRISSE (S)

MEDICATION(S)

TAGRISSE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC. Tumors are positive for epidermal growth factor receptor (EGFR) T790M mutation. The patient has experienced disease progression on or after one of the following EGFR Tyrosine Kinase Inhibitors (TKIs): Gilotrif (afatinib), Iressa (gefitinib), Tarceva (erlotinib).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TALTZ (S)

MEDICATION(S)

TALTZ AUTOINJECTOR (3 PACK), TALTZ SYRINGE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: Failure, contraindication, or intolerance to either Enbrel (etanercept) or Humira (adalimumab), OR for continuation of prior Taltz therapy. Patient is not receiving Taltz in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Plaque psoriasis (Initial): Prescribed by or in consultation with a dermatologist.

COVERAGE DURATION

All indications (Initial, reauth): 12 months

OTHER CRITERIA

All indications (Reauth): Documentation of positive clinical response to Taltz therapy. Patient is not receiving Taltz in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].

TARCEVA (S)

MEDICATION(S)

TARCEVA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): Diagnosis of locally advanced or metastatic (Stage III or IV) NSCLC AND Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. Pancreatic Cancer: Diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer AND TARCEVA will be used in combination with gemcitabine.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Indications: Prescribed by or in consultation with an oncologist

COVERAGE DURATION

All Indications: 12 months

OTHER CRITERIA

All Indications: Approve for continuation of prior therapy.

TARGRETIN (S)

MEDICATION(S)

BEXAROTENE, TARGRETIN 1% GEL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cutaneous T-Cell Lymphoma (CTCL): Diagnosis of CTCL. History of failure, contraindication, or intolerance to at least one prior therapy (including skin-directed therapies [eg, corticosteroids {ie, clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate}] or systemic therapies [eg, interferons]).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TASIGNA (S)

MEDICATION(S)

TASIGNA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic myelogenous leukemia (CML): Diagnosis of Ph+ CML

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist or hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TAZORAC (S)

MEDICATION(S)

TAZAROTENE 0.1% CREAM, TAZORAC

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acne vulgaris (initial): Diagnosis of acne vulgaris AND History of failure or intolerance to at least two topical acne products (e.g., tretinoin, adapalene, benzoyl peroxide, clindamycin, erythromycin, or azelaic acid). Plaque psoriasis (initial): Diagnosis of stable moderate to severe plaque psoriasis AND Patient has body surface area (BSA) involvement of less than 20 percent AND History of failure or intolerance to at least two topical psoriasis product (e.g., medium to high potency corticosteroids and/or vitamin D analogs).

AGE RESTRICTION

Acne (initial): 12 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All uses (Initial and reauth): 12 months

OTHER CRITERIA

Acne, Plaque psoriasis (reauth): Documentation of positive clinical response to therapy .

TECENTRIQ (S)

MEDICATION(S)

TECENTRIQ

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Urothelial carcinoma: Diagnosis of locally advanced or metastatic urothelial carcinoma. One of the following: A) History of disease progression during or following platinum-containing chemotherapy, OR B) History of disease progression within 12 months of neoadjuvant or adjuvant chemotherapy, OR C) Patient is not eligible for cisplatin-containing chemotherapy. Non-small cell lung cancer: All of the following: A) Diagnosis of metastatic non-small cell carcinoma (NSCLC), and B) Patient has disease progression following platinum-containing chemotherapy, and C) One of the following: 1) Patient does not have epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement OR 2) Both of the following: patient has an EGFR mutation AND history of failure, contraindication, or intolerance to at least one anti-EGFR therapy (e.g., Gilotrif [afatinib], Iressa [gefitinib], Tarceva [erlotinib]) OR 3) Both of the following: patient has ALK rearrangement AND history of failure, contraindication, or intolerance to at least one ALK inhibitor (e.g., Xalkori [crizotinib])

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TECFIDERA (S)

MEDICATION(S)

TECFIDERA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

TECHNIVIE (S)

MEDICATION(S)

TECHNIVIE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline, AND B) Patient is not receiving Technivie in combination with another HCV direct acting antiviral agent [eg, Harvoni (ledipasvir-sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir)], AND C) ONE of the following: History of intolerance or contraindication to Harvoni and Zepatier therapy OR patient is currently on Technivie therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

TESTOSTERONE (S)

MEDICATION(S)

ANDRODERM, ANDROGEL 1.62% GEL PUMP, ANDROGEL 1.62%(1.25G) GEL PCKT, ANDROGEL 1.62%(2.5G) GEL PCKT, STRIANT, TESTOSTERON CYP 1,000 MG/10 ML, TESTOSTERON CYP 2,000 MG/10 ML, TESTOSTERONE CYP 100 MG/ML, TESTOSTERONE CYP 200 MG/ML

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Hypogonadism (HG) (Initial): Diagnosis (dx) of HG in a male patient. 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Gender Identity Disorder (GID) (off-label): Dx of GID. Patient is a female-to-male transsexual.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

HG(init): (New to T tx:6 mo. New to plan and cCont T tx:12 mo), (reauth): 12 mo. GID: 12 mo.

OTHER CRITERIA

HG (Reauth): 1) Total serum T level within or below the normal limits of the reporting lab, or 2) Total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Calculated free or bioavailable T level within or below the normal limits of the reporting lab, or calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.

TESTOSTERONE ENANTHATE (S)

MEDICATION(S)

TESTOSTERON ENAN 1,000 MG/5 ML, TESTOSTERONE ENAN 200 MG/ML

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Hypogonadism (HG) (Initial): Diagnosis (dx) of HG in a male patient. 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Delayed puberty (DP): Dx of DP in males. Breast cancer (BC): Dx for the palliative treatment of inoperable BC in women. Gender Identity Disorder (GID) (off-label): Dx of GID. Patient is a female-to-male transsexual.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

HG(init): (New to T tx:6 mo. Cont T tx:12 mo), (reauth): 12 mo. BC, GID: 12 mo. DP: 6 mo.

OTHER CRITERIA

HG (Reauth): 1) Total serum T level within or below the normal limits of the reporting lab, or 2) Total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Calculated free or bioavailable T level within or below the normal limits of the reporting lab, or calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.

THALOMID (S)

MEDICATION(S)

THALOMID

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple myeloma (MM): Diagnosis of MM. Used in combination with dexamethasone, unless the patient has an intolerance to steroids. Erythema nodosum leprosum (ENL): Diagnosis of moderate to severe ENL with cutaneous manifestations. Thalomid is not used as monotherapy if moderate to severe neuritis is present.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

MM: Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TOPICAL RETINOID (S)

MEDICATION(S)

AVITA, TRETINOIN 0.01% GEL, TRETINOIN 0.025% CREAM, TRETINOIN 0.025% GEL, TRETINOIN 0.05% CREAM, TRETINOIN 0.05% GEL, TRETINOIN 0.1% CREAM, TRETINOIN MICROSPHERE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

One of the following: Acne: Diagnosis of acne. Actinic keratosis (off-label): Diagnosis of actinic keratosis. Alopecia areata (off-label): Diagnosis of alopecia areata. Hyperkeratosis (off-label): Diagnosis of hyperkeratosis. Keloid scar (off-label): Diagnosis of keloid scar. Systematized epidermal nevus (off-label): Diagnosis of systematized epidermal nevus.

AGE RESTRICTION

PA applies to members 26 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

TRELSTAR (S)

MEDICATION(S)

TRELSTAR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. History of failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TRETINOIN/CLINDAMYCIN (S)

MEDICATION(S)

CLINDAMYCIN PHOS-TRETINOIN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Acne: Diagnosis of acne.

AGE RESTRICTION

PA applies to members 26 years of age or older

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

TYKERB (S)

MEDICATION(S)

TYKERB

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Breast Cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer. Used in combination with one of the following: Herceptin (trastuzumab), Xeloda (capecitabine), or aromatase inhibitors [eg, Aromasin (exemestane), Femara (letrozole), Arimidex (anastrozole)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

TYMLOS (S)

MEDICATION(S)

TYMLOS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Initial: Patient is a postmenopausal woman. Either of the following: set I) diagnosis of osteoporosis defined as bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND one of the following: a) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm or b) trial and failure, contraindication, or intolerance to one osteoporosis treatment [e.g., alendronate, risendronate, zoledronic acid, Prolia (denosumab)], or set II) diagnosis of osteopenia defined as BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) and one of the following: a) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or b) both of the following: history of failure, contraindication, or intolerance to one osteoporosis treatment [e.g., alendronate, risedronate, zoledronic acid, Prolia (denosumab)] and one of the following FRAX (Fracture Risk Assessment Tool) 10-year probabilities: major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or hip fracture is 3% or more in the U.S., or the country-specific threshold in other countries or regions. Treatment duration with Tymlos and if taken in the past, Forteo (teriparatide), has not exceeded a total of 24 months during the patient's lifetime.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial, reauth: 12 months

OTHER CRITERIA

N/A

TYSABRI (S)

MEDICATION(S)

TYSABRI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses). Failure, contraindication, or intolerance (F/C/I) to one of the following: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone or Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Rebif (interferon beta-1a), or Tecfidera (dimethyl fumarate). Patient is not taking Tysabri in combination with another MS agent [eg, Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Lemtrada (alemtuzumab), Rebif (interferon beta-1a), or Tecfidera (dimethyl fumarate)]. Crohn's Disease (CD) (initial): Diagnosis of moderate to severe CD with evidence of inflammation (eg, elevated C-reactive protein [CRP], elevated erythrocyte sedimentation rate, presence of fecal leukocytes). History of inadequate response or intolerance to one of the following conventional therapies: corticosteroids, 6-mercaptopurine (6MP [Purinethol], azathioprine (Imuran), methotrexate, aminosalicylates (eg, sulfasalazine, mesalamine, olsalazine). History of inadequate response or intolerance to a TNF-inhibitor (eg, Cimzia [certolizumab pegol], Humira [adalimumab], Remicade [infliximab]). CD (initial and reauth): Patient is not taking Tysabri in combination with an immunosuppressant (eg, 6-MP, azathioprine, cyclosporine, or methotrexate) or a TNF-inhibitor (eg, Enbrel [etanercept], Humira [adalimumab], or Remicade [infliximab]).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

MS: 12mo. CD (Init): 3 mo. CD (Reauth): 6 mo if not on steroids. Otherwise, 3 mo.

OTHER CRITERIA

CD (reauth): Diagnostic and/or clinical documentation (eg, improved disease activity index) that indicates patient has experienced clinical benefit from receiving (induction) Tysabri therapy by week 12.

UPTRAVI (S)

MEDICATION(S)

UPTRAVI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (initial): Diagnosis of PAH AND Patient is symptomatic AND One of the following: a) Diagnosis of PAH was confirmed by right heart catheterization OR b) patient is currently on any therapy for the diagnosis of PAH. One of the following: a) History of inadequate response, contraindication, or intolerance to a PDE5 inhibitor (ie, Adcirca, Revatio) or Adempas (riociguat), and History of inadequate response, contraindication, or intolerance to an endothelin receptor antagonist [e.g. Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)] OR b) For continuation of prior Uptravi therapy. Not taken in combination with a prostanoid/prostacyclin analogue (eg, epoprostenol, iloprost, treprostinil).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist

COVERAGE DURATION

Initial: 6 months Reauth: 12 months

OTHER CRITERIA

PAH (Reauth): Documentation of positive clinical response to Uptravi therapy. Not taken in combination with a prostanoid/prostacyclin analogue (eg, epoprostenol, iloprost, treprostinil)

VALCHLOR (S)

MEDICATION(S)

VALCHLOR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) (initial): All of the following: 1) diagnosis of Stage IA MF-CTCL, OR diagnosis of Stage IB MF-CTCL, AND 2) patient has received at least one prior skin-directed therapy [e.g., topical corticosteroids, bexarotene topical gel (Targretin topical gel), topical nitrogen mustard, etc.].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist or dermatologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

VELCADE (S)

MEDICATION(S)

VELCADE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Multiple myeloma (MM): Diagnosis of MM. Mantle cell lymphoma (MCL): Diagnosis of MCL.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

MM, MCL: Prescribed by or in consultation with an oncologist/hematologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

VENCLEXTA (S)

MEDICATION(S)

VENCLEXTA, VENCLEXTA STARTING PACK

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL): Diagnosis of CLL or SLL with 17p deletion or TP53 mutation. Patient has received at least one prior therapy for CLL/SLL [e.g., Cytosan (cyclophosphamide), Fludara (fludarabine), Rituxan (rituximab)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist or oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

VENTAVIS (S)

MEDICATION(S)

VENTAVIS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

PAH (Initial): Prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE DURATION

PAH (Initial): 6 months. (Reauth): 12 months

OTHER CRITERIA

Subject to Part B vs D review. PAH (Reauth): Documentation of positive clinical response to therapy.

VIEKIRA (S)

MEDICATION(S)

VIEKIRA PAK, VIEKIRA XR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND B) ONE of the following: 1) Patient has a contraindication or intolerance to Harvoni and Zepatier OR 2) For continuation of prior Viekira therapy AND C) Patient is not receiving Viekira Pak in combination with another HCV direct acting antiviral agent [e.g., Harvoni (ledipasvir-sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir)], AND D) Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C), AND E) ONE of the following: 1) Patient has not experienced prior failure with an NS5A inhibitor or NS3/4A protease inhibitor-containing regimen OR 2) patient has failed prior therapy with an NS5A inhibitor or NS3/4A protease inhibitor AND submission of medical records documenting that the patient does not have NS3 protease inhibitor or NS5A inhibitor resistance-associated variants detected using commercially available assays.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 to 24 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

VIVITROL (S)

MEDICATION(S)

VIVITROL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Alcohol dependence (init): History of alcohol dependence and confirmed abstinence at treatment initiation. Opioid dependence (init): History of opioid dependence and confirmed opioid detoxification at treatment initiation.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Alcohol dependence, opioid dependence (init, reauth): 24 weeks

OTHER CRITERIA

Alcohol dependence, opioid dependence (reauth): Confirmation of clinical benefit to the patient.

VOSEVI (S)

MEDICATION(S)

VOSEVI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Criteria will be applied consistent with current AASLD/IDSA guideline. Submission of medical records (e.g., chart notes, laboratory values) documenting diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6. All patients: Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C), and patient is not receiving Vosevi in combination with another HCV direct acting antiviral agent [e.g., Harvoni, Zepatier]. All genotype 1 and 4: trial and failure, intolerance, or contraindication to Harvoni and Zepatier therapy OR for continuation of prior Vosevi therapy. All genotype 2 and 3: trial and failure, intolerance, or contraindication to Epclusa OR for continuation of prior Vosevi therapy. All genotype 5 and 6: trial and failure, intolerance, or contraindication to Epclusa and Harvoni therapy OR for continuation of prior Vosevi therapy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

VOTRIENT (S)

MEDICATION(S)

VOTRIENT

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Renal cell carcinoma (RCC): Diagnosis of advanced/metastatic RCC. Soft tissue sarcoma: Diagnosis of advanced soft tissue sarcoma and patient received at least one prior chemotherapy (e.g., ifosfamide, doxorubicin, cisplatin, dacarbazine, docetaxel, oxaliplatin, etc.)

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All Uses: Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

MEDICATION(S)

VPRIV

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Gaucher disease: Diagnosis of type 1 Gaucher disease. Patient has evidence of symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Gaucher disease: 12 months

OTHER CRITERIA

N/A

VYTORIN (S)

MEDICATION(S)

EZETIMIBE-SIMVASTATIN 10-80 MG

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Patient has been taking simvastatin 80 mg per day chronically (12 months or more) and no evidence of muscle toxicity/myopathy (eg, muscle pain, muscle tenderness, muscle weakness) on simvastatin 80 mg per day.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

12 months

OTHER CRITERIA

N/A

VYXEOS (S)

MEDICATION(S)

VYXEOS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Newly diagnosed therapy related acute myeloid leukemia (t-AML): Diagnosis of t-AML. Acute myeloid leukemia myelodysplasia-related changes (AML-MRC): Diagnosis of AML-MRC.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

XALKORI (S)

MEDICATION(S)

XALKORI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): Diagnosis of locally advanced or metastatic (stage IIIB or IV) NSCLC AND One of the following: A) Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility or B) Patient has MET amplification- or ROS1 rearrangements-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

NSCLC: Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

XELJANZ (S)

MEDICATION(S)

XELJANZ, XELJANZ XR

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Rheumatoid arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria), OR for continuation of prior tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

RA (Initial): Prescribed by or in consultation with a rheumatologist

COVERAGE DURATION

RA (initial, reauth): 12 months

OTHER CRITERIA

RA (Reauth): Documentation of positive clinical response to tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).

XENAZINE (S)

MEDICATION(S)

TETRABENAZINE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chorea associated with Huntington's Disease (HD) (Initial): Diagnosis of chorea in patients with Huntington's disease. Tardive dyskinesia (Initial): Patient has stereotypies associated with tardive dyskinesia. Tourette's syndrome (Initial): Patient has tics associated with Tourette's syndrome. Failure, contraindication, or intolerance to Haldol (haloperidol).

AGE RESTRICTION

Tardive dyskinesia (Initial): Age greater than or equal to 18 years.

PRESCRIBER RESTRICTION

HD (Initial): Prescribed by or in consultation with a neurologist. Tardive dyskinesia, Tourette's syndrome (Initial): Prescribed by or in consultation with neurologist or psychiatrist.

COVERAGE DURATION

All indications: (Initial) 3 months, (Reauth) 12 months.

OTHER CRITERIA

All indications (Reauth): Documentation of clinical response and benefit from therapy.

XEOMIN (S)

MEDICATION(S)

XEOMIN 50 UNIT VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cervical Dystonia (CD) (init): Diagnosis of CD (also known as spasmodic torticollis). Blepharospasm (initial): Diagnosis of blepharospasm. History of previous use of Botox (onabotulinumtoxinA) for the treatment of blepharospasm. Upper limb spasticity (ULS) (init): Diagnosis of upper limb spasticity.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All indications (init, reauth): 3 months (for 1 dose)

OTHER CRITERIA

All indications (reauth): Confirmed improvement in symptoms with initial Xeomin treatment. At least 3 months have elapsed since the last treatment with Xeomin

XGEVA (S)

MEDICATION(S)

XGEVA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Bone metastasis from solid tumors (BMST) (initial): Both of the following: 1) diagnosis of solid tumors (eg, breast cancer, kidney cancer, lung cancer, prostate cancer, thyroid cancer), AND 2) documented evidence of one or more metastatic bone lesions. Giant cell tumor of bone (GCTB): Both of the following: 1) diagnosis of giant cell tumor of bone AND 2) One of the following: a) tumor is unresectable, OR b) surgical resection is likely to result in severe morbidity. Hypercalcemia of malignancy (HCM) (initial): Both of the following: 1) diagnosis of hypercalcemia of malignancy, AND 2) history of failure, contraindication, or intolerance to one intravenous bisphosphonate (eg, Aredia (pamidronate), Zometa (zoledronic acid)).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

GCTB, HCM (initial): Prescribed by or in consultation with an oncologist

COVERAGE DURATION

BMST, GCTB: 12 mo. HCM (initial, reauth): 2 mo.

OTHER CRITERIA

GCTB (reauth): Approve for continuation of therapy. HCM (reauth): Documentation of positive clinical response to Xgeva therapy.

XIFAXAN (S)

MEDICATION(S)

XIFAXAN

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Travelers' diarrhea (TD) (200 mg strength only): Diagnosis of travelers' diarrhea, AND one of the following: a) History of failure, contraindication, or intolerance to one of the following: Cipro (ciprofloxacin), Levaquin (levofloxacin), ofloxacin, Zithromax (azithromycin) OR b) resistance to all of the following: Cipro (ciprofloxacin), Levaquin (levofloxacin), ofloxacin, Zithromax (azithromycin). Prophylaxis of hepatic encephalopathy (HE) recurrence (550mg strength only): Used for the prophylaxis of hepatic encephalopathy recurrence, AND failure, contraindication or intolerance to lactulose. Irritable bowel syndrome with diarrhea (IBS-D) (550mg strength only) (initial): Diagnosis of IBS-D, AND history of failure, contraindication or intolerance to an antidiarrheal agent [eg, loperamide].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

TD: One time only. HE: 6 months. IBS-D (initial, reauth): 2 weeks.

OTHER CRITERIA

IBS-D (reauth): Patient experiences IBS-D symptom recurrence.

XIIDRA (S)

MEDICATION(S)

XIIDRA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Initial: Diagnosis of dry eye disease. Patient has suppressed tear production due to ocular inflammation as determined by at least one of the following diagnostic tests: Schirmer test (aqueous tear production and clearance), tear break-up time, ocular surface dye staining, tear film osmolarity, or fluorescein clearance test/tear function test. Failure, contraindication, or intolerance to Restasis at an optimal dose and frequency for at least 2 weeks

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Initial, reauth: 12 months

OTHER CRITERIA

Reauth: Documentation of positive clinical response to Xiidra therapy (e.g., increased tear production or improvement in dry eye symptoms).

XTANDI (S)

MEDICATION(S)

XTANDI

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Metastatic castration-resistant prostate cancer (mCRPC): Diagnosis of mCRPC. History of failure, contraindication or intolerance to Zytiga.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed or in consultation with an oncologist or urologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

XYREM (S)

MEDICATION(S)

XYREM

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Narcolepsy with cataplexy (Narcolepsy Type 1)(initial): Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), AND symptoms of cataplexy are present, AND symptoms of excessive daytime sleepiness (eg, irrepressible need to sleep or daytime lapses into sleep) are present. Narcolepsy without cataplexy (Narcolepsy Type 2)(initial): Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), AND symptoms of cataplexy are absent, AND symptoms of excessive daytime sleepiness (eg, irrepressible need to sleep or daytime lapses into sleep) are present, AND history of failure, contraindication, or intolerance to one of the following: 1) amphetamine-based stimulant (eg, amphetamine, dextroamphetamine), OR 2) methylphenidate-based stimulant.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

All uses (initial, reauth): 12 months

OTHER CRITERIA

Narcolepsy Type 1 (reauth): Documentation demonstrating a reduction in the frequency of cataplexy attacks associated with Xyrem therapy, OR documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with Xyrem therapy. Narcolepsy Type 2 (reauth): Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with Xyrem therapy.

YERVOY (S)

MEDICATION(S)

YERVOY 50 MG/10 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Unresectable or metastatic melanoma: Diagnosis of unresectable, metastatic melanoma. Cutaneous melanoma: Diagnosis of cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm. Patient has undergone resection, including total lymphadenectomy.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ZALTRAP (S)

MEDICATION(S)

ZALTRAP 100 MG/4 ML VIAL

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Colon and/or rectal cancer: Diagnosis of metastatic colon and/or rectal cancer. Ziv-aflibercept is being used in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) regimen. Patient has disease that is resistant to or has progressed following an oxaliplatin-containing regimen [e.g., 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)].

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ZARXIO (S)

MEDICATION(S)

ZARXIO

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Bone marrow/stem cell transplant (BMSCT): One of the following: 1) patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy, AND age greater than or equal to 55 years. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with a history of FN during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Patient is receiving National Cancer Institute's Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia (ANC less than or equal to 500 cells/mm³), AND 2) patients with FN at high risk for infection-associated complications. Severe chronic neutropenia (SCN): Pts with SCN (ie, congenital, cyclic, and idiopathic neutropenias with chronic ANC less than or equal to 500 cells/mm³).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by hematologist/oncologist except HIVN: Prescribed by hematologist/oncologist or infectious disease specialist

COVERAGE DURATION

BMSCT,AML,CFN,secondary prophylaxis of FN,NDDC:3mo or duration of tx. HIVN:6mo.Tx of FN,ARS:1 mo.SCN:12mo

OTHER CRITERIA

HIV-related neutropenia (HIVN)(off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm³).

ZAVESCA (S)

MEDICATION(S)

ZAVESCA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Gaucher disease: Diagnosis of mild to moderate type 1 Gaucher disease. Patient is unable to receive enzyme replacement therapy due to one of the following conditions: allergy or hypersensitivity to enzyme replacement therapy, poor venous access, unavailability of enzyme replacement therapy (e.g., Cerezyme, VPRIV).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

N/A

COVERAGE DURATION

Gaucher disease: 12 months

OTHER CRITERIA

N/A

ZEJULA (S)

MEDICATION(S)

ZEJULA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer. Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy

ZELBORAF (S)

MEDICATION(S)

ZELBORAF

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (eg, cobas 4600 BRAFV600 Mutation Test) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ZEPATIER (S)

MEDICATION(S)

ZEPATIER

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline AND B) Patient is not receiving Zepatier in combination with another HCV direct acting antiviral agent, AND D) patient does not have moderate to severe hepatic impairment (eg, Child-Pugh Class B or C), AND E) For genotype 1a, patient has been tested for the presence of NS5A resistance-associated polymorphisms (ie, polymorphisms at amino acid positions 28, 30, 31, or 93).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine

COVERAGE DURATION

12 to 16 wks. Criteria will be applied consistent with current AASLD/IDSA guideline

OTHER CRITERIA

N/A

ZOLINZA (S)

MEDICATION(S)

ZOLINZA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Cutaneous T-cell lymphoma (CTCL): Diagnosis of CTCL. Progressive, persistent or recurrent disease on or contraindication or intolerance to two systemic therapies (e.g., bexarotene, romidepsin, etc.).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a hematologist/oncologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ZORBTIVE (S)

MEDICATION(S)

ZORBTIVE

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Short Bowel Syndrome (SBS): Diagnosis of SBS. Patient is currently receiving specialized nutritional support (eg, intravenous parenteral nutrition, fluid, and micronutrient supplements). Patient has not previously received 4 weeks of treatment with Zorbtive.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with a gastroenterologist.

COVERAGE DURATION

SBS: 4 weeks.

OTHER CRITERIA

N/A

ZORTRESS (S)

MEDICATION(S)

ZORTRESS

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prevention of kidney transplant organ rejection: The medication is being used for prevention of kidney transplant organ rejection. Patient is at low-to-moderate immunologic risk. Patient is prescribed concurrent therapy with reduced doses of cyclosporine AND corticosteroids. Prevention of liver transplant organ rejection: The medication is being used for prevention of liver transplant organ rejection. Thirty (30) or more days have passed since the transplant procedure. Patient is prescribed concurrent therapy with reduced doses of tacrolimus and corticosteroids.

AGE RESTRICTION

All indications: 18 years of age or older

PRESCRIBER RESTRICTION

All indications: Prescriber is experienced in immunosuppressive therapy and management of transplant patients.

COVERAGE DURATION

12 months

OTHER CRITERIA

Subject to Part B vs. Part D review. Approve for continuation of prior therapy.

ZYDELIG (S)

MEDICATION(S)

ZYDELIG

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Used in combination with Rituxan (rituximab). The patient has relapsed on at least one prior therapy (eg, purine analogues [fludarabine, pentostatin, cladribine], alkylating agents [chlorambucil, cyclophosphamide], or monoclonal antibodies [rituximab]). Patient is a candidate for Rituxan (rituximab) monotherapy due to presence of other comorbidities (eg, coronary artery disease, peripheral vascular disease, diabetes mellitus, pulmonary disease [COPD]). Follicular Lymphoma (FL): Diagnosis of FL. The patient has relapsed on at least two prior systemic therapies (eg, rituximab, alkylating agents [cyclophosphamide, chlorambucil], anthracyclines [doxorubicin, daunorubicine], purine analogs [fludarabine]). Small lymphocytic lymphoma (SLL): Diagnosis of SLL. The patient has relapsed on at least two prior systemic therapies (eg, rituximab, alkylating agents [cyclophosphamide, chlorambucil], anthracyclines [doxorubicin, daunorubicine], purine analogs [fludarabine]).

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

All uses: Prescribed by or in consultation with an oncologist/hematologist.

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ZYKADIA (S)

MEDICATION(S)

ZYKADIA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC that is metastatic or recurrent. Tumor is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility.

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prescribed by or in consultation with an oncologist

COVERAGE DURATION

12 months

OTHER CRITERIA

Approve for continuation of prior therapy.

ZYTIGA (S)

MEDICATION(S)

ZYTIGA

COVERED USES

All medically accepted indications not otherwise excluded from Part D.

EXCLUSION CRITERIA

N/A

REQUIRED MEDICAL INFORMATION

Prostate Cancer: Diagnosis of metastatic castration-resistant (chemical or surgical) prostate cancer
AND Used in combination with prednisone

AGE RESTRICTION

N/A

PRESCRIBER RESTRICTION

Prostate Cancer: Prescribed by or in consultation with an oncologist or urologist

COVERAGE DURATION

Prostate Cancer: 12 months

OTHER CRITERIA

Approve for continuation of prior therapy

